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The neurotransmitters serotonin (5-HT) and dopamine (DA) play roles in eating 
disorders, mood disorders, such as depression and anxiety, and in the regulation of 
locomotion. The 5-HT2C receptor is one of fourteen 5-HT receptor subtypes that is 
expressed in regions of the brain including the hippocampus, amygdala, dorsal 
striatum, nucleus accumbens (NA) and substantia nigra, and is therefore implicated 
in behaviours and disorders associated with these regions. 5-HT has been shown to 
exert both a tonic and phasic inhibitory control, through the 5-HT2C receptor, on the 
firing rate and bursting activity of DA-containing neurones in the ventral tegmental 
area which enhances DA release in the NA and prefrontal cortex. In addition, the 5-
HT2C receptor is under the control of a monophasic diurnal rhythm and is in a 
position to alter circadian regulation and behaviour due to its expression in the 
suprachiasmatic nucleus (the light entrainable oscillator (LEO)). 
It was hypothesised that elevating expression of the 5-HT2C receptor would have a 
detrimental effect on mood and cause hypolocomotion while reducing 5-HT2C 
receptor expression would improve mood, cause hyperphagia, obesity and 
hyperlocomotion. In order to investigate these hypotheses mouse models that either 
over- or under-expressed the 5-HT2C receptor were implemented.  The 5-HT2C 
receptor expression pattern and levels were confirmed in all mouse lines. A 
behavioural phenotype of hypolocomotion and increased anxiety in the 5-HT2C 
receptor over-expressing mice and hyperphagia, obesity and hyperlocomotion in the 
5-HT2C receptor under-expressing mice were found the latter is conistent with 
current literature. During backcrossing of the mouse lines onto the C57Bl/6 genetic 
background the abnormal behavioural phenotypes were lost suggesting that 5-HT2C 
receptor function is particulary sensitive to the genetic background on which it is 
being expressed.  In response to altered expression levels of 5-HT2C receptor, 
compensatory alterations were found in the 5-HT system, with an inverse 
relationship existing between both the 5-HT1A receptor mRNA expression levels and 
5-HT release in the hippocampus with the expression levels of the 5-HT2C receptor. 
Over-expression of 5-HT2C receptor appears to inhibit DA release in the cortex.  The 
circadian experiments showed that under-expressing the 5-HT2C receptor did not 




alter the regulation of the food entrainable oscillator and there was a suggestion that 
the regulation of the LEO was affected. 
In summary, these results demonstrate that altered expression of 5-HT2C receptors 
results in abnormal behaviours consistent with its role in psychiatric disorders, but 
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1.1 The 5-HT system 
In the central nervous system (CNS), 5-hydroxytryptamine (5-HT) is a 
monoaminergic neurotransmitter that due to its diffuse anatomical distribution, 
modulates many different aspects of brain function, and has been implicated in a 
variety of brain disorders. In particular it is involved in many psychiatric disorders 
including anxiety, depression and obsessive compulsive disorder. Maurice Rapport 
first isolated and named 5-HT (to indicate its origin from blood serum and its effect 
on vascular tone) in 1948 (Rapport et al., 1948) and Gaddam later discovered its 
presence in the CNS (Green., 2008; Murphy., 2008).   
 
1.1.2 5-HT Synthesis 
5-HT is one of the less abundant neurotransmitters in the brain and is a biogenic 
amine with a pK of 9.8, which means that it is charged at physiological pH and so is 
unable to cross the blood-brain barrier (BBB) or diffuse into cells from the extra-
cellular space (Diksic & Young., 2001).  For this reason 5-HT must be synthesised 
within neurons which are defined as 5-HT neurons due to the presence of the 
necessary enzymes required for 5-HT synthesis. The two-step metabolic pathway of 
5-HT synthesis (see Figure 1a) requires the amino acid L-tryptophan (Trp), obtained 
from the diet, which is hydroxylated by tryptophan hydroxylase (TPH) into 5-
hydroxy-L-tryptophan (5-HTP). 5-HTP is then converted to 5-HT by aromatic amino 
acid decarboxylase (AAADC).  There are two TPH isoforms; TPH1 which controls 
5-HT synthesis in the periphery and TPH2 which is brain specific (Walther et al., 
2003; Zhang et al., 2004; Gutknecht et al., 2009). The TPH gene, which codes for 
the rate-limiting enzyme of 5-HT biosynthesis, has been cloned (Boularand et al., 
1990) and mapped on 11p15.3-p14 (Craig et al., 1991). Expression of the TPH gene 
is under tight regulation at both the transcriptional and post-transcriptional levels 
(Cote et al., 2002). This first step requires Trp plus two additional substrates which 
are oxygen and tetrahydrobiopterin. Tetrahydrobiopterin is sometimes referred to as 




a cofactor as it is converted to dihydrobiopterin, then reduced back to 
tetrahydrobiopterin and reused. TPH is not saturated with any of its substrates so 
increasing the level of terabhydrobiopterin (in rat: Miwa et al., 1985), oxygen (in rat: 
Davis et al., 1973; in dog: Diksic et al., 1991) or Trp increases the rate of 5-HT 
synthesis. Interestingly genetic polymorphisms in both TPH1 and TPH2 can 
influence susceptibility to anxiety and depression (Nash et al., 2005, Zhang et al., 
2005). A single nucleotide polymorphism at the mTPH2 locus (C1473G) reduced 5-
HT synthesis by 55% when expressed in PC-12 cells (Zhang et al., 2004) and in 
mice this polymorphism determines differences in 5-HT synthesis rates but not tissue 
content in C57BL/6 mice (Siesser et al., 2010). Female Tph2 KO mice have 
increased aggressive behaviour (Alenina et al., 2009) and female aggression is 
directly linked to anxiety and depressive disorders (Bosch et al., 2005). There is also 
evidence that the expression of TPH is affected by ovarian hormones which suggests 
a possible mechanism for premenstrual stress syndrome and postpartum depression 
(Hiroi et al., 2006). AADC is not a rate limiting step but does require pyridoxal 
phosphate as a cofactor. 
 
Immediately following synthesis a 5-HT binding protein (SBP) protects both cystolic 
5-HT and 5-HT in growth cones from monoamine oxidase (MAO) before it is stored 
into vesicles (Tamir & Gershon., 1979; Ivgy-May et al., 1994;Tamir et al., 1994; 
Velez-Pardo et al., 1998). 5-HT is released throughout the brain by a diffuse 
modulatory system (see Figure 1b) which originates in the raphe nuclei of the brain 
stem and projects to the hypothalamus and limbic structures, involved in emotion, 
through the medial forebrain bundle. 
 
Central serotonin activity has a diurnal rhythm, with higher 5-HT release in the 
hippocampus during the active period (Kalén et al., 1989). The actions of 5-HT are 
generally inhibitory and are mediated by G-protein coupled receptors (GPCRs) prior 
to re-uptake into the axon terminal (see Section 1.1.4). 
 










Figure 1.1: a) 5-HT production pathway (taken from internet); b) 5-HT projections 
throughout brain originating at the raphe nuclei 




1.1.2 5-HT Transporter 
 
The serotonin transporter (SERT) reuptakes 5-HT in the synaptic cleft, regulating the 
concentration of 5-HT available and finally terminating the actions of 5-HT in the 
synapse. SERT gene has been localised to chromosome 17q11.1-q12 (Ramamoorthy 
et al., 1993), spans 31kb and consists of 14 exons (Lesch et al., 1994).  The short 
variant polymorhism in the 5-HT transporter gene (SERTPR) is associated with 
anxiety and increased vulnerability to social stressors (Lesch et al., 1996; Grabe et 
al., 2005). In recurrent mood disorders the time course for improvement of core 
depressive and somatic anxiety symptoms by SSRIs is increased by the SERTPR 
polymorphism (Serretti et al., 2007). Another polymorphism of the SERT gene is a 
44-bp insertion (L)/depletion (S) in the promoter region (SERTLPR). Controversial 
results on the association of the SERTLPR polymorphism and mood disorders have 
been found (Anguelova et al., 2003) and no association was detected recently 
between suicide and this polymorphism (Helbecque et al., 2006).  Perturbation of the 
5-HT system by disruption of the gene encoding the 5-HT transporter has region-
specific compensatory alterations in 5-HT receptors.  5-HT1A receptors were 
decreased in the dorsal raphe and increased in the hippocampus (Fabre et al., 2000; 
Li et al., 2000), 5-HT1B receptors were decreased in the substantia nigra (Fabre et al., 
2000) and 5-HT2A receptors were decreased in the claustrum, cerebral cortex and 
lateral striatum (Rioux et al., 1999) of 5-HTT KO mice.  The density of 5-HT2A 
receptors (increased in hypothalamus and septum but reduced in striatum) and 5-
HT2C receptors (increased in amygdala and choroid plexus) are changed in a region-
specific manner in 5-HTT KO mice (Li et al., 2003). 
 
The high capacity plasma membrane monoamine transporter (PMAT) demonstrated 
capability to transport 5-HT and DA. mPMAT is expressed in neuronal cells but not 
in astrocytes and is co-expressed in many brain regions with the high affinity 5-HT 
transporter (SERT) and dopamine transporter (DAT), but it is also found in certain 




sites that receive monoamine innervarion but lack significant expression of SERT or 
DAT (Dahlin et al., 2007).  
 
1.1.3 Breakdown of 5-HT 
MAO-A and MAO-B both breakdown 5-HT, but only MAO-B is present in 
serotonergic neurons. Although 5-HT is the preferred substrate for MAO-A, MAO-B 
is present in such a large excess thats its affinity for 5HT is substantial (Km = 
1150µM, Fowler & Tipton., 1982). MAO-B can deaminate 5-HT in serotonergic 
neurons (Fagervall & Ross., 1986). MAO catabolises 5-HT (Berry et al., 1994) into 
5-hydroxyindoleacetic acid (5-HIAA). The MAO-A has been mapped to Xp11.23 
and is suggested to influence the mechanism of action of SSRIs through interaction 
with the 5-HT transporter (Sabol et al., 1998).  
 
1.1.4 Action of 5-HT & Serotonin System Receptor Families 
The classification of 5-HT receptors began in 1957 by Gaddum and Picarelli 
(Gaddum & Picarelli., 1957) when it was demonstrated that the effects of 5-HT, in 
guinea-pig ileum, could be partially blocked by morphine (M) and partially by 
dibenzyline (D).  Two 5-HT receptor subclasses, 5-HT M and 5-HT D, were 
proposed to act by two different mechanisms with 5-HT M receptors suggested to be 
present in the nervous tissue while 5-HT D receptors were suggested to be in the 
muscles.  In 1979, Peroutka and Snyder (Peroutka & Snyder; 1979) demonstrated 







H]LSD to label binding sites and these 5-HT receptor 
populations were designated 5-HT1 ([
3
H]5-HT binding) and 5-HT2 (by 
[
3
H]spiroperidol binding) with [
3
H]LSD binding to both receptors to a similar extent.  
The M receptor, proposed by Gaddum, was found to be distinct from both the 5-HT1 
and 5-HT2 receptors in function and distribution while the D receptor resembled the 
5-HT2 receptor pharmacologically.  In 1986, Bradley et al (Bradley et al., 1986), 
proposed a framework for the classification of 5-HT receptors into 3 families based 




primarily on functional criteria, named 5-HT1-like, 5-HT2 and 5-HT3 (corresponding 
to the M receptor) receptors.  Between 1987 and 1992 most known or suspected 5-
HT receptors were cloned leading to the identification of a number of new receptors 
and subsequent revision of the classification of 5-HT receptor families.  The new 
nomenclature system was proposed by the Serotonin Club Receptor Nomenclature 
Committee and was based on structural, operational and transduction information 
(Humphrey et al., 1993).  The current classification system is progressively adapted 
to incorporate new information from both recombinant and native receptors and to 
avoid species differences the nomenclature favours alignment with the human 
genome (Hoyer et al., 1994; Hartig et al., 1996; Hoyer & Martin 1997; Hoyer et al., 
IUPHAR Receptor Database., 2006; doi:10.1786/543800763668).  5-HT receptors 
that are GPCRs belong to the type A family of GPCRs, contain the DRY motif in the 
third transmembrane spanning region and have significant sequence homology to 
adrenergic, dopaminergic and rhodopsin receptors (Hannon & Hoyer., 2008).  At 
present there are seven families of 5-HT receptors that are classified based on 
pharmacology, transduction and structure with 14 different receptor subtypes 
(Barnes & Sharp., 1999).  5-HT receptors are membrane bound receptors (Peroutka 
& Howel., 1994) that interact with G-proteins to influence a variety of intracellular 
effects on systems with the exception of 5-HT3, which is unique among monoamine 
receptors in functioning as a ligand-gated ion channel.  Studies of these receptors 
have been complex and troublesome for many years due to the lack of selective 
pharmacological agents together with the nature of the receptors, such that they 
down-regulate upon ligand binding. 
 
The 5-HT1 receptor family comprises 5 receptor subtypes; 5-HT1A, 5-HT1B, 5-HT1D, 
5-ht1E and 5-ht1F which are encoded by intronless genes that are between 365 and 
422 amino acids in length with an overall sequence homology of 40-63% (in 
humans).  5-HT1 receptors are seven transmembrane GPCRs which are mostly linked 
to Gi/o and are thought to be negatively linked to the adenylyl cyclase pathway 
leading to membrane depolarisation and inhibition of firing in cells.  The 5-HT1D 
receptor is located on chromosome 1p34.3 to p36.3; the product of the gene has 374 




to 377 amino acids and is negatively coupled to cAMP production with a 61% 
sequence homology to the 5-HT1B receptor (Hamblin et al., 1992).  The 5-ht1F 
receptor is less well characterised.  This receptor is highly expressed in regions of 
the cortex, hippocampus, the caudate putamen and thalamic regions.  
 
The 5-HT1A receptor is situated on the human chromosome 5cen-q11.2-q13 (Hoyer 
et al., 1994) and is widely distributed in the CNS, in regions associated with control 
of mood such as the hippocampus, amygdala and septum, as well as being present in 
the PNS. 5-HT1A receptor RNA is intronless and produces a polypeptide chain of 
421 to 422 amino acids.  No splice variants are known but two polymorphisms have 
been found which alter the extracellular amino terminal region of the receptor from 
Gly
22
 to Ser and from Ile
28
 to Val (Nakhai et al., 1995).  This receptor preferentially 
couples to Gi/o to inhibit adenylate cyclase activity (Hoyer & Schoeffter., 1991; 
Julius 1991) but has also been shown to be capable of activating the protein kinase C 
cascade (Fargin et al., 1991). Activation of the 5-HT1A receptor causes neuronal 
hyperpolarisation mediated through G-protein-coupled K
+
 channels.    There is also 
evidence that in the presence of Gi2 and adenylate cyclase type II, 5-HT1A receptors 
stimulate cyclic AMP formation (Albert et al., 1999; Markstein et al., 1999).  
Agonist binding leads to G-protein mediated suppression of cyclic AMP production 
and enhancement of K
+
-channel conductance (Lüscher et al., 1997). 
 
In the raphe nuclei 5-HT1A receptors are somatodendritic and act as autoreceptors 
causing a reduction in 5-HT synthesis, release into post synaptic sites and electrical 
activity (Blier et al., 1998; Richardson-Jones et al., 2010).  It is proposed that 
desensitisation of the 5-HT1A autoreceptors may underlie the ability of chronic, not 
acute, SSRI administration to raise synaptic cleft 5-HT (Invernizzi et al., 1994). In 
suicide victims that suffered from major depression, 5-HT1A autoreceptors were 
increased suggesting decreased 5-HT activity (Stockmeier et al., 1998).  
 




Anxiety and depression are associated with down-regulation of 5-HT1A receptors 
(Gross et al., 2000) and disruption of the 5-HT1A receptor gene increases anxiety-like 
behaviours (Heisler et al., 1998; Parks et al., 1998; Ramboz et al., 1998; Gingrich & 
Hen., 2001; Olivier et al., 2001) with transgenic re-expression of 5-HT1A receptor in 
the hippocampus and amygdala during the early postnatal period being sufficient to 
rescue this behavioural phenotype (Gross et al., 2002).  5-HT1A receptors play a role 
in some of the cognitive disturbances of schizophrenia, specifically attention, in 
response to antipsychotic drugs (Sumiyoshi et al., 2010).  Agonists of this receptor 
induce spontaneous tail flicks in rodents (Bervoets & Millan., 1994, in rat). Motor 
coordination is not altered in 5-HT1A receptor knock-out (KO) mice (Heisler et al., 
1998).   
 
The human 5-HT1B receptor is located on chromosome 6q13, is G-protein coupled 
and is expressed in the CNS concentrated in the basal ganglia, striatum and frontal 
cortex (Hannon & Hoyer et al., 2008).   5-HT1B receptors are expressed both pre and 
postsynaptically and act as autoreceptors in the 5-HT system (Hopwood & 
Stamford., 2001; Threlfell et al., 2010).  The receptor has 386 to 390 amino acids 
and is negatively coupled to cAMP production (Schoeffter & Hoyer., 1989; 
Zgombick & Branchek., 1998).  5-HT1B receptors are involved in aggressive 
behaviour with 5-HT1B receptor KO mice reported to be highly aggressive (Ramboz 
et al., 1996) while 5-HT1B receptor agonists potently suppress aggressive behaviour, 
food intake and sexual behaviour.  An increase in anxiety and locomotion is found 
following activation of the 5-HT1B receptors.   
 
The 5-HT2 receptor family exhibit 46 – 50% sequence homology and preferentially 
couple to Gq/11 increasing inositol phosphates and cytosolic [Ca
2+
] and causing 
stimulation within the brain.  Coupling may also occur through G12/13 to mediate 
long term structural changes in cells.  The 5-HT2A receptor gene is located on human 
chromosome 13q13 to 13q21 and encodes for 471 amino acids in rat, mouse and 
humans.  The 5-HT2A receptor is highly expressed in the cortex, ventral striatum, 




hippocampus, amygdala and basal ganglia and activation of this receptor stimulates 
the secretion of hormones such as ACTH and corticosterone (Van de Kar., 2001). 
The structures where 5-HT2A receptors are expressed modulate anxiety-like 
behaviours (Millan et al., 2003). Global disruption of 5-HT2A receptor signalling in 
mice reduces anxiety-like behaviour with selective restoration of 5-HT2A receptor 
signalling in the cortex normalising behaviour suggesting a specific role for cortical 
5-HT2A receptor function (Weisstaub et al., 2006). Depressive-like or fear-
conditioned behaviour is unaltered in 5-HT2A receptor KO mice (Weisstaub et al., 
2006).  Other psychiatric disorders like anorexia nervosa and bulimia nervosa 
(Nacmias et al., 1999) and bipolar disorder (Bonnier et al., 2002) are associated with 
the 5-HT2A receptor.  5-HT2A receptors KO mice display reduced non rapid eye 
movement sleep expression (Popa et al., 2005).  
 
The 5-HT2B receptor is located on human chromosome 2q36.3 to 37.1 (Le Coniat et 
al., 1996) and encodes a 482 residue protein (Kursar et al., 1994). An alternative 5-
HT2B receptor has been reported (Bonhaus et al., 1995). Expression of this receptor 
is in the periphery (gut, heart, kidney and lung) and in the brain (particularly the 
cerebellum, dorsal hypothalamus and medial amygdala; Bonhaus et al., 1995). 
Activation of 5-HT2B receptors causes anxiolysis and reduces grooming (Kennett et 
al., 1997; Duxon et al., 1997).  
 
1.2 5-HT2C receptor 
 
5-HT2C receptor could be a potentially important therapeutic target for the treatment 
of major health conditions including mood disorders, locomotor dysfunction and 
eating disorders (Gleason et al., 2001; Schuhler et al., 2005; Harada et al., 2008).   
 
 





The 5-HT2C receptor has been mapped to human chromosome Xq 24 and is X-linked 
in both humans and mice. Expression of the 5-HT2C receptor is of moderate density 
throughout the forebrain and hind brain, particularly in the choroid plexus. It is 
widely distributed in neocortical areas, hippocampus, nucleus accumbens, amygdala, 
dorsal striatum and substantia nigra (Lopez-Gimenez et al., 2007). Expression of the 
5-HT2C receptor is under the control of a monophasic diurnal rhythm with mRNA 
levels peaking shortly after the light phase begins (Holmes et al., 1997). Activation 
of 5-HT2C receptors triggers signalling pathways which result in phosphatidylinositol 
(PI) turnover (Conn and Saunders-Bush., 1986; Conn et al., 1986). These receptors 
are able to couple to several G-protein α-subunits, including Gαq, Gαi/o, Gα11, Gα12 
and Gα13 (Bockaert et al., 2006; Cussac et al., 2002; McGrew et al., 2002; Price et 
al., 2001) allowing modulation of function of several intracellular signalling 
pathways. The best characterised signalling pathway modulated by the 5-HT2C 
receptor is the Gαq/11 phospholipase Cβ pathway (Conn et al., 1986; Qiu et al., 2007) 
which stimulates hydrolysis of phosphatidylinositol (4,5)-bis-phosphate (PIP2) 
leading to the accumulation of inositol triphosphate (IP3) that mobilizes intracellular 
Ca
2+















Figure 1.2: 5-HT2C receptor activating the phospholipase Cβ pathway.                               
The 5-HT2C receptor becomes activated upon 5-HT binding and activates intracellular signalling 
pathways through coupling with G-proteins such as Gαq.  G-proteins consist of α, β and γ 
subunits. On activation of the 5-HT2C receptor, Gαq binds to the second intracellular loop of the 
receptor. GDP is phosphorylated into GTP which activates the α subunit and exposes sites of the  
βγ subunit complex. The α subunit then activates phospholipase C which in turn cleaves PI 4,5 
biphosphate (PIP2) into DAG (which is in the membrane) and IP3. IP3 binds to the IP3 receptor on 
the membrane of the endoplasmic reticulum which causes Ca2+ to exit the endoplasmic reticulum 
into the cytosol. The Ca2+ inds to protein kinase C causing activation and translocation to the 
membrane where it binds to DAG. The substrate protein in combination with ATP then forms 
phosphoprotein and generates a response.  
 
Figure 1.2: 5-HT2C receptor activating the phospholipase Cβ pathway 




1.2.2 Regulation of the 5-HT2C receptor 
 
Regulation of 5-HT2C receptor is complex and involves many variables including 5-
HT levels and exposure to stress (Prioleau et al., 2002; Maas et al., 2003; Gurevich 
et al., 2002a; Marion et al., 2004). At least two splice variants of the receptor have 
been found and intron editing occurs. 5-HT2C receptors are also capable of post 
translational modification by A to I RNA editing of the exon, whereby adensosine 
residues can be represented as guanosine. This occurs in the second intracellular loop 
and yields at least eleven variants with differing affinities for binding 5-HT. 
Residues in the second intracellular loop connecting helices three and four in GPCRs 
have been demonstrated to play an important role in G-protein coupling. This editing 
occurs through ADAR 1 and 2 in the brain (Burns et al., 1997; Wang et al., 2000; 
Price et al., 2001; Flomen et al., 2004). Edited forms of the receptor require more 
ligand to be activated as well as coupling less efficiently to G-proteins (Burns et al., 
1997, Fitzgerald et al., 1999, Niswender et al., 1999; Berg et al., 2008) suggesting 
unique signal transduction signatures in vivo dependent on the extent of editing. 
Editing at site C, A and B and/or D reduces 5-HT2C receptor ability to activate 
phsopholipase C (Tohda et al., 2010) but editing levels of 5-HT2C receptor were 
unaltered in mice lacking Gαq (Canal et al., 2009). Isoforms with a fully unedited 
genomic sequence have also been shown to have constitutive activity (Herrick-Davis 
et al., 1999, Niswender et al., 1999).  The extent of editing also varies between 
genetically different mouse strains. The BALB/c strain, for example, encodes 
predominately the nonedited isoform which has the highest constitutive activity and 
agonist affinity compared to C57BL/6 which has ABCD or ABD edited isoforms 
constituting over 60% of its receptors (Englander et al., 2005). Editing levels may 
play a role in the pathophysiology of depression and the action of antidepressants 
with 5-HT2C receptor editing being increased in depression (Dunlop et al., 2006) and 
depressed suicide victims were found to have significantly increased edited 5-HT2C 
receptor isoforms (Niswender et al., 2001; Gurevich et al., 2002b; Schmauss., 2003; 
Dracheva et al., 2008a,b). Stress increases editing to isoforms which have reduced 
ligand sensitivity (Englander et al., 2005; Iwamoto et al., 2005) and early life stress 




may permanently set this shift in editing levels accompanied by an increase in Gαq 
transcripts and protein in cerebral cortex (Bhansali et al., 2007).  Depletion of 5-HT 
decreases the amount of editing and increases the pool of mRNA encoding receptor 
isoforms that have the highest constitutive activity and the highest affinity for 5-HT 
(Gurevich et al., 2002a).   
 
Mice that express either the non-edited (5-HT2CR-INI) or the fully-edited (5-HT2CR-
VGV) form of the 5-HT2C receptor have recently been developed.  No difference in 
signal density was found between 5-HT2CR-INI and 5-HT2CR-VGV mice suggesting 
unaltered levels of Gαq and Gα11 protein (Canal et al., 2009).  However, 5-HT2CR-
VGV mice have reduced ability to activate G-proteins which is masked by an 
increase in 5-HT2C receptor binding sites in these mice (Olaghere da Silva et al., 
2010). The 5-HT2CR-VGV mice have phenotypic characteristics that are similar to 
that of Prader-Willi Syndrome, with decreased somatic growth, neonatal muscular 
dystrophy and reduced food consumption followed by hyperphagia after weaning 
(Morabito et al., 2010). 5-HT2CR-VGV mice have reduced fat mass and lipid 
accumulation in adipose tissue yet are hyperphagic compensated for by increased 
energy expenditure (Kawahara et al., 2008).  5-HT2CR-INI mice have a depressive-
like phenotype while complete editing of the 5-HT2C receptor in 5-HT2CR-VGV 













1.2.3 5-HT2C receptor knock-out mice (5-HT2C receptor KO 
mice) 
 
Mice lacking the 5-HT2C receptor were found to have a lowered seizure threshold 
and a more rapid progression of seizure activity, with 5-HT2C receptor knock-out 
mice (5-HT2C receptor KO mice) suffering from spontaneous seizures from the fifth 
postnatal week, resulting in death in hemizygous mutant male mice, with a 60% 
survival rate by 25 weeks (Tecott et al., 1995).  These mice were created by insertion 
of a nonsense mutation into exon 5 of the cognate gene which placed a stop codon 
within the fifth putative transmembrane segment of the 5-HT2C receptor, eliminating 
the carboxyterminal half of the 5-HT2C receptor protein (Tecott et al., 1995).  The 
mutation was confirmed using immunocytochemical analysis of brain sections and 
whole-cell voltage-clamp recordings in Xenopus oocytes injected with RNA from 
WT or mutant mice (Tecott et al., 1995).  5-HT2C receptor KO mice had age 
dependent susceptibility to sound induced convulsions (AGS) with most KO mice 
displaying AGS by 75 days and complete penetrance by 120 days (Brennan et al., 
1997). 5-HT2C receptor KO mice implicated a role for 5-HT and 5-HT2C receptor in 
the modulation of neuronal network excitability (Applegate & Tecott., 1998; Heisler 
et al., 1998). No alterations were found in 5-HT receptor subtypes (5-HT 1A, 1B/1D, 
1F, 2A, 2B, 4 and 7) in 5-HT2C receptor KO mice (Lopez-Gimenez et al., 2002).   
 
 
1.2.4 5-HT2C receptor and associated behaviours 
 
The 5-HT2C receptor is implicated in the regulation of food intake with non-selective 
agonists, such as mCPP, causing advancement in satiety and reducing food intake 
while specific 5-HT2C receptor antagonists are able to block these anorectic effects 




(Kennett & Curzon., 1988; Clifton et al., 2000; Vivkers et al., 2001; Hewitt et al., 
2002; Schuhler et al., 2005).  5-HT2C receptor KO mice were found to be 
hyperphagic and both plasma glucose levels and insulin were similar in KO 
compared to WTs when on a standard paired feeding analysis (Tecott et al., 1995).  
Due to larger white fat stores 5-HT2C receptor KO mice develop obesity in later life 
but no alteration in the level of brown adipose tissue was found compared to WT. 
This hyperphagia and obesity is due to behavioural abnormalities as opposed to 
metabolic defects (Tecott et al., 1995).  It has been shown recently as early as 10 
days (before obesity develops) 5-HT2C receptor KO pups are hyperphagic, 
hypometabolic and hypoactive but more competent at thermoregulation, choosing a 
warmer ambient temperature to defend core body temperature instead of expending 
metabolic energy (Akana et al., 2008). In a recent paper it was suggested that mis-
timed and higher leptin levels during early life in 5-HT2C receptor KO mice 
(increased leptin levels found at 16, 18 and 20 days old) could programme a change 
in both feeding and stress neurocircuits (Akana et al., 2008).   
 
Table 1.1 Commonly used ligands affecting the 5-HT2C receptor 
Ligand Behavioural effect Receptors through which 
effect achieved 
mCPP - Reduced food intake 
- Reduced locomotion 
- Increased anxiety 
5-HT receptors  
including 5-HT1A/2B/2C 
receptors 
mCPP - Increased locomotion in 5-
HT2C receptor KO mice 
5-HT receptors  
excluding 5-HT2C receptor 
RO 60-0175 - No effect on anxiety 5-HT2 receptor subtypes 
RO 60-0175 - Decreased locomotion in 
5-HT2C receptor KO mice 
5-HT2 receptor subtypes  
excluding 5-HT2C receptor 
S32006 - Anxiolytic 
- Antidepressant properties 
5-HT2C receptor  
 
Agomelatine - Antidepressant 
- Improves sleep 
disturbances 
5-HT2C receptor and 
 melatonin receptor 
WAY163909 - Antidepressant 5-HT2C receptor  
 
 
The 5-HT2C receptor is implicated in mood and has specific effects on anxiety, with 
agonists such as mCPP having an anxiogenic and hypolocomotor effect in novel 
environments while antagonists act as anxiolytics (Jenck et al., 1998; Kennett et al., 




1989; Lucki et al., 1989; Fone et al., 1996; Kennett et al., 1992; Harada et al., 2008). 
5-HT2C receptor KO mice had an anxiolytic phenotype (Heisler et al., 2007b) but 
more recent investigation showed no difference in anxiety-like or depressive-like 
behaviours (Hill et al., 2010).  Alterations in 5-HT levels also play a role in mood 
with selective serotonin reuptake inhibitors (SSRIs) used as a treatment for major 
depression (Deshauer et al., 2008) and as effective in the treatment of panic disorder 
as tricyclic (TCA) antidepressants. (Bell and Nutt., 1998). 
 
The 5-HT2C receptor plays a role in the production of corticosterone through the 
regulation of CRF in hypothalamic regions (Heisler et al., 2007a), therefore 
influencing the HPA axis. 5-HT release and activation of 5-HT2 receptors, 
particularly within the amygdaloid complex, have been associated with generating 
anxiogenic behaviours and emotional stress (Chaouloff et al., 2000; Kawahara et al., 
1993; Stein et al., 2000) as well as facilitating conditioned fear in rodents (Graeff et 
al., 1997; Mora et al., 1997) and learned fear in humans (Graeff et al., 1996).  The 5-
HT2C receptor has been shown to have an anxiolytic effect in conditioned anxiety 
(Davis et al., 1986) and activation within the basolateral amygdala (BLA) potentiates 
innate fear responses (Campbell and Merchant., 2003). Another point of interest is 
that the 5-HT2C receptor is expressed on both the projection neurones and 
interneurons in the BLA (Stein et al., 2000) which could have opposing actions on 
GABA release (Rainnie et al., 1999; Stutzmann et al., 1999). 
 
In addition to the 5-HT2C receptor being involved in anxiety-like behaviour 
regulation, it is also associated with depressive-like behaviour however the literature 
on the effects of agonists and antagonists is conflicting. Antagonists, in addition to 
being anxiolytic, have antidepressive properties (Millan et al., 2006) such as the 
potent 5-HT2C receptor antagonist, S32006 (Dekeyne et al., 2008).  DBA/2N mice 
have lower brain 5-HT levels and are found to be insensitive to citalopram, a SSRI, 
but when a 5-HT2C receptor antagonist is administered in combination with 
citalopram this restores its antidepressant effect (Calcagno et al, 2009).  Other 5-




HT2C receptor antagonists augment the actions of SSRIs (Cremer et al., 2004).  
Agomelatine, a 5-HT2C receptor antagonist and melatonin receptor agonist (Auinot et 
al., 2003; Chagraoui et al., 2003; Millan et al., 2003), is effective in the treatment of 
major depressive disorder as well as SAD disorder (Millan et al., 2005; Kennedy & 
Emsley., 2006; Zupancic & Guilleminault., 2006; Pjerk et al 2006; Olié & Casper., 
2007). The antidepressant effect of agomelatine is in part due to its actions on the 
melatonin receptors, and has been found to improve sleep disturbances (Thase 2000; 
Pandi-Perumal et al., 2009) which often accompany chronic mild stress and 
depression (Gorka et al., 1996). There is evidence that agonists of the 5-HT2C 
receptor may also be efficacious antidepressants (Dunlop et al., 2006). As mentioned 
previously, there is a role for editing in the pathophysiology of depression and action 
of antidepressants as depressed suicide victims show increased editing of the 5-HT2C 
receptor (Gurevich et al., 2002b).  
 
Agonists that act on the 5-HT2C receptor have been shown to cause hypolocomotion 
which can be blocked by antagonist administration (Gleason & Shannon., 1998; 
Stiedl et al., 2007). Administration of the mixed 5-HT2C receptor agonist mCPP 
produces dose-dependent hypolocomotion (Fone et al., 1998, Gleason et al., 2001; 
Kennett & Curzon., 1988). 5-HT2C receptor KO mice are hyperactive (Heisler & 
Tecott., 2000; Dalton et al., 2004) but on mCPP administration elicits hyperactivity 
(Heisler & Tecott., 2000; Dalton et al., 2004) which could be due to activation of 5-
HT1B and 5-HT2A receptors. 
 
1.2.5 5-HT2C receptor ligands 
In rodent studies, mCPP induces anxiety (Cornelio et al., 2007, Fone et al., 1996, 
Hackler et al., 2007, Kennett et al., 1992), reduces food intake (Hewitt et al., 2002, 
Kennett et al., 1988, Samanin et al., 1979) and inhibits locomotion (Lucki et al., 
1989; Fone et al., 1998; Gleason et al., 2001; Stiedle et al., 2007).  In 5-HT2C 
receptor KO mice mCPP actually elicits hyperactivity (Heisler & Tecott., 2000; 
Dalton et al., 2004). The actions of mCPP are a combined result of its activation of 




several serotonin receptor subtypes, including the 5-HT2B receptor and 5-HT2A 
receptor (Dalton et al., 2004, Lee et al., 2004, Nonogaki et al., 2003).   
 
Recently, more selective 5-HT2C receptor agonists, such as RO 60-0175, have also 
been shown to have a degree of action on other 5-HT2 receptor subtypes 
(Damjanoska et al., 2003, Higgins et al., 2001, Martin et al., 1998, Porter et al., 
1999). A sedative-like effect of RO 60-0175, with no effect on anxiety, has been 
reported (Kennett et al 2000). RO 60-0175 produced hypolocomotion in the 5-HT2C 
receptor KO model (Fletcher et al., 2009). 
 
 
1.3 5-HT system and 5-HT2C receptor regulation of the DA 
system 
 
It is believed that 5-HT exerts a tonic and phasic inhibitory control over both the 
mesolimbic and nigrostriatal DA systems (see Section 1.4.1). The substantia nigra 
(SN) receives dense serotonergic input and 5-HT2C receptors are expressed in the cell 
bodies of GABA-containing neurones in both the SN pars reticulate and the VTA 
(Moga & Moore., 1997; Moyer & Kennaway., 1999; Di Matteo et al., 2001; Bubar 
& Cunningham., 2007).  This positions the 5-HT2C receptor to be a strong candidate 
through which 5-HT is able to regulate the DA system. 5-HT2C receptor antagonists 
increase DA release in the nucleus accumbens and prefrontal cortex by increasing 
the firing rate and bursting activity of DA-containing neurons in the VTA (Di Matteo 
et al 2001; McMahon et al 2001; Blackburn et al., 2002; Di Matteo et al 2002; 
Higgins & Fletcher 2003; De Deurwaerdere et al 2004). Local administration of 
SB206553 (5-HT2C receptor inverse agonist when administered to specific sites) into 
the striatum increased DA efflux in a dose-dependent manner (Alex et al., 2005). 
This suggests 5-HT2C receptors in the dorsal striatum play an important role in the 
regulation of the nigrostriatal system. Under basal conditions 5-HT2C receptor KO 
mice show no difference in DA levels in the nucleus accumbens or dorsal striatum 




(Rocha et al., 2002).  However, more recently, increased basal DA levels were 
shown in the nucleus accumbens of 5-HT2C receptor KO mice (Abdallah et al., 
2009).  5-HT2C receptor agonists suppress both dopamine (DA) and noradrenaline 
(NA) pathways in the frontal cortex (Millan et al., 1998; Gobert et al., 2000).  
 
Agomelatine enhances extracellular levels of DA and NA in the frontal cortex which 
reflects its antagonist properties at the 5-HT2C receptor, reducing inhibition to 
ascending dopaminergic and noradrenergic pathways (Millan et al., 2000; 2003; De 
Deurwaerdére et al., 2004; Millan., 2005). 
 
1.4 The Dopamine System 
1.4.1 DA synthesis and projection pathways 
In 1957, Carlsson showed that dopamine (DA) was a neurotransmitter in the brain 
(Carlsson., 1993) and not just a precursor for noradrenaline (NA).  DA is a 
catecholamine neurotransmitter which plays many roles in behaviour such as reward, 
motivation and movement.  It is synthesised by a two-step pathway with the first step 
being hydroxylation of L-tyrosine to L-DOPA by the enzyme tyrosine hydroxylase 
(TH). Tyrosine hydroxylase is the rate limiting enzyme in DA production and is 
present in DA synthesising cell groups which are situated within these three areas 
(i.e. VTA, SNc and retrorubral fields; O‟Byrne et al 2000). L-DOPA is 
decarboxylated by dopa decarboxylase into DA (see Figure 1.3). DA receptors are 
also present on these synthesising cells which means that both pathways have 
autoreceptors which are thought to be the D2 receptor and possibly the D3 receptor 
to a lesser extent. 
 
 






There are two main DA projection pathways; the nigrostriatal system which projects 
from the substantia nigra pars compacta (SNc) to the STR and is involved in motor 
functions and the mesolimbic system which projects from both the retrorubral fields 
and the ventral tegmental area (VTA) to cortical and limbic structures, in particular 




Figure 1.3: DA production pathway            
DA is produced by a two step pathway, in which tyrosine hydroxylase is the rate 
limiting step (taken from internet)  







Figure 1.4: Catecholamine projection pathways                         
The two main DA projections pathways (a), the nigrostriatal (represented in blue) and the 
mesocorticolimbic (represented in red) project from the VTA and SN. The NA projection 











1.4.2 Breakdown of DA 
 
There are two degradation pathways for DA that both result in the production of 
homovanillic acid (HVA).  The action of DA is either terminated by reuptake by the 
DA transporter (DAT1) and broken down by monamine oxidase (MAO) into 3,4-
Dihydroxyphenyl-acetic acid (DOPAC) which is then converted to HVA by 
catechol-O-methyl-transferase (COMT; Cooper et al., 1991). Alternatively in regions 
where the DAT1 is sparse, the noradrenaline transporter (NAT) reuptakes DA, which 
is then broken down by COMT to 3-metoxytryptamine (3-MT). HVA is produced 
from the breakdown of 3-MT by MAO. 
 
DA is also the precursor for noradrenaline (NA) which is synthesised from DA by 
dopamine β-hydroxylase which requires ascorbate as a cofactor (see Figure 1.5).  
The NA system originates in the locus coeruleus and the lateral tegmental field and 
projects to limbic regions, cerebral cortex and spinal cord (see Figure 1.4b). NA is 
involved in depression, influences the reward system and is involved in attention 
deficit/ hyperactivity disorder (Perona et al., 2008; Dell‟Osso et al., 2010; Lim et al., 
2010).  In addition to its role in regulation of DA release, the 5-HT2C receptor 
agonist, RO 60-0175, suppresses frontal cortex NA levels in rats while the 5-HT2C 
receptor antagonist, SB-242084, increases NA levels. (Millan et al., 1998). 
 
5-HT and noradrenaline reuptake inhibitors (SNRIs) are used in the treatment of 
some anxiety disorders and so increased concentration of NA at the synapse is 
predicted to have a beneficial effect on mood, including recovery of motivation 











1.4.3 Action of DA & Dopamine system receptor families 
At present there are two DA receptor families; the D1-like family includes the 
dopamine 1 and 5 receptors (D1; D5) which have similar pharmacological profiles 
and are coupled to adenylate cyclase through G-proteins.  These receptors are 
intronless, have short third intracytosolic loops and short C-terminal tails.  The D2-
like family consists of the dopamine 2, 3 and 4 receptors (D2, D3, D4), each of 
which has unique pharmacological features.  They are coupled to second messenger 
systems though inhibitory G-proteins.  Due to the fact that they contain introns there 
 
 
Figure 1.5: DA breakdown                               
DA can be broken down by one of two pathways, which both result in the 
production of HVA (taken from internet) 




is the possibility of isoforms due to alternative splicing of their mRNAs and Drd2 
and D3 receptor isoforms have been identified.  
 
D1 and D2 receptors are homogeneously distributed in the dorsal striatum (STR), 
hippocampus and nucleus accumbens and are thought to play a role in motor and 
limbic functions (Yung and Bolam., 2000). D1 and D2 receptors are present on 
different populations of spiny projection neurones in the dorsal CPu.  The direct 
pathway projects from the CPu to the substantia nigra and entopeduncular nucleus 
(the output nuclei of the basal ganglia) and the neurons that give rise to these 
projections have high levels of D1 receptor and the neuropeptides substance P and 
dynorphin.  The indirect pathway projects from the CPu to the globus pallidus and 
the basal ganglia output nuclei indirectly and the neurons that give rise to this 
projection express high levels of D2 receptor and enkephalin (Drago et al 1994).  D2 
KO mice have reduced wakefulness (Qu et al., 2010) and reduced spontaneous 
movements in behavioural tests (Baik et al., 1995). The D3 receptor is expressed in 
the striatum and hippocampus but high expression is only found in the nucleus 
accumbens which suggests that it plays a role in limbic function (Suzuki et al., 
1998), the nucleus accumbens shell responds sensitively to drugs of abuse 
suggesting a role for D3 receptors in addiction (Filip & papla., 2001).   
 
 
1.4.4 Actions on behaviour with links to the 5-HT2C receptor 
 
Dopamine (DA) is of vital importance in many core behaviours including pleasure 
and movement.  Dysfunction of this system can have devastating consequences as 
can be seen in Parkinson‟s disease where DA is depleted by a gradual degeneration 
of the substantia nigra pars compacta cells projecting to the striatum and results in a 




loss of movement (Bossy-Wetzel et al., 2004).  Depletion of DA signalling in the 
forebrain shown to cause a reduction in locomotion (Sedelis et al., 2001). 
 
The DA system is implicated in mood disorders with DA system over-activity 
associated with schizophrenia and levels of HVA are increased in the plasma of 
schizophrenic patients (Arrúe et al., 2010). DA signalling is known to play a 
significant role in the reward mechanism that underlies some behavioural symptoms 
of depression when dysregulated (Naranjo et al., 2001). 5-HT and NA reuptake 
inhibitors (SNRIs) are used in the treatment of some anxiety disorders (Dell‟Ossoet 
al., 2010).  
 
As well as being involved in some symptoms of depression, DA also plays a role in 
addiction, with DA release in the NA shell mediating motivation and reward 
(Volkow et al., 2004).  5-HT2C receptor is implicated in the serotonergic suppression 
of DA-mediated behavioural responses to cocaine (Rocha et al., 2002). The 
reinforcing efficacy of cocaine is increased in the absence of 5-HT2C receptor as self-
administration is elevated in KO mice (Heisler & Tecott., 2000). A possible 
therapeutic use of the antidepressant, venlaxafine, in cocaine abuse has been 
suggested due to the ability of this antidepressant combined with a D3 receptor 
agonist to mimic the effects of cocaine in rats (Filip & Papla., 2001).  There is also a 
role for the interaction of 5-HT2C receptor and DA system in alcohol addiction 
(Pandey & Pandey., 1996; Thanos et al., 2005). 
 
Both the 5-HT and dopamine systems are proposed to be involved in obsessive 
compulsive disorder (OCD).  Reduced availability is found in the dopamine 
transporter in the striatum and 5-HT transporter in midbrain, brainstem and 
thalamic/hypothalamic in OCD patients (Hesse et al., 2005). It was found that 
selective serotonin reuptake inhibitors (SSRIs) alleviated symptoms of OCD in some 
cases and a recent study showed that treatment with SSRIs normalized the DA 




function in the basal ganglia which correlated to a clinical improvement in 
compulsive symptoms (Kim et al 2007).  5-HT2C receptor KO mice have been 
suggested to be a potential model for obsessive compulsive disorder.  In a recent 
study the KO were found to have increased clay chewing and head dipping 
behaviour (Chou-Green et al., 2003).  They also chewed plastic mesh screens in a 
„neat‟ manner.   
 
1.5 Circadian Biology 
Circadian rhythms allow organisms to adapt to their environment, coordinate vital 
activities, such as feeding behaviour and the sleep-wake cycle, and coordinate 
physiological and biochemical mechanisms.  These rhythms are controlled by an 
internal molecular clock which allows them to be maintained in the absence of 
external cues.  In mammals this master clock is situated in the suprachiasmatic 
nucleus (SCN) of the hypothalamus (Ralph et al., 1990) and synchronises the body‟s 
physiological activities.  The master clock can be adjusted by internal stimuli, such 
as information regarding physiological and behavioural status, and by external 
stimuli such as light.  Zeitgeber is the term given to an environmental signal that the 
clock can entrain to.  The timing of peripheral pacemakers in other physiological 
systems is coordinated by the SCN (Guo et al., 2006; Kohsaka & Bass., 2006). 
 
1.5.1 Light entrainable oscillator 
 
The LEO is located within the SCN and allows the endogenously generated circadian 
rhythm to maintain synchronisation with the exogenous light dark cycle.  The 
retinohypothalamic tract (RHT), which utilises glutamate, enables photic stimuli to 
be relayed to the SCN.  Light signals present during the early subjective night delay 
the clock whereas signals during the late subjective night produce a phase advance in 
the circadian rhythm. 





The molecular mechanism underlying the master/circadian clock involves rhythmic 
transcription of clock genes.  Per1 and per2 are rhythmically expressed in the SCN 
with levels peaking around midday.  If light stimulation occurs during the night the 
mRNA levels of per1 and per2  rise after fifteen minutes, peak one to two hours later 
and return to baseline within three hours (per2 slightly lagging behind per1).  They 
are able to mediate the effect of light on the state of the clock and it is indicated that 
these genes are necessary for photic entainment (Albrecht et al., 1997; Miyake et al., 
2000; Asai et al., 2001; Yan & Silver., 2002). 
 
1.5.2 Serotonin system and Circadian Rhythms 
Several neurotransmitters have the ability to phase advance the master clock via non-
photic input pathways.  Treatment with these neurotransmitters during the day 
decreases the midday rise of  per1 and/or per2.  It is already established that 5-HT is 
one of the neurotransmitters with the ability to phase-advance the LEO via non-
photic input pathways (Prosser et al., 1990; Kohler et al., 1999; Kalkowski & 
Wollnik., 1999), with various 5-HT receptors suggested to be involved (Kennaway et 
al., 1996; Gannon et al., 2009).   
 
5-HT2C receptor expression shows a monophasic diurnal rhythm (Holmes et 
al.,1997).  The receptor is associated with sleep regulation, being implicated in both 
primary and secondary sleep disorders (Teegarden et al., 2008; Wafford & Ebert 
2008) and 5-HT2C receptor KO mice having disrupted sleep-wake periods and longer 
periods of wakefulness (Frank et al., 2002). Blockade of the 5-HT2C receptor reduces 
REM sleep time and produces fewer nonREM – REM sleep transitions (Sharpley et 
al., 1994; Benington & Heller., 1995; Frank et al., 2002), while agomelatine, a 5-
HT2C receptor antagonist and melatonin agonist, improves sleep disturbances and is a 
potential treatment of seasonal affective disorder (SAD; Millan et al., 2005; Pjerk et 
al., 2006; Descamps et al., 2009; Pandi-Perumal et al., 2009). As previously 




mentioned the 5-HT2C receptor is involved in depression and the internal clock is 
profoundly disturbed by depression (Mendlewicz., 2009).  
 
One potential mechanism through which the 5-HT2C receptor might influence the 
circadian control of sleep is via regulation of the main circadian oscillator; the light 
entrainable oscillator (LEO) located in the suprachiasmatic nucleus (SCN) of the 
hypothalamus (Ralph et al., 1990). This region receives a dense serotonergic input 
from the raphe nucleus and 5-HT2C receptor is present in the outer layer which puts it 
in a position to potentially influence circadian entrainment (Moyer & Kennaway; 
1999; Varcoe & Kennaway., 2008).  As previously mentioned two of the clock genes 
expressed in the SCN are per1 and per2 which are essential for rhythm responses to 
external stimuli such as light (Albrecht et al., 2001; Bae et al., 2001).  The 
expression of both per1 and per2 is induced by a light pulse given in the dark phase 
(Albrecht et al., 1997; Miyake et al., 2000; Yan & Silver., 2002).  Interestingly, 
systemic administration of a 5-HT2C receptor agonist in the first half of the dark 
phase also induced per1 and per2 expression (Kennaway & Moyer., 1998; 
Kennaway et al., 2001; Varcoe et al., 2003). Activation of 5-HT2C receptors in a 
denervated SCN in culture induced the expression of per1 indicating a post-synaptic 
mode of function (Varcoe & Kennaway., 2008). 
 
 
1.5.3 Food Entrainable Oscillator 
A second oscillator has been identified that entrains to food availability termed the 
food entrainable oscillator (FEO) of which the location (periphery or the CNS) is 
currently unknown.  This was discovered as when the SCN is not functioning, either 
through a lesion or mutation such as the VPR2 KO mouse, food anticipatory running 
behaviour is seen when animals are fed at one time point each day.  When food is 
presented outside the normal activity period the circadian rhythm regulated by the 
LEO and that of the FEO are dissociated.  This results in two distinct behavioural 
components which can be monitored, one is the normal nocturnal activity regulated 




by the master clock and entrained by the LEO and the other is food anticipatory 
running behaviour regulated by the FEO. 
 
A body of literature documents the involvement of the 5-HT2C receptor in regulation 
of food intake, with agonists being powerful appetite suppressants and some forms 
of obesity possibly associated with lowered 5-HT2C receptor levels (Schuhler et al., 
2005; Vickers et al., 2001). As food intake is influenced by the 5-HT2C receptor and 
due to the 5-HT2C receptor being expressed in a circadian manner (Holmes et al., 
1997) it is possible that the 5-HT2C receptor could influence the circadian eating 





















Aims of Thesis 
The main aims of this body of work were to: 
1. Establish the levels of over- or under-expression of the 5-HT2C receptor in the 
mouse lines and determine if a behavioural phenotype resulted. 
2. Examine if there were compensatory alterations within the 5-HT system itself 
or in catecholamine levels in response to differing 5-HT2C receptor levels 
3. Determine if the 5-HT2C receptor may play a role in the regulation of either 
the food entrainable oscillator or the light entrainable oscillator using the 5-
































































Unless otherwise stated, suppliers are located in the United Kingdom and all 
chemicals and reagents were purchased from Sigma-Aldrich Company Ltd., Poole, 
Dorset.  
 
2.1.1 General Chemicals 
Amersham Biosciences, Chalfont, Buckinghamshire:             
NICK Sephadex G-50 DNA column
®
 




BDH-Merck, Poole, Dorset:                       
Formaldehyde, Glacial Acetic Acid 
Bio-Rad Laboratories:                     
Bio-Rad DC Protein Assay Reagent A, Bio-Rad DC Protein Assay Reagent B, Bovine 
Serum Albumin: Bio-Rad Protein Assay Standard II (1.48mg/ml) 
Biowhittaker Molecular Applications, Wokingham, Surrey:           
SeaKem
®
 LE Agarose 
Bright Instruments Co Ltd., Huntingdon, Cambridgeshire:                          
Cryo-m-bed Embedding Compound 
Decon Laboratories Limited, Sussex:                        
Decon
®
 90  
Fisher Scientific, Loughborough, Leicester:                               
Chromacol Vials (Clear screw vial, 9mm cap size), Duolite Mixed Resin, 
Hydrochloric Acid, Pre-cut silicone/PTFE caps 9mm, Sodium Sulfate (NaSO4 
Anhydrous)  
 




Fluka Chemicals Ltd., Gillingham, Dorset:              
Acetic Anhydride, Triathanolamine 
Greiner Bio-one:                 
CELLSTAR
®
 96 well plate (flat bottom, with lid, sterile) 
Invitrogen, Paisley, Renfrewshire:                    
ATP, CTP, Custom primers for genotyping, 1kb DNA ladder, DNase 1 amplification 
grade, dNTP mix,  GTP, Low Melting Point Agarose, Random primers, RNase 
OUT, Superscript III reverse transcriptase, TRIzol
®
, Yeast tRNA 




Merck Biosciences, Nottingham:                      
Dithiothreitol (DTT), LB broth 
Millipore Corporation:                                             
Nitrocellulose filter (0.22µm) 
Promega Ltd., Southampton, Hampshire:              
Buffer H, dATP, dCTP, dGTP, DNase 1 (RNase free), dTTP, HB101, Nucleus-free 
H2O, Nucleotides, Restriction Enzymes (BamHI, EcoRI, HindIII, NcoI), RNA 




 Hot Start 
Polymerase, Transcription Optomised Buffer (5x), Vectors (PGem-Teasy)  
Qiagen Ltd., Crawley, West Sussex:                       
HotStarTaq DNA Polymerase, QIAprep
®
 Spin Miniprep Kit, QIAquick Gel 
Extraction Kit, QIAquick PCR Purification Kit, RNeasy
®
 Mini Kit 
Roche Diagnostics Ltd., Lewes, East Sussex:                   








Sigma-Aldrich Company Ltd., Poole, Dorset:             
Costar SPIN-X
®
 centrifuge tube filters (cellulose acetate membrane, pore size 22µm 
non-sterile), Kodak Biomax MR film 
Viagen Biotech Ltd., Los Angeles, California, USA:     
DirectPCR Lysis Reagent (Ear) 
VWR International, Lutterworth, Leicester:                 
Acetone, Ethanol, NaH2PO4, Na2HPO4, Paraformaldehyde, SuperFrost Plus Slides 
Whatman
®
 International Ltd., Maidstone, Kent:                     
Whatman 3mm Chromatography Paper, Whatman Filter Paper 
Zinsser Analytic, Maidenhead, Berkshire:                
Aquasafe 300 Plus Scintillant 
          
2.1.2  Radioisotopes 
Amersham Biosciences, Chalfont, Buckinghamshire:              
[N6-methyl-3H] Mesulergine (TRK 845), 
35
S-UTP (30 TBq/mmol; 1.48 MBq/ µl) 
 
2.1.3 Animals 
Special Diet Services (SDS) Witham, Essex:                
Rat and Mouse No.3 Breeding (RM3(E)) Chow (55.7% carbohydrate, 22.4% protein, 
4.3% oil) 
 
2.1.4 Injected Ligands 
Sigma-Aldrich Company Ltd., Poole, Dorset:           
mCPP (1-(m-chlorophenyl)-piperazine hydrochloride), SB 242084 dihydrochloride 
 




Tocris Bioscience:                      
RO 60-0175 fumarate, SB 206553 hydrochloride  
 
2.1.5 Equipment 
Amersham Biosciences, Chalfont, Buckinghamshire:             
GeneQuant RNA/DNA Calculator, Hypercassette
™
 
Beckman Coulter Ltd., High Wycombe, Buckinghamshire:                
Beckman Centrifuge Tubes, Beckman Optima
™
 TLX Ultracentrifuge, TLA 100.3 
rotor 
Bio-Tek Instruments Inc., Winooski, Vermont, USA:               
EL 312e Bio-Kinetics Microplate Reader 
Bio-Rad:                            
Bio-Rad Power Pac 200, Bio Rad Sub-Cell Model 96 
Carl Zeiss, Welwyn Garden City, Hertfordshire:                        
Zeiss Stemi 100 Dissection Microscope 
Dage Inc., Michigan City, Indiana, USA:               
Dage MTI CCD72S Imaging Camera 
Decon Ultrasenics Ltd, England:                    
Decon F5 Minor Sonicator 
Denver Instruments:                       
pH meter 
Eppendorf Ltd., Histon, Cambridge:                 
Centrifuge 5415R 
Fuji Photo Film Company Ltd., Tokyo, Japan:         
Phosphoimager FLA-2000, Phosphoimager screens 
 




Heraeus Sepatech GmBH, Osterode, Germany:      
Megafuge 3.0R 
Hooke & Tucker Instruments, Croydon, Surrey:               
Rotamixer 
Hybaid Ltd., Basingstoke, Hampshire:                                
Hybaid Omni Slide Wash Module 
Ika, Labortechnik, Staufen, Germany:              
Ultra-Turrax T8 Auto-Homogeniser 
Interfocus Imaging Ltd., Linton, Cambridgeshire:        
Northern Light Illuminator 
Jencons-PLS, East Grinstead, West Sussex:          
Techne Dri-Block DB3, Techne Genius Thermal Cycler, Techne Hybridiser HB-1D, 
Techne Hybridisation Bottles 
Konica Minolta, Milton Keynes, Buckinghamshire:          
Konica SRX-101 X-ray Developer 
Leica Microsystems Ltd., Milton Keynes, Buckinghamshire:          
Leica Cryostat CM1900 
Mettler-Toledo, Leicester:             
Mettler HK60 Semi-Microbalance 
Nikon, Japan:                 
OPTIPHOT-2 microscope 
Packard Instruments, Berks, UK:                      








PerkinElmer, LAS (UK) Ltd., Beaconsfield, Buckinghamshire:         
Wallac 1450 Microbeta Plus Scintillation Counter, Wallac Victor2 1420 MultiLabel 
Counter 
Plastics Company, Edinburgh:                
Elevated Plus Maze, Open Field 
Schimadzu UK Ltd., Milton Keynes, Buckinghamshire:     
Shimadzu UV-160A Spectrophotometer 
Skatron Instruments, Lier, Norway:             
Combi Cell Harvester 
Spectronics Corporation, Westbury, New York, USA:          
Spectrolinker XL-1500 UV Crosslinker 
Starstedt, Numbrecht, Germany:                            
Microvette Tubes, EDTA coated 
Technical & Scientific Equipment, Germany:               
Food & Drink Cages 
Techniplast UK Ltd., Kettering, Northamptonshire:         
Mouse Wheel Running Cages 
Ugo Basile, Comerio, Italy:                        
Passive Avoidance Apparatus, Rotorod 
UVItec Ltd., Cambridge:              
UVIpro Gel Documentation System 
Waters Corpopration:               
Waters 2475 Multi λ Fluorescence Detector Waters 2695 seperations module, 
Waters Sunfire 3.5µm C18 column 
 
 




Weiss-Gallenkamp, Loughbourgh, Leicestershire:             
Gallenkamp Fan Incubators 
 
2.1.6 Software 






InterFocus Imaging Ltd., Linton, Cambridgeshire:                     
MCID Analysis 
Raytest Scientific Ltd., Sheffield:               
Aida 2.0 Auto Image Data Analyser, Fujifilm Fluorescent Image Analyser FLA-200 
Technical & Scientific Equipment, Germany:               
Drink 
The Mathworks Ltd., Cambridge:                   
MATLAB 6.5 
UVItec Ltd., Cambridge:                                  
UVIpro Acquisition Software 
 
2.1.7 Buffers and Solutions 
Box Buffer (100ml): 20ml 20x SSC buffer, 50ml deionised formamide and 30ml 
DEPC-H2O. 
Citrate Buffer: 0.1M sodium acetate (anhydrous), 0.1M sodium acetate tri-hydrate, 
0.1M citric acid, 0.4mM octane sulphonic acid in HPLC grade water pH3.5. Stored 
at 4
o
C and filtered through a 0.22µm nitrocellulose filter prior to use. 
 
 




Deionised Formamimde: 150ml formamide mixed with 15g mixed bed ion-
exchange resin (Duolite) for 2 to 3 hrs, filtered twice through Whatman filer paper 
and stored protected from light using sterile glassware. 
DEPC-H2O: dH2O mixed with diethyl pyrocarbonate (DEPC; 1 drop/ 100ml), 
shaken , left for 30 mins, shaken again, and left for 1 hr prior to autoclaving. 




1 kb DNA ladder loading mixture: 20µl ladder, 20µl loading dye and 160µl 
nucleus free water 
250mM EDTA (pH8.0; 100ml): 80ml dH2O was added to 9.3g Na2EDTA.2H2O. pH 
adjusted with NaOH and volume adjusted to 100ml.  Autoclaved before use. 
Ethanol in Ammonium Acetate:               
50%: 11.55g Ammonium Acetate dissolved in 250ml ethanol, made up to 500ml 
with dH2O. 
70%: 11.55g Ammonium Acetate dissolved in 350ml ethanol, made up to 500ml 
with dH2O. 
90%: 11.55g Ammonium Acetate dissolved in 450ml ethanol, made up to 500ml 
with dH2O. 
2x Hybridisation Buffer: 1.2M NaCl, 20mM Tris-HCl (pH7.5), 2x Denhardt‟s 
solution, 2mM EDTA (pH8.0), 0.2mg salmon sperm DNA (11mg/ml), 0.2mg yeast 





Loading buffer:  2g Ficoll
®
 400, 100mg SDS, 25mg bromophenol blue, made up to 
10mls with 0.1M EDTA pH8. 
4% Paraformaldehyde in 0.1M Phosphate Buffer (pH7.5): 20mM NaH2PO4, 
80mM Na2HPO4 in 1L DEPC-H2O, heated to 80
o
C prior to addition of 40g 




paraformaldehyde using sterile glassware.  Stirred for 1 hr to dissolve and stored at 
4
oC. 
1% PEI: 1ml polyethylenimine per 100mls water 
10 x Phosphate Buffered Saline (PBS): 80g NaCl, 29g Na2HPO4.2H2O, 2g 
KH2PO4, 2g KCl dissolved in 1L DEPC-H2O. Autoclaved prior to use. 
2 x Pre-Hybridisation Buffer: 1.2M NaCl, 20mM Tris-HCl (pH7.5), 2x Denhardt‟s 
solution, 2mM EDTA (pH8.0), 10mg salmon sperm DNA (11mg/ml) and 0.2mg 
yeast tRNA (50mg/ml) in DEPC-H2O, stored at -20
o
C. 
Radiolabelled buffer: 50mM Tris-HCl, 10mM MgCl2, 1mM EDTA and 50nM 
spiperone at pH7.4 with the addition of ~70,000 counts of 
3
H-mesulergine. 
RNase A Solution:  25mg RNase A (Roche) dissolved in 1mM Tris, 15mM NaCl 
made up to 2.5ml with dH2O (10mg/ml). Heated to 100
o
C for 15 mins then cooled to 
room temperature and stored at -20
o
C.  RNase A (10mg/ml) added to buffer 
(3µl/ml). 
RNase Buffer: 0.5M NaCl, 10mM Tris, 1mM EDTA in dH2O. 
Room temperature buffer: 50mM Tris-HCl, 10mM MgCl2, 1mM EDTA and 50nM 
spiperone at pH7.4 
20 x SSC (Saline Sodium Citrate Buffer; pH7.0): UltraPure™ Gibco, Invitrogen  
5M NaCl: 29.55g added to 100ml DEPC-H2O. 
0.32M sucrose-50mM Tris-HCl (pH7.4): 0.1% ascorbate containing protease 
inhibitors 
10x TBE Buffer: 0.9M Tris base, 0.9M Boric acid, 20mM EDTA (pH8.0) in dH2O. 
Autoclaved before use. 
TE Buffer (pH8.0): 10mM Tris-HCl (pH8.0), 1mM EDTA (pH8.0) in DEPC-H2O. 
Autoclaved before use. 




0.1M Triethanolamine (pH8.0):  13.3ml Triethanolamine (Fluka) dissolved in 
800ml DEPC-H2O, adjust pH to 8.0 with HCl, adjust volume to 1L, using sterile 
glassware. 
50mM Tris-HCl (pH7.4): 0.1% ascorbate containing protease inhibitors 
5-HT Buffer: 50mM Tris-HCl, 10mM MgCl2, 1mM EDTA, 50nM spiperone and 






















Mice were maintained under conditions of controlled lighting (lights on 0700 -1900 
h) and temperature (19-21
o
C) and allowed ad libitum access to water and food (rat 
and mouse No 3, Special Diet Services, Witham, Essex, UK).   All studies were 
performed to the highest standards of humane animal care under the aegis of the 
United Kingdom Animals Scientific Procedures Act, 1986 and approved by the 
ethics committee Edinburgh. For in vitro experiments, brains were taken from male 
mice (30-35g) after CO2, and the tissue was immediately removed, frozen quickly on 
crushed dry ice and stored at -80
o
C until use.  For information on the generation of 
C2CR.10 and C2CR.33 mouse lines see Appendix 1 and for TetO-2CR mice see 
Appendix 2.   
 
2.2.2 Genotyping 
Ear notches were taken at time of weaning and tail tips at time of culling for 
genotyping.  Both were stored at -20
o
C until DNA extraction.  Extraction was 
performed using separate reagent kits: NucleoSpin® Tissue (Macherey-Nagel) or 
DirectPCR Lysis Reagent (Viagen Biotech) with proteinase K.  Genotyping was 
performed by polymerase chain reaction (PCR) using one protocol for C2CR.10 and 
C2CR.33 mice and another for TetO-2CR mice. 
 
The following primers, corresponding to both the HA tag (5‟ forward primer) and 
complementary to the 5-HT2C receptor cDNA (reverse primer) were used to 
genotype C2CR.10 and C2CR.33 mice.  Forward primer: 5‟-
ATGTACCCATACGATGTTCCAGATTACGCT-3‟ and reverse primer: 5‟-
CAGAGGTGCATGGACGC-3‟.  This PCR was performed in a 50µl reaction 
mixture containing: 5µl buffer (from Taq Bead
™
 Hot Start kit), 3 µl MgCl2 (from  






 Hot Start kit), 1µl dNTP mix (Invitrogen), 1 µl forward primer, 1 µl 
reverse primer, 38 µl filtered water, 1 µl DNA and 1 from Taq Bead
™
 Hot Start 
polymerase (Promega).  Thermal cycling conditions compromised an intitial 
denaturation step at 96
o
C for 15 mins and 35 annealing and extension cycles of; 
96
o
C for 45 secs, 62
o
C for 45 secs and 72
o
C for 1 min followed by a final extension 
step at 72
o
C for 10 mins in a Techne Genius thermal cycler (Jencons-PLS). 
 
The following primers, corresponding to both the targeting cassette (5‟ forward 
primer) and complementary to the 5-HT2C receptor coding region (reverse primer) 
were used to genotype TetO-2CR mice.  Forward primer: 5‟ GCC CTT GGA ATT 
GAC GAG TAC G 3‟and reverse primer: 5‟ GTG AGC CAA GAT TGT GCC ACT 
G 3‟.  This PCR was performed in a 50µl reaction mixture containing: 5µl 10xPCR 
buffer (Qiagen), 2µl dNTP mix (Invitrogen), 2 µl forward primer, 2 µl reverse 
primer (10µM), 0.5 µl HotStarTaq DNA polymerase (Qiagen), 36 µl filtered water 
and 0.5 µl DNA.  Thermal cycling conditions compromised an intitial denaturation 
step at 96
o
C for 15 mins and 35 annealing and extension cycles of; 96
o
C for 45 secs, 
62
o
C for 45 secs and 72
o
C for 1 min followed by a final extension step at 72
o
C for 
10 mins in a Techne Genius thermal cycler (Jencons-PLS). 
 
For all samples β-globin was used as a house keeping gene to detect the presence of 
DNA in all samples.  The same programme was used as above but the primers were 
replaced with beta globin forward primer:  
CCAATCTGCTCACACAGGATAGAGAGGGCAGG and reverse primer: CCT 
TGA GGC TGT CCA AGT GAT TCA GGC CAT CG. The reaction mixture 
consisted of 5µl 5x buffer, 2 µl dNTPs, 2 µl forward primer, 2 µl reverse primer, 2.5 
µl DNA, 0.5 µl HotStarTaq DNA polymerase and 36.5 µl filtered water. 
 
5 µl 10 x loading buffer was added to 50 µl PCR products and 10 µl of this was 
loaded onto a 1% agarose (Biowhittaker Molecular Applications) gel containing 0.5x 




TBE and ethidium bromide (1 µl/100ml gel).  A 1kb DNA ladder (Invitrogen; 20 µl 
ladder, 20 µl loading buffer and 160 µl filtered water; 5 µl of ladder mix was loaded) 
was run to allow assessment of the size of the bands obtained.  The gel was run at 
100V until adequately separated and the results viewed on and photographed using 
the UVIpro gel documentation system (UVItec Ltd.). The presence of a 420 bp band 
indicates a C2CR.10 or C2CR.33 positive genotype. 
   
 
2.3 Behavioural Testing of Mice 
All behavioural tests were carried out between 0900 and 1300 hr, to coincide with 
the nadir of the corticosterone (CORT) circadian rhythm.  Subjects were housed in a 
quiet room in groups of 2-3 mice with littermates.  Mice were selected from within a 
cage in a random order for each test and the order of testing, for example mice that 
were tested last from a cage, did not alter the behavioural performance in the test.   
 
Mouse cages were moved from the quiet holding room to the behaviour room 12 hr 
prior to the test for acclimatisation. Behavioural tests were carried out in a random 
order, except when they were scheduled for EPM testing. This was always carried 
out first as behaviour in this test was modified by previous testing. All apparatus was 
cleaned thoroughly with 90% ethanol between mice.  The investigator was always 
blind to the genotype and/or drug treatment of the mice and all WT mice were 
littermate control mice used to limit the effect of the mixed genetic background 









2.3.1 Elevated Plus Maze Test 
The elevated plus maze (EPM) is a common behavioural test that has been used 
extensively to investigate the psychological and neurochemical basis of anxiety and 
in the discovery of novel anxiolytic agents (Dawson & Tircklebank, 1995).  The test 
has been validated in mice (Lister, 1987) and evokes an approach-avoidance 
response in rodents, based on their natural exploratory drive and their innate fear of 
open spaces.  Thus, a highly anxious mouse will tend to avoid the open arms on an 
elevated plus-maze and spend the majority of time on the closed arms (Pellow and 
File, 1985, 1986). 
 
The elevated plus-maze consisted of a plus-shaped platform made from black plastic 
and coated in white-sheeting, raised 1m above ground.  One opposing pair of arms 
was enclosed by high walls (15.5 cm; closed arms) and the other opposing arms of 
the same size were exposed (open arms; 28cm).  A central area of 6 cm
2
 connected 
all four arms. 
 
Each mouse was placed in the central area facing one of the open arms and allowed 
to explore the maze freely for 5 mins.  During this time the behaviour of each mouse 
was monitored and recorded immediately using a computer tracking system, 
(Limelight version 2.2 software (Actimetrics, IL, USA)).  The following 
spatiotemporal parameters were determined; number of open arm entries, time spent 
in the open arms and the distance travelled within the open arms. Ethological 
parameters such as stretch attend (stretching out from enclosed arms over the side of 









2.3.2 Open Field Test  
The open field (OF) test measures the exploratory and anxiety-like behaviour in a 
large square novel environment and plays on the natural instinct of rodents to avoid 
open spaces.  It was originally described in 1934 (Hall) and has since been 
comprehensively used in psychopharmacology (reviewed in Prut and Belzung, 
2003). 
 
The open field arena consists of a square box (50cm × 50cm, 25cm high, grey 
polymer, covered in white plastic sheeting) and was lit by two lamps (2 x 60W) 
which were angled at the centre. Limelight version 2.2 software (Actimetrics, IL, 
USA) was used to analyse the behaviour and movement of the mice. Mouse 
behaviour was continuously monitored by video camera and captured by 
Limelight™ Actimetrics software, the computer tracking programme, to allow for 
full spatiotemporal analysis.   It superimposed three zones onto the floor of the arena 
to allow calculation of movement in separate areas of the field which as indicative of 
different types of behaviour.  The zone adjacent to the wall represented a protected 
field, named „outer zone‟, considered less anxiogenic than the inner zones which 
represented an exposed field, named „inner zone‟. C2CR.10, C2CR.33 or TetO-2CR 
and WT mice were tested during the first half of their light phase in their light/dark 
cycle, and each test was initiated by placing an individual mouse in the centre of the 
arena and allowing free movement for 5 minutes and on occasion this test was 
extended to 30 mins.   
 
Parameters collected during each test comprised of the percentage distance covered 
in the inner zones, total distance covered in both zones, percentage time spent and 
percentage crossings in the inner zones.  The ethological parameters recorded 
comprised of the following behaviours: outer zones rearing, inner zones vertical 
motions, grooming and the number of faeces laid during the test.  
 




2.3.3 Sucrose Preference Test 
TetO-2CR and WT mice were individually housed in a quiet behaviour room  for 
one week prior the start of the test.  Mice were given a choice of two-water bottles 
(labelled A and B) to drink from and throughout the test both water-bottles were 
weighed and their position switched daily to exclude preference for a particular 
bottle and any location bias.  Once the mice had been trained to drink from both 
water-bottles (once preference for each water bottle was near 50% ±10%) the test 
was started and the fluid consumed was measured daily by weighing the bottles 
while the location of the bottles was continued to be switched daily.  On days 1 and 
2 both water-bottles were filled with water (w/w condition), days 3 and 4 both 
bottles were filled with a 1% solution of sucrose dissolved in drinking water (s/s 
condition) and on days 5-8 bottle A contained 1% sucrose solution above while B 
contained water (w/s condition, preference stage of test).  The total fluid 
consumption was calculated as [VolA + VolB] and averaged across the days of each 
bottle condition.  The preference on each day for each mouse was calculated as 
100(VolA/[VolA+VolB]) and averaged across the days for each bottle condition (w/w, 
s/s or w/s).  The values were body weight corrected for each mouse.   
 
2.3.4 Tail Suspension Test 
The tail suspension test is used to indicate depressive-like characteristics indicated 
by the time spent immobile during the test.  Mice were individually suspended above 
the table top using an adhesive tape placed ~0.5 cm from the tip of the tail.  Total 
duration of immobility was measured over a period of 6 minutes.  Mice were 
considered to be immobile only when they hung down passively and were 
completely motionless.  Mice were scored every 5 seconds as either S (struggling) or 








2.3.5 Passive avoidance 
The passive avoidance (PA) box (length - 39cm; width - 9.5cm; height – 16.5 cm; 
UGO Basile) features two chambers of equal sizes, both with gridded flooring.  One 
chamber is made of white opaque polymer and is brightly lit, whilst the other is 
made of black polymer and is not illuminated.  The two chambers are separated by a 
door which can be automatically opened and closed.  On day one, mice were placed 
individually in the light chamber facing away from the doorway, which was open, 
and allowed to freely explore both chambers for 5 mins and the time spent in the 
light chamber recorded.  On day two, mice were placed in the light chamber facing 
away from the closed door.  After a 90 secs delay the door was opened and upon 
entering the dark chamber, the door closed and mice received an inescapable 0.3mA 
footshock for 3 secs and were left for a further 5 secs before being removed.  This 
was repeated 6 hrs later, although no footshock was administered.  The latency to 
enter the dark chamber during both trials was noted and the increased latency to 
enter following footshock represents a measure of fear-related memory. 
 
2.3.6 Rotorod 
The rotorod tests the general agility and balance of the mice and consists of a 
rotating rod which gradually increases in rotation velocity.  Mice were individually 
placed onto the rod and given 10 secs to acclimatise.  The rotorod speed was then 
continuously increased and at this point timing started.  The trial ended when the 
mouse was unable to maintain balance on the rotorod (circled or fell off).  The time 









2.3.7 Voluntary Wheel Running Behaviour 
This protocol allows the level and pattern of activity to be measured for individual 
mice and therefore the effect of altered 5-HT2C receptor levels on activity to be 
analysed.  C2CR.10, C2CR.33 or TetO-2CR and respective WT control mice were 
individually housed in wheel cages (Techniplast; wheel diameter 23.5cm) and 
allowed to habituate to the environment.  Wheel revolutions were monitored using 
Clocklab acquisition software (ActiMetrics, IL, USA) throughout the whole period. 
Data was averaged over the number of days of the test, excluding the habituation 
period (Clocklab analysis software (ActiMetrics, IL, USA)).  30 mins following ip 
administration of a drug wheel running activity was monitored for 1-2 hrs 
(coinciding with the first 1-2 hrs from the start of the dark phase) to determine drug-
induced effects.  The same time period from the previous day was used as basal data. 
 
2.4 Circadian Experiments 
2.4.1 Food and drink monitoring 
TetO-2CR and WT mice were individually housed in food and drink monitoring 
cages and their food and drink intake measured every minute using Drink (Technical 
& Scientific Equipment). Average hourly intakes were calculated for the 24 hour 
cycle.     
 
2.4.2 Light altered wheel running 
TetO-2CR and WT mice were individually housed in wheel cages (wheel diameter 
23.5cm) and wheel revolutions counted using Clocklab acquisition and analysis 
computer software (ActiMetrics, IL, USA) throughout the whole period. Average 
daily revolutions were calculated following an acclimatisation period of 7 to 14 days.  
Following a period of collection under normal light conditions the light cycle was 
altered from on 0700 off 1900 (14 days) to on 0300 off 1500 (7 to 14 days) then off 
constantly (12 to 24 days) before returning to on 0700 to 1900 (14 days). 





2.4.3 Light pulses during wheel running 
Following a period of acclimatisation under normal light conditions mice were 
subjected to a series of light pulses lasting 1 to 2 hours during the dark phase.  
Average hourly revolutions were calculated. 
 
2.4.4 Food restriction in wheel cages 
Following an acclimatisation period access to food was gradually restricted until it 
was presented at 11 am and removed at 5pm daily.  Wheel rotations were counted for 
14 days under food restriction before mice were put into constant darkness (9 to 14 
days).   Average hourly wheel rotations were calculated throughout.      
 
2.5 Drug treatments 
To elucidate the role of 5-HT2C receptors in the behavioural tests, animals were 
injected with 5-HT receptor agonists (1-(m-chlorophenyl)-piperazine hydrochloride; 
mCPP, 0.3-3mg/kg; Sigma; (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine 
fumarate, RO 60-0175, 3-5mg/kg; Tocris Bioscience) 5-HT2C receptor antagonist (6-
chloro-5-methyl-1-[6-(2-methylpiridin-3-yloxy)pyridin-3-yl carbamoyl] indoline; 
SB242084; 3 mg/kg; Sigma), 5-HT2C receptor inverse agonist (5-methyl-1-(3-
pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f] indole hydrochloride; SB206553; 
1-5mg/kg; Tocris Bioscience), or vehicle (10% ethanol in saline for all drugs except 
mCPP which was dissolved in saline), via i.p. 30 min prior to testing or (for wheel 








2.6 In Situ Hybridisation Histochemistry 
In situ hybridisation allows for the visualisation of the structural location and 
quantification of specific mRNAs (indicating transcription of the corresponding 
gene) by hybridisation of a 
35
S-labelled „antisense‟ RNA probe to the mRNA of 
interest.  
35
S-UTP labelled RNA „sense‟ probes of similar length, nucleotide content 
and specific activity were included in order to assess the specificity of the 
hybridisation reaction. 
 
To prevent the degradation of target mRNA by exogenous RNases only RNase free, 
sterile solutions and equipment were used for all in situ hybridisation experiments.  
All restriction enzymes and RNA polymerases were obtained from Promega UK Ltd. 
 
2.6.1 Slide Preparation 
To prevent section dehiscence, glass microscope slides were coated in 3-
aminopropyltriethoxysilane prior to use.  Slides were racked and washed in the 
following series of solutions; 0.2M HCl for 3 mins, DEPC-H20 for 3 mins, 2% 3-
aminopropytriethoxysaline in acetone (acetone dehydrated by filtering though 
NaSO4) for 10 secs, acetone for 3 mins (twice) and finally DEPC-H2O for 3 mins.  
Slides were air-dried for 30 mins before baking at 50
o
C for 4 – 16 hr.  Dried slides 
were wrapped in aluminium foil and stored at room temperature for up to 3 months. 
 
2.6.2 Tissue Section Preparation 
Whole brains were routinely frozen on crushed dry ice immediately after dissection 
from the animal in the first half of the light cycle and stored at -80
o
C until required. 
Frozen tissue sections were cut using a cryostat (Leica).  Brains were later placed in 
the cryostat chamber at -18
o
C and allowed to equilibrate for approximately 45 mins, 
slides were also put in to cool.  Following equilibrium, brains were embedded in 




Cryo-m-bed embedding compound (Bright Instruments) and positioned in the correct 
orientation for sectioning.  15µm thick coronal sections were collected and 
transferred to the prepared slides, and stored at -80
o
C until required. 
 
2.6.3 Preperation of probe templates 
Templates were made by PCR from mouse brain RNA. 
2.6.3.1 Identification of PCR primers for each gene 
Regions of homology were determined for each gene by using the BLAST software 
(NCBI) with exon transcripts from Ensembl for dopamine transporter (DAT1), 
dopamine receptor 1 (Drd1), dopamine receptor 2 (Drd2), dopamine receptor (Drd3), 
5-HT transporter and tryptophan hydroxylase 2 (TPH2).  Possible primer sequences 
within mRNA sequences that were unique to that gene were identified using 
computer software (Primer 3) which allows the length of the requested primer 
sequences to be controlled in addition to the GC percentage content within the 
primer.  The desired primers were 20 – 22 nucleotides long, had GC% of between 45 
and 55%, ends of primer sequences were not complementary (to prevent primer 
dimmers forming) and primer pairs gave a product of between 300 and 600 bp.  Each 
individual primer sequence and the product sequence were checked using BLAST to 
ensure the primers did not detect any other gene and that the product was specific for 
the gene of interest.  Some primer sequences had to be selected by hand in order that 
they met the desired criteria.  Primers were obtained from Eurogentec, Belgium. 
 
2.6.3.2 RNA Extraction for PCR 
Brains were removed from male mice before being frozen immediately in crushed 
dry ice.  All samples were then stored at -80
o
C until use.  Samples were weighed and 
a maximum weight of 30mg transferred into a 2ml eppendorf and kept on dry ice.  
The element of the homogeniser had been soaked in a 10% solution of hydrogen 
peroxide in DEPC-H2O for a minimum of 15 mins, then rinsed thoroughly in DEPC-




H2O and wipe down with RNase free tissue.  Total RNA was extracted using an 
RNeasy Mini Kit (Quiagen) and the standard protocol provided. RNA concentration 
was determined with a NanoDrop spectrophotometer (Thermo Fischer Scientific). 
 
2.6.3.3 Preparation of cDNA templates by PCR 
cDNA templates were prepared for various genes of interest, to be used subsequently 
for the synthesis of RNA probes for in situ hybridisation analysis. The cDNA was 
made using 1µg of RNA sample from the whole brain homogenate.  The reaction 
mix contained 1 µl random primers, 1 µl 10mM dNTP mix and 11 µl diluted RNA (1 
µg) and was incubated at 65
o
C for 5 mins to linearise strands.  Put on ice and then 4 
µl 5x buffer, 1 µl 0.1M DTT, 1 µl RNase out and 1 µl superscript III were added and 
the reaction mix incubated at 25
o
C for 5 mins, 50
o
C for 60 mins ( for enzymes to be 
active and stops coiling) and 70
o
C for 15 mins. 
 
A PCR was carried out on the cDNA for each set of primers (See Table for primer 
details).  Each PCR had a reaction mixture consisting of 5 µl 5x buffer, 2 µl 10mM 
dNTPs, 2 µl forward primer, 2 µl reverse primer, 0.5 µl cDNA, 0.5 µl HotStartTaq 
polymerase and 38 µl NFW. The resulting cDNA PCR product was run through 
Roche high pure PCR product purification kit and the nanodrop was used to 
determine the concentration (ng/ µl).  200ng of each cDNA sample was run on an 
agarose gel, to check a clear band of the correct size was achieved.  The PCR 
product was ligated into PGem-Teasy vector (Promega) using 1 µl T4 enzyme, 3 µl 
of purified PCR product and 1 µl vector (50ng/ µl) and 5 µl buffer by incubating for 
4 hr at room temperature.  5 µl of each ligation incubated with HB101 on ice for 25 
mins followed by a heat shock at 42
o
C for 45 secs before being put back on ice.  LB 
broth (300 µl) was added to each ligated culture and incubated at 37
o
C for 1 hr in a 
shaker at 180rpm.  Culture was pipetted onto ampicillin (100mg/ml) agar plates and 
incubated at 37
o
C overnight.  Ten colonies from each plate were selected to be added 
separately to 5mls of media with the addition of 5 µl ampicillin and incubated 
overnight at 37
o
C in the shaker at 180rpm.  Each culture was pelleted by a 5 min spin 




at 2000rpm and then a QIAprep spin miniprep kit (Qiagen) used (45 µl elution 
buffer) to extract DNA from the bacterial preparation.  The nanodrop was used to 
determine the concentration of each product (desired concentration was between 
200ng/ µl and 400 ng/ µl) then 1 µl of each sample was incubated with 9 µl of 
master mix (64 µl 10x buffer H, 20 µl ECORI and made up to 576 µl with NFW) at 
37
o
C for 1 hr.  Samples were loaded (with the addition of 2 µl  loading buffer) and 
run on an agarose gel. All riboprobes cDNA with a distinct band were checked by 
sequence analysis (500 µl culture added to 500 µl glycerol to give 400ng per 
sample). 
 
2.6.4 Linearising Riboprobe 
A restriction digest was carried out to linearise riboprobes.  The reaction mixture 
containing 6 µl template (10 µl for 5-HT1A receptor), 4 µl buffer, 4 µl diluted BSA 
(1 µl BSA and 9 µl DEPC-H2O), 22 µl DEPC-H2O and 4 µl of the appropriate 
restriction enzyme (see Table 2.1) was incubated for 1 hr at 37
o
C.  To check the 
template was cut correctly 1 µl  of each riboprobe was mixed with 2 µl loading 
buffer and 7 µl NFW and loaded onto a 1% agarose gel containing 0.5xTBE and 
ethidium bromide (1 µl/100ml gel).  Each sample was then purified using a 
QIAquick PCR Purification Kit (Qiagen Kit) using 15 µl elution buffer and stored in 














Table 2.1 Characteristics of Probe Generation for In Situ Hybridisation 













910 bp Hind III T7 37 
2AR Blueskript 
SK 
900 bp Bam HI T7 37 
2CR pGEM T 
easy 
450 bp Nco I SP6 40 
5-HTT pGEM T 
easy 
366 bp Nco I T7 37 
TPH2 pGEM T 
easy 
503 bp Nco I T7 37 
TH Pc DNA 3 400 bp Eco RI T7 37 
Drd 1 pGEM T 
easy 
592 bp Nco I T7 37 
Drd 2 pGEM T 
easy 
420 bp Nco I T7 37 
 





RNA polymerase) for 60-90mins in a reaction mixture containing 1mM ATP, CTP 
and GTP, 4 µl 
35
S-UTP (1.48MBq/ µl; Amersham Ltd), 10mM DTT (Merck 
Biosciences), 0.5 µl RNase inhibitor (RNasin 40U/µl; Promega), and 1 µl 
appropriate polymerase (Promega) (Table 2.1) in a total volume of 10µl 5X 
transcription optimised buffer.  Following incubation, the probe was cooled on ice 
before 1µl DNase l (RNase free) was added and reactions incubated at 37
o
C for a 
further 15min to degrade the DNA template, after which probes were placed on ice 
for 1min and purified using NICK Sephadex column (Amersham Biosciences), to 
remove unincorporated radioactivity.  The column was prepared by washing through 
with 3ml TE buffer (pH 8.0).  40µl of DEPC water was added to the probe mixture 




before it was applied to the column.  The column was then washed with 400µl TE 
buffer, and the initial elutant discarded, to wash off any unbound 
35
S-UTP.  The 
radiolabelled probe was eluted in an additional 400µl TE buffer. 
 
For each probe, the total activity was estimated by counting 1µl of probe in 1ml 
PicoFluor 40 scintillant fluid in duplicate in a β-counter (Wallac 1450 MicroBeta 
Windows Workstation Version 4.01.014).  The minimum activity required was 
2x10
5
cpm/ l and all probes used were 10M/ml.  Probes were stored at -20
o
C until 
required, for a maximum of 7 days. 
 
2.6.5 Fixation Protocol 
Tissue sections (previously cut using a cryostat) were removed from -80
o
C freezer 
and kept on dry ice until the start of the fixation procedure.  Sections were fixed in 
ice cold 4% paraformaldehyde in 0.1M phosphate buffer (to maintain tissue 
morphology and inhibit endogenous ribonucleases; 2.76g NaH2PO4, 11.3g Na2HPO4 
in 1 l DEPC-water, with 40g paraformaldehyde added at 80
o
C) for 10min, rinsed 
twice in 1x phosphate buffered saline (PBS, 10x diluted from 10x PBS (80g NaCl, 
29g Na2HPO4.2H2O, 2g KH2PO4, 2g KCl in 1 l DEPC-water)) for 5min, acetylated 
in 0.1M triethanolamine with 0.25%   acetic anhydride (to reduce non-specific 
binding of the probe to positively charged amino groups in tissues; 13.3ml 
triethanolamine in 1 l DEPC-water, pH 8.0, 0.75ml acetic anhydride added prior to 
transfer of slides) for 10min to prevent loss of signal and rinsed in lx PBS for 3min.  
Following dehydration through a series of ethanol solutions (70, 80 and 95% ethanol 










Following fixation, slides were pre-hybridised with 200µl/slide buffer (2x pre-
hybridisation buffer consisting of 1.2M NaCl, 20mM Tris-HCl pH7.5, 2x Denhardt‟s 
solution, 2mM EDTA, 10mg/ml salmon sperm DNA and 0.2mg/ml yeast tRNA in 
DEPC water diluted 1:1 with deionised formamide (Sigma)), at 50
o
C for 2 hr.  
Dampening two layers of Whatman chromatography paper with box buffer (50% 
deionised formamide (deionised using 10% Duolite mixed resin), 20% 20 x SSC, 




Sense and antisense ribo-probes were thawed and added to 50% 2x hybridisation 
buffer (1.2M NaCl, 20mM Tris-HCl pH7.5, 2x Denhardt‟s solution, 2mM EDTA, 
0.2mg/ml salmon sperm DNA, 2g Dextran sulphate and 0.2mg/ml yeast tRNA in 
DEPC-H2O plus riboprobe) diluted in 50% deionised formamide to give a final 
probe concentration of 10x10
6
 cpm/ml.  Probes were denatured at 75
o
C for 10min 
and placed on ice before addition of 10mM DTT.  Pre-hybridisation buffer was 
drained from slides and 200µl of the appropriate probe was applied to sections.  
Slides were hybridised in sealed, humidified boxes (box buffer as above) at 50
o
C for 
an optimum of 16 hours. 
 
2.6.8 RNase Treatment to digest unbound ribo-probe 
Following hybridisation, slides were washed three times in 2x SSC for 5min and 
carefully wiped dry around the sections with lens tissue.  200µl of RNase A 
(30mg/ml in RNase buffer, consisting of 0.5M NaCl, 0.01M Tris-HCl pH7.5, 1mM 
EDTA in DEPC-H2O) was applied to each slide and left to incubate at 37
o
C for 1 hr 
in humidified boxes (1 layer of Whatman No.3 chromatography paper dampened 
with RNase buffer as above) to remove unhybridised probe. 





2.6.9 Washes and dehydration of sections 
Following RNase treatment, slides were washed in 2x SSC at room temperature for 1 
hr, once in 0.1x SSC at 60
o
C for 1 hr min, and then once in 0.1x SSC at 60
o
C cooling 
to ambient for 1 hr.  After washes, slides were dehydrated through a series of ethanol 
solutions containing 0.3M ammonium acetate (2 mins in each of 50, 70 and 90% 
ethanol) and air-dried. 
 
2.6.10 Visualisation of Hybridisation 
Slides were exposed to autoradiographic film (Kodak Biomax-MR) and left for 
varying periods of time (1 to 14 days) depending on the specific activity of the probe 
used and the abundance of the gene transcript.  Films were developed using Konica 
SRX-101 (JET X-ray, London). 
 
2.6.11 Image Analysis 
For image analysis, autoradiographic films were scanned on a high resolution flatbed 
scanner and any damaged or inadequate sections were excluded.  The background 
was low with sense section backgrounds having a greyscale level not significantly 
different to zero.  Digital image analysis was performed using MCID image analysis 
system (InterFocus Imaging) by optical densitometry.  The appropriate section was 
selected per animal, 10 measurements were taken per area (five from each 
hemisphere), with the background subtracted.  The specific signal was measured in 








2.7 Radioligand binding assay for 5-HT2C receptors 
2.7.1 Development of technique 
Firstly the spin conditions required to gain an optimal membrane preparation were 
tested and for this one large pooled WT mouse homogenate was used to remove 
individual animal variation while the technique was optimised.  All spin fractions 
were tested to ensure the membrane sample contained all membranes.  Varying 
membrane concentrations were then tested (0mg/ml up to 5mg/ml).  The incubation 
temperature and time were also varied from 37
o
C for 15min, 30min or 45min, room 
temperature (~22
o
C) for 30min, 45min or 60min and at 4
o
C for overnight.  A 
combination of methysergide and mianserin were used to block 
3
H-mesulergine 
binding however using 5-HT was found to be more effective. Lastly the 
concentration of 
3
H-mesulergine added to the incubate were altered varying from 
concentrations such as 5nM, 20nM and then by varying the counts of 
3
H-
mesulergine within the buffer varying from 70,000 to 140,000 counts.  
 
2.7.2 Sample Preparation 
Whole brains were removed from male mice and cut into forebrain, midbrain and 
hindbrain sections (for C2CR.10 mice the hindbrain was removed and the forebrain 
was left in one piece) frozen on dry-ice and stored at -80ºC until use. 
 
Samples were homogenised in 0.32M sucrose-50mM Tris-HCl (pH 7.4), 0.1% 
ascorbate containing protease inhibitors (Mini Protease inhibitor cocktail tablets, 
Roche Applied Science, West Sussex, UK) then centrifuged at 300g for 5 min at 
4ºC.  The supernatant was removed and centrifuged at 50,000g for 15 min at 4
o
C.  
The resulting pellet was washed and resuspended in ice-cold 50mM Tris-HCl (pH 
7.4), 0.1% ascorbate containing protease inhibitors for use in the assay.  
 




The protein concentration of tissue supernatants were determined colorimetrically 
using a protein assay kit (Bio-Rad) and bovine serum albumin (BSA) standards 
(0.05-0.5 mg protein/ml). Samples were diluted in dH2O to give concentrations in 
the standard range.  Briefly, 25 µl Bio-Rad protein assay reagent A and 200 µl Bio-
Rad protein assay reagent B were added to triplicate 10 µl aliquots of samples and 
standards in a 96-well plate.  After 15 mins incubation at room temperature, the 
absorbance in each well was measured at 750nm (A750) in a microplate reader.  The 
concentration of protein in each sample was calculated from the standard curve (A750 
vs. Mg/ml protein concentration).  For the binding assay, samples were then diluted 
to 1.2mg/ml protein, which ends up as 0.6mg/ml per well.  Samples were kept on ice 
at all times. 
 
2.7.3 Membrane Binding 
Total binding in membranes (0.6mg/ml protein) was determined in the presence of 
10nM 
3
H-mesulergine and 100nM spiperone (to block 
3
H-mesulergine binding to 5-
HT2A receptors) while non-specific binding was determined with the addition of 
100µM 5-HT.  96-well plates were first loaded with 25µl of either buffer (room 
temperature buffer containing 50mM Tris-HCl, 10mM MgCl2, 1mM EDTA and a 
final concentration of 50nM spiperone, pH7.4) or 5-HT buffer (same as buffer above 
with the addition of final concentration of 100µM 5-HT) before 50µl of each sample 
(1.2mg/ml) was added in quartet, mixed gently and left to incubate at room 
temperature for 20mins.  25µl of radioloabelled buffer (same as buffer above with 
the addition of ~70,000 counts of 
3
H-mesulergine) was added before an incubation at 
37
o
C for 30 min.  Membrane incubation was terminated by rapid filtration using a 
Combi cell harvester (Skatron Instruments, Lier, Norway) onto a filter sheet that had 
been soaked in 1% PEI for 15 min.  Filters were washed and left to dry for at least 1-
3hrs.  25µl of the prepared radiolabelled buffer was put into vials, in triplicate, for 
counting to determine the number of counts of 
3
H-mesulergine used in the 
incubations. 
 




2.7.4 Counting Specific Binding 
3mls of scintillant fluid (Aquasafe 300 Plus Scintillant) was added to each sample 
(and the vials containing 25µl radiolabelled buffer to determine counts of 
3
H-
mesulergine) and left to incubate for 6 hr at room temperature.  Samples were 
counted on a liquid scintillation counter (Packard tri-carb 2100TR, Packard 
Instruments, Berks, UK) for 5 mins per samples.  Samples were arranged to be 
counted in order with their radiolabelled and 5-HT buffer sample ordered for 
counting following on from one another to eliminate the incubation time in the 
scintillant fluid from having an effect on the result.  
 
 
2.8 High Performance Liquid Chromatography (HPLC) of 
brain tissue 
HPLC grade solutions were used throughout, and all solutions were filtered through 
a 0.22µm size filter using a vacuum filter.  
 
2.8.1 Development of HPLC running conditions 
Standard solutions of each compound being measured in the sample were required to 
develop the chromatography run conditions.  1mg/ml of each standard, 5-HT 
creatinine sulphate (5-HT, Sigma), 5 hydroxy-3-indole acetic acid (5HIAA, Sigma), 
dopamine 3-hydroxytryptamine (DA, Sigma), and the internal control methyl-5-
hydroxytryptamine (CH3 5-HT, Sigma), were made dissolved in HPLC grade water, 
while noradrenaline (NA, Sigma) and homovanillic acid (HVA, Sigma) were 
dissolved in 0.1M HCl as they are unstable in H2O.  These stocks were stored at -
20
o
C.  Each standard was run individually, and the retention time recorded, before 
standards were mixed together one by one and the percentage of methanol and 
temperature of column altered to ensure all standards had distinct retention times.  A 
stock solution containing 0.3µg/µl of each standard in citrate buffer was prepared 




and serially diluted 1:2 to obtain several solutions of known concentration (0.3, 0.15, 
0.075, 0.0375, 0.01875, 0.009375, 0.004688, 0.002343, 0.001172, 0).  The 
concentration of CH3 5-HT remained constant throughout standard curve dilutions 
and samples (0.3µg/µl).  Ideally standards should also be diluted in PCA (instead of 
citrate buffer) to ensure all conditions are the same between the standards and 
samples.         
 
2.8.2 Sample Preparation 
Brains were removed from male mice and dissected into the hippocampus, 
cerebellum, cortex and the remainder, which contains thalamic regions, before being 
frozen immediately in crushed dry ice.  All samples were then stored at -80
o
C until 
use.  Frozen tissues were weighed and homogenised in 200µl 0.1M perchloric acid 
(PCA), sonicated twice for 10secs and spun (10,000 g) for 5 mins at 4
o
C. The 
supernatant was extracted and 0.3µg/µl of internal standard (methyl-5-
hydroxytryptamine, CH3 5-HT, Sigma) was added before being filtered through a 
22µm cellulose acetate centrifuge filter by application to a COSTARspinX column 
(Corning Life Science) and spun at 10,000 g for 1 min at 4
o
C.  A further 100µl 0.1M 
PCA was added to wash through the column and spun at 10,000 g for 1 min at 4
o
C. 
Samples were kept on ice prior to chromatography and were run within 10 mins of 
preparation. 
 
2.8.3 Running Samples 
Samples were loaded into a Waters 2695 seperations module (Waters Corpopration) 
which autoinjected 10µl into a Waters Sunfire 3.5µm C18 column (Waters 
Corporation) with a mobile phase delivered at a constant flow rate of 0.4ml/min.  
Each sample took 35 mins to complete and the column was maintained at a 
consistent temperature of 25
o
C.  Natural fluorescence of the indole and 
catecholamines was detected by a Waters 2475 Multi λ Fluorescence Detector 
(Waters Corporation) at 284nm and 335 nm. The mobile phase consisted of 6% 




methanol (BDH, HPLC grade) and 94% citrate buffer (pH3.5) filtered through a 
0.22µm nitrocellulose filter (Millipore Corporation) and was kept in an isocratic 
mode throughout. A standard curve of all the standards was carried out to check 
retention times and throughout sample runs random standard curve points were 
selected to be checked.   
 
2.8.4 Analysing data 
Emission peak profiles for each sample were compared to those obtained from the 
standards in order to identify the catecholamine molecules of interest.  The area of 
the emission peak was used to determine the concentration of each molecule from 
the standard curve.  This was then corrected for the recovery rate, determined by 
comparing the mean internal control areas obtained from the samples to the mean 
internal control areas obtained from the standards.  The concentration of each 
molecule in each sample was corrected by the tissue weight and volume of 
supernatant. 
 
2.9 Statistical Analysis  
Data are expressed as mean±SEM.  Comparisons between groups were analysed by 
the most appropriate method including either an unpaired t-test, one and two-way 
analysis of variance (ANOVA) or a repeated measures (RM) one-way ANOVA, with 
Tukey‟s multiple comparison test or Bonferroni post-hoc testing; p< 0.05 was 
considered significant. For the HPLC data ANOVA were used to analyse the data as 








Appendix 1: Generation of transgenic mice overexpressing 5-
HT2C receptors in forebrain 
This mouse line was generated by Gavin MacColl. The full length (unedited) rat 5-
HT2C receptor cDNA was amplified by PCR from a plasmid template (pMV7-sr1cm 
gift from David Julius, San Francisco, USA). An influenza hemagglutinin (HA) 
epitope tag was added at the N-terminus of the receptor by subcloning a double 
stranded oligonucleotide encoding the HA tag at a KpnI site generated by PCR at the 
translation start of 5-HT2C receptor cDNA. Receptor function is not altered by the N-
terminal addition of this tag (Hurley et al., 1999). The HA-5-HT2C receptor cDNA 
was then subcloned into the EcoRV site of pNN265 (Mayford et al., 1996). Transient 
transfection of this plasmid into Cos7 cells conferred binding of the 5-HT2C receptor 
ligand 
3
H-mesulergine (data not shown). A Not1 fragment including HA-5-HT2C 
receptor (HA-2CR) cDNA was then inserted into the NotI site of pMM403, encoding 
the mouse calcium-calmodulin-dependent protein kinase (CamK) IIα promoter 
(Mayford et al., 1996), to create the transgene construct, CamKII-HA-2CR (Figure 
2.1). All constructs were verified by DNA sequencing. Transgenic mice were 
generated by pronuclear injection of the 11kb linearised CamKIIα-HA-2CR 
minigene construct into C57BL/6J x CBA embryos. Four founder mice (designated 
C2CR) were obtained, all of which transmitted the transgene. Two C2CR lines 
(C2CR.10 and C2CR.33) were selected for further characterisation, with similar 
results between lines, and mice were backcrossed to C57BL/6. In some experiments, 
genotypes were confirmed by southern blot analysis of EcoRV digested genomic 
DNA from C2CR mice, probed with a 
32
P-labelled DNA fragment comprising the 
2.7kb BamH1 fragment of the transgene. Southern blotting was also used to confirm 
a single integration site of the transgene in C2CR.10 and C2CR.33 mice, consistent 
with the observed ~50% transmission rate for the transgene. Gestation length is 
normal in both C2CR.10 and C2CR.33 mice with an average litter size of 7 pups in 
C2CR.10 mice and 6 pups in C2CR.33 mice. All controls were WT littermate 
control mice to control for generation during the backcrossing process onto 
C57BL/6. 
 






Figure 2.1: Transgenic construct                   
The over-expression of the 5-HT2C receptor in the forebrain were generated by insertion of 
the above transgene containing 5-HT2C receptor under the control of the CamK IIα promoter 
in a C57Bl/6/CBA cross. An haemagglutinin epitope tag was added at the N-terminus of  the 
receptor which does not alter the function of the receptor. Due to the transgene containing 5-
HT2C receptor cDNA, no introns are present and therefore these receptors are not subject to 
A to I RNA editing. Male mice carrying the transgene were then bred with C57Bl/6 females 
to eventually have the transgene expressed on a C57Bl/6 genetic background. 
 
Appendix 2: Generation of Targeted Mice Underexpressing 5-
HT2C receptors throughout brain 
The targeting cassette used to generate this mouse line was named triTAUBi and was 
obtained from John Adleman, of the Vollum Institute, Portland, Oregon (Bond et al., 
2000). This construct had a tetracycline activator (TetA) following the translation 
start, neomycin (NEO) resistance and URA3, which is used for selection in yeast. 
The construct was modified by Gavin MacColl, who replaced the URA3, of the 
original cassette, with an HPRT minigene obtained from David Melton (Moore et 
al., 1995) before homology arms were put on either side of the cassette for the 5-
HT2C receptor gene (5‟ length 1.8kb and 3‟ length 7kb). A 129-derived embryonic 
stem (ES) cell line was microinjected with the adapted targeting cassette by David 
Melton and following homologous recombination (see Figure 2.2), cells containing 
the correctly incorporated targeting construct were identified using Southern blot 
analysis by Karen French and Gavin MacColl. Following this selection the cells 
were microinjected into blastocysts and put into pseudo pregnant females and the 
chimera offspring were back crossed onto a C57BL/6 background creating C57BL/6 
generation 1 of TetO-2CR mice. Additional DNA in the construct can decrease and 
even inhibit the action of the tetracycline (Tet). The HPRT minigene had floxP sites 
on either side which allowed it to be removed from the cassette by mating TetO-2CR 
offspring with a CRE-deleter mouse obtained from David Melton. This mouse line 
was actually found to under-express 5-HT2C receptors and so TetO-2CR mice were 
used as an under-expressing model. 
Due to the CRE-deleter mouse being of an undefined genetic background these 
offspring were backcrossed onto C57BL/6 to generate C57BL/6 generation 1 of 




TetO-2CR mice. In all experimental procedures wild-type (WT) littermate mice were 

































Figure 2.1: TetO-2CR mice targeting cassette inserted into 5-HT2C receptor gene       
The cassette encodes the binary tetracycline controlled trans-activator (tTA) protein controlled by a 
preceding adenovirus tripartite leader sequence that confers efficient translation initiation and followed 
by the polyadenylation/transcriptional termination sequence from SV40. The next portion of the 
cassette contains the bacterial neomycin resistance gene driven by the herpes simplex virus 
thymidine kinase promoter and the yeast URA3 gene. These selectable markers are flanked by loxP 
sites and followed by the polyadenylation/transcription termination sequence from the human growth 
hormone gene. The final part of the cassette contains 5 copies of the tet operator fused to the minimal 
cytomegalovirus (teto5 CMV) promoter. The native (5-HT2C) promoter drives expression of the tTA that 
induces transcription of the 5-HT2C gene from the tet o5 CMV promoter. 













CHAPTER 3:  
BASIC ANALYSIS OF 
TRANSGENIC MICE OVER-EXPRESSING 
















This experimental chapter examines the 5-HT2C receptor over-expressing mouse 
lines and has the following aims: 
1. To fully validate the 5-HT2C receptor expression pattern and levels in 
C2CR.10 and C2CR.33 mice 
2. To establish any behavioural phenotype that may be present due to 5-HT2C 
receptor over-expression 
3. To examine functionality of the 5-HT2C receptors in these models using 
ligand studies 
It was hypothesised that 5-HT2C receptor activity would be increased causing a 


























The 5-HT2C receptor could be a potentially important therapeutic target for the 
treatment of psychiatric diseases including mood disorders, locomotor dysfunction 
and eating disorders (Chapter 1; Gleason et al., 2001; Schuhler et al., 2005; Harada 
et al., 2008).  It has been difficult to elucidate the precise function and 
pathophysiological role of the 5-HT2C receptor for multiple reasons, in particular a 
lack of availability of selective pharmacological agents due to large regions of 
homology between 5-HT receptor subtypes.  However, studies using 1-(m-
chlorophenyl)-piperazine (mCPP), a non-selective 5-HT receptor agonist with 
preferential affinity for the 5-HT2C receptor, show mCPP induces anxiety (Kennett et 
al., 1992; Fone et al., 1996; Cornelio et al., 2007; Hackler et al., 2007), reduces food 
intake (Samanin et al., 1979; Kennett et al., 1988; Hewitt et al., 2002) and inhibits 
locomotion (Lucki et al., 1989, Stiedle et al., 2007).  Although these studies infer a 
role for the 5-HT2C receptor in these functions, the actions of mCPP are a combined 
result of its activation of several serotonin receptor subtypes, including the 5-HT2B 
receptor and 5-HT2A receptor (Nonogaki et al., 2003; Dalton et al., 2004; Lee et al., 
2004).  Recently, more selective 5-HT2C receptor agonists, such as RO 60-0175, 
have also been shown to have a degree of action on other 5-HT2 receptor subtypes 
(Damjanoska et al., 2003, Higgins et al., 2001, Martin et al., 1998, Porter et al., 
1999). Hence a definitive assessment of 5-HT2C receptor function is not possible 
using pharmacological methods alone. 
 
The 5-HT2C receptor is under complex regulation of both receptor density and 
activity (Chapter 1). The 5-HT2C receptor is also subject to A to I RNA editing of the 
pre-RNA transcript which alters its sensitivity to ligands (Niswender et al., 1999; 
Englander et al., 2005).  In vitro edited forms of the receptor require more ligand to 
activate intracellular signalling pathways due to a coupling deficiency to G-proteins 
(Burns et al., 1997, Fitzgerald et al., 1999, Niswender et al., 1999) compared to the 
unedited form. The non-edited (genomic sequence) isoform exhibits constitutive 
activity (Herrick-Davis et al., 1999, Niswender et al., 1999) but the fully-edited 
isoform (VGV) does not.  The extent of editing of the 5-HT2C receptor varies 




between genetically different mouse strains. The BALB/c strain, for example, 
expresses predominately the nonedited isoform which has the highest constitutive 
activity and agonist affinity compared to C57BL/6 in which the ABCD or ABD 
edited isoforms constitute over 60% of the receptors (Englander et al., 2005).  
Following early life stress, such as infant maternal separation, editing of the 5-HT2C 
receptor is increased (Bhansali et al., 2007), while depletion of 5-HT decreases the 
amount of editing and increases the pool of mRNA encoding receptor isoforms that 
have the highest constitutive activity and the highest affinity for 5-HT (Gurevich et 
al., 2002a).  A possible reason for 5-HT2C receptor editing being altered following 
sustained alterations of serotonergic neurotransmission could be to maintain normal 
responses.  Editing is altered in a  site specific manner in human post-mortem brains 
from depressed suicide victims, indicating mood disorders can affect the pattern of 
5-HT2C receptor editing (Gurevich et al., 2002b).  
 
The most appropriate way to examine the action of the 5-HT2C receptor could be the 
development of a transgenic mouse model as even if truly specific ligands were to 
become available, you could not account for the other factors (such as A to I RNA 
editing) which could influence receptor function. In this study a transgenic approach 
has been taken to elucidate the effect of over-expressing the 5-HT2C receptor in the 
forebrain by using mouse lines where the 5-HT2C receptor is under the transcriptional 
regulation of the CamKIIα promoter to generate CamKIIα-5-HT2C mice termed 
C2CR.10 and C2CR.33 mice (created by Gavin McColl).  To minimise the effect of 
editing, the transgene was created from 5-HT2C receptor cDNA which lacks introns 
and so is not subject to RNA editing.  This created a model where (a) levels of 5-
HT2C receptor were increased and (b) the balance of edited isoforms should be 
considerably modified in favour of the non edited isoform compared to WT mice.  
The aim of this chapter is to determine whether increased 5-HT2C receptor receptor 
expression results in behavioural dysfunction. A full validation of the receptor 
expression pattern and levels in each transgenic line will be carried out and 
compared to the behavioural outcome particularly locomotion and anxious-like 
behaviours to obtain unequivocal evidence for the 5-HT2C receptor in these 
behaviours. 




3.2 Initial characterisation of transgenic mouse lines 
3.2.1 Transgene expression (indicated by 5-HT2C receptor 
mRNA) was widespread in C2CR.33 mice but more restricted 
in C2CR.10 mice 
 
The regions of the brain where the transgene had generated increased 5-HT2C 
receptor mRNA expression was determined by in situ hybridisation. This technique 
allows semi quantification of 5-HT2C receptor mRNA levels in brain sections and 
therefore clearly shows the expression pattern and level within these sections 
compared to WT mice (see Figure 3.0).  Compared to WT mice, C2CR.10 mice 
(backcrossed to C57BL/6 for 2 generations) had significantly increased 5-HT2C 
receptor mRNA levels in various regions of the forebrain from frontal regions 
moving to more posterior regions (Figure 3.1). Firstly in regions of the frontal 
forebrain such as the caudate putamen (CPu) and nucleus accumbens core (AcbC) 
and shell (AcbSh), C2CR.10 mice were found to have significantly increased 5-HT2C 
receptor mRNA levels in the AcbC (Figure 3.1a; interaction of genotype and region: 
F4,34=9.46; p<0.0001; effect of genotype: F1,34=58.18; p<0.0001 ). In more posterior 
forebrain regions such as the dorsal hippocampus (CA1, CA3, DG), basolateral 
amygdaloid nucleus (BLA), cortex and choroid plexus (CP) there was a significant 
effect of the genotype of the mouse and its interaction with the regions tested (Figure 
3.1b F5,53=7.43; p<0.0001), with the transgene causing over-expression of 5-HT2C 
receptor mRNA in the dorsal hippocampus (CA1, CA2/3 and DG) but not in the 
amygdala, CP or cortex. Finally, in sections containing ventral limbic regions, such 
as the cortex, ventral hippocampus (CA1, CA2, CA3, DG) and substantia nigra (SN) 
a significant interaction of the genotype and region tested was found (Figure 3.1c; 
F5,54=4.08; p=0.003) with significant elevations in 5-HT2C receptor mRNA in 
C2CR.10 mice compared to WT mice in both the CA3 field of the ventral 

























Figure 3.0: Example autorad photographs for 5-HT2C receptor mRNA levels in 
C2CR.10 and C2CR.33 mice.                   
The differing levels of 5-HT2C receptor mRNA can be visualised using autoradiographs.  






(a) 5-HT 2C receptor mRNA
Frontal Forebrain
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Figure 3.1: 5-HT2C receptor mRNA expression frontal to posterior in adult male C2CR.10 
mice                         
5-HT2C receptor mRNA expression is increased in C2CR.10 mice compared to WT littermate 
control mice in (a) frontal forebrain, (b) posterior forebrain and (c) ventral limbic regions. Expression 
levels were measured by optical densitometry of in situ hybridisation autoradiographs. Data are 
expressed as mean±SEM in males backcrossed to C57BL/6 for 2 generations and analysed by 
unpaired, 2-way ANOVA with Bonferroni posttests; n= 5 per group. * p<0.05; ** p<0.01; *** 
p<0.001.  
CPu = caudate putamen; AcbN = nucleus accumbens core; AcbSh = nucleus accumbens shell; S1 
= primary somatosensory cortex; M1/M2 = primary/secondary motor cortex; CA1, CA2 or CA3 = 
CA1, CA2 or CA3 field of the hippocampus; DG = dentate gyrus; BLA = basolateral amygdaloid 
nucleus (anterior); CP = choroid plexus; SN = substantia nigra.  




C2CR.33 mice backcrossed to C57BL/6 for 2 generations also had significantly 
increased 5-HT2C receptor mRNA levels compared to WT mice across the forebrain 
(Figure 3.2). This increase was considerably more dramatic than that observed in 
C2CR.10 mice. Firstly, in regions of the frontal forebrain such as the CPu, Acb and 
cortex, C2CR.33 mice had significantly elevated 5-HT2C receptor mRNA levels in 
all regions compared to WT mice (Figure 3.2a; effect of genotype F1,45=151.56; 
p=<0.0001). In more posterior forebrain regions such as the cortex, dorsal 
hippocampus (CA1, CA2/3, DG), BLA and CP, there was a significant effect of the 
genotype of the mouse and its interaction with the regions tested (Figure 3.2b; 
F5,60=15.84; p=<0.0001) with 5-HT2C receptor mRNA levels elevated in all regions 
with the exception of the CP. Finally in ventral limbic regions such as the cortex, 
ventral hippocampus (CA1, CA2, CA3, DG) and the SN (Figure 3.2c), 5-HT2C 
receptor mRNA levels were increased in the cortex and all regions of the ventral 
hippocampus in C2CR.33 mice compared to WT mice (Figure 3.2c; interaction of 
genotype and region F5,42=6.15; p=0.0002) consistent with the increases described 
above. There was, however, no alteration in 5-HT2C receptor mRNA levels in the SN 
of C2CR.33 mice.  
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Figure 3.2: 5-HT2C receptor mRNA expression frontal to posterior in adult male C2CR.33 mice  
5-HT2C receptor mRNA expression is increased in C2CR.33 mice compared to WT littermate control 
mice in (a) frontal forebrain, (b) posterior forebrain and (c) ventral limbic regions. Expression levels 
were measured by optical densitometry of in situ hybridisation autoradiographs. Data are expressed 
as mean±SEM in males backcrossed to C57BL/6 for 2 generations and analysed by unpaired, 2-
way ANOVA with Bonferroni posttests; n= 6 per group. * p<0.05; ** p<0.01; *** p<0.001.  
CPu = caudate putamen; AcbN = nucleus accumbens core; AcbSh = nucleus accumbens shell; S1 
= primary somatosensory cortex; M1/M2 = primary/secondary motor cortex; CA1, CA2 or CA3 = 
CA1, CA2 or CA3 field of the hippocampus; DG = dentate gyrus; BLA = basolateral amygdaloid 
nucleus (anterior); CP = choroid plexus; SN = substantia nigra.  
 






The transgene generated over-expression of 5-HT2C receptor is higher in C2CR.33 
mice than C2CR.10 mice (Table 1).  Appetite and food intake is unaltered in these 
lines because 5-HT2C receptor expression is unaltered in the hypothalamus, the 
centre for appetite regulation (Suzuki et al., 2010).  
 
 
Table 3.1: Percentage increase in 5-HT2C receptor mRNA levels in C2CR>10 or 
C2CR.33 mice compared to WT mice        
C2CR.33 mice have higher % increase in 5-HT2C receptor mRNA than C2CR.10 mice 
backcrossed to C57BL/6 for 2 generations. C2CR.10 and C2CR.33 mice compared to WT 
littermate control mice by two-way ANOVA with Bonferroni posttests. 
Brain Region C2CR.33 C2CR.10 
Acb C 1770.9 ± 322.71 221.02 ± 43.5 
Dorsal CA1 1688.09 ± 210.53 709.79 ± 80.66 
Dorsal CA3 2376.64 ± 319.28 634.55 ± 67.62 
Dorsal DG 3164.94 ± 369.52 20311.99 ± 1976.26 
Ventral CA3 726.90 ± 149.25 191.49 ± 19.33 
 
 
To determine if transgene expression results in a regulation of the endogenous 
receptor, hence altering the total levels and potentially the ratio of edited isoforms, 
the endogenous 5-HT2C receptor was measured in all lines.  The endogenous 5-HT2C 
receptor mRNA expression in C2CR.10 and C2CR.33 mice was found to be 
unaltered by the elevated 5-HT2C receptor expression resulting from the transgene 
with no effect when compared to WT mice (Figure 3.3; p=0.333). 
 







3.2.2 5-HT2C receptor binding sites were increased in 
C2CR.10 mice in the hindbrain and in C2CR.33 mice in the 
forebrain 
 
It is vital to establish if the increase in 5-HT2C receptor mRNA found by in situ 
hybridisation (section 3.3.1) results in increased protein activity.  In order to assess 
this, 5-HT2C receptor levels were measured using a 
3
H-mesulergine (a ligand specific 
for 5-HT2C receptor) binding assay in membrane preparations.  C2CR.10 mice, 
backcrossed to C57BL/6 for 5 generations, showed no difference in binding 
compared to WT mice in the forebrain plus midbrain (Figure 3.4A; p=0.995).  
































Figure 3.3: Endogenous 5-HT2C receptor mRNA expression in C2CR.10 and C2CR.33 mice 
No alteration in the endogenous 5-HT2C receptor mRNA expression is found in C2CR.10 or 
C2CR.33 mice compared to WT mice.  Experiment carried out by A. Kimura; analysed by P. 
Stevenson.  Expression levels were measured by optical densitometry of in situ hybridisation 
autoradiographs. Data are expressed as mean±SEM, in males backcrossed to C57BL/6 for 2 
generations.  C2CR.10 and C2CR.33 mice compared to WT littermate control mice by unpaired, 2-
way ANOVA with Bonferroni posttests; n=2-3 per group.   
CA3 = CA3 field of the ventral hippocampus; post thal = post thalamic regions. 
 




prepared from the hindbrain of C2CR.10 mice compared to WT mice (p=0.0006) 
which could indicate transgene expression in the cerebellum even though the CamK 
promoter is usually associated with a forebrain specific expression pattern. There 
was a two-fold increase in 
3
H-mesulergine binding to membranes prepared from the 
forebrain of C2CR.33 mice (backcrossed to C57BL/6 for 4 generations) compared to 
WT mice (Figure 3.4b; p=0.045), indicating that the increased 5-HT2C receptor 
mRNA level was translated into protein expressed at the cell surface or internal 
membranes.  In membranes from the hindbrain, where the transgene is not expected 
to be expressed, 
3
H-mesulergine binding was unaltered in C2CR.33 mice compared 






























































(a) C2CR.10 mice (b) C2CR.33 mice
 
Figure 3.4: 5-HT2C receptor number in adult male C2CR.10 and C2CR.33 mice determined by 
3
H-mesulergine binding assay                                                                                
5-HT2C receptor number was unaltered in the forebrain and midbrain membrane preparations and 
increased in the hindbrain membrane preparation of C2CR.10 mice compared to WT mice (a).  In 
forebrain membrane preparations from C2CR.33 mice, 5-HT2C receptor number was increased 
compared to WT mice, with no alterations between genotypes in the hindbrain membrane 
preparation (b).  C2CR.10 mice backcrossed to C57BL/6 for 5 generations and C2CR.33 mice 
backcrossed to C57BL/6 for 4 generations.  Data are expressed as mean±SEM; C2CR.10 and 
C2CR.33 mice compared to WT littermate control mice for each region using unpaired Student‟s t 
test; n=4 per group. * p<0.05, *** p<0.001. 
 




3.2.3 5-HT2C receptor over-expression in C2CR.10 and 
C2CR.33 mice increases anxiety-like behaviour 
 
The 5-HT2C receptor has been implicated widely in the control of mood and in 
particular anxiety, with agonists reported to be anxiogenic while antagonists are 
anxiolytic (Chapter 1). In order to examine whether the over-expression of 5-HT2C 
receptor in C2CR.10 and C2CR.33 mice affects anxiety-like behaviour, the elevated 
plus maze (EPM) and the open field (OF) tests were used. These are both well-
established standard tests of anxiety-like behaviour in rodents and rely on the natural 
instinct of rodents to avoid brightly lit exposed regions of the mazes. In this set of 
experiments all mice used had been backcrossed to C57BL/6 for 3 generations. 
 
In the EPM, anxiety-like behaviour is indicated by a decrease in exploration, time 
and/or distance travelled, in the elevated and exposed, light open arms in comparison 
to control animals. The OF works on a similar principle, with decreased time and/or 
distance travelled in the exposed, brightly lit central region of the maze indicating 
increased anxiety-like behaviour.  Both of these measures (percentage time and 
percentage distance travelled) must be considered before a conclusion can be drawn 
for both the EPM and the OF.  C2CR.33 mice were found to spend a similar 
percentage of time in the open arms of the EPM compared to WT mice (Figure 3.5a, 
p=0.225).  In the OF, C2CR.33 mice spent significantly less time in the inner zone, 
compared to WT mice (Figure 3.5b, p=0.031), indicating an increase in anxiety-like 
behaviour.  
 
Some mice may freeze when they enter the exposed regions and so although their 
percentage time would not show significance, their percentage distance would.  This 
was found to be the case in C2CR.33 mice in the EPM with the percentage distance 
travelled within the open arms significantly reduced compared to WT mice (Figure 
3.5c, p=0.024). This indicates that although C2CR.33 mice spend the same 
percentage of time in the open arms compared to WT mice, they travel a 
significantly lower distance in these regions compared to controls, indicating that 
they have frozen due to increased anxiety.  In the OF C2CR.33 mice show no 




alteration in the percentage of distance travelled in the exposed zone compared to 









































(c) Elevated Plus Maze











































(d) Open  Field



































(a) Elevated Plus Maze






























Figure 3.5: Behaviour in the elevated plus maze and open field test in male C2CR.33 
mice                                                                     
No alterations were found in the time spent (a) in the open arms of the EPM between 
genotypes.  The percentage of time spent in the inner zones of the OF (b) was reduced in 
C2CR.33 mice compared to WT mice. The percentage of distance travelled in the open arms 
of the EPM (c) was reduced in C2CR.33 mice compared to WT controls.  No alterations 
between genotypes were found in the percentage of distance travelled in the inner zones of 
the OF (d).  All mice were males backcrossed to C57BL/6 for 3 generations. Data are 
expressed as mean±SEM; generated by A. Kimura. C2CR.33 mice compared to WT 
littermate control mice by unpaired Student‟s t test; EPM n =9-11 per group and OF n =5-6 
per group * p <0.05. 







Compared to WT, C2CR.10 mice showed no alterations in their behaviour in the 
EPM in the distance travelled in the open arms (% distance in open arms WT = 
54.27 ±8; C2CR.10 = 53.38 ±8.5).  In the OF, C2CR.10 mice showed a trend to 
spend less time (Figure 3.6a; p= 0.089) and fewer crossings within the inner zone 




































































Figure 3.6: Behaviour in the open field in C2CR.10 mice                    
C2CR.10 mice show a trend to spend less time (a) and fewer crossings (b) within the inner zone of 
the OF compared to WT mice. All mice were backcrossed to C57BL/6 for 3 generations. Data are 
expressed as mean±SEM. C2CR.10 mice were compared to WT littermate control mice by 
unpaired Student‟s t test; n=6 per group. 





Total locomotion during the EPM and OF tests was measured to determine if 
locomotion in a novel environment with a component of stress was altered by over-
expression of 5-HT2C receptor in the forebrain. In the EPM, C2CR.33 mice travelled 
a similar total distance during the test compared to WT mice (Figure 3.7a, p=0.504), 
but they travelled significantly less than WT mice in the OF (Figure 3.7b, p=0.027), 
indicating hypolocomotion in response to a novel environment.  No hypolocomotor 
phenotype was found in C2CR.10 mice compared to WT mice (total distance 

































































Figure 3.6: Behaviour in the open field test in male C2CR.10 mice            
         The percentage of time spent (a) and the percentage of crossings (b) within 
the inner zone of the OF was reduced in C2CR.10 mice compared to WT mice.  All mice 
were males backcrossed to C57BL/6 for 3 generations. Data are expressed as 
mean±SEM; generated by A. Kimura. C2CR.33 or C2CR.10 mice compared to WT 
littermate control mice by unpaired Student‟s t test; EPM n =9-11 per group and OF n =5-

















































Figure 3.7: Distance travell  in the elevated plus maze and open field in al C2CR.33 
mice                    
The total distance travelled in the EPM (a) was unaltered between genotypes but was reduced in 
C2CR.33 in the OF (b).  All mice were males backcrossed to C57BL/6 for 3 generations. Data are 
expressed as mean±SEM,. C2CR.33 mice compared to WT littermate control mice by unpaired 
Student‟s t test; EPM n=9-11per group and OF n=5-6 per group. * p<0.05.  







In summary, C2CR.33 mice show a slight anxiety phenotype, in both the EPM and 
the OF, and hypolocomotion in the novel environment with a component of stress 
(OF only) compared to WT mice, while C2CR.10 mice only show a very slight 
anxiety phenotype in the OF and no locomotor phenotype. 
 
 
3.2.4 5-HT2C receptor over-expression causes 
hypolocomotion in C2CR.10 and C2CR.33 mice 
 
5-HT2C receptor transmission has been implicated in activity/locomotion, with 
agonists, such as mCPP causing hypolocomotion (Gleason et al., 2001). As 
C2CR.33 mice travelled less distance in the OF compared to WT mice, voluntary 
wheel running was tested in these mice to investigate their general activity.  
Voluntary wheel running allows the locomotion of an individual mouse to be 
monitored over an indefinite period of time in their home cage, providing data on the 
total activity as well as the circadian pattern of wheel running throughout the 
experiment. In C2CR.10 mice wheel running activity was significantly decreased 
compared to WT mice, entirely due to reduced activity in the dark phase (Figure 
3.8a; interaction F2,30=7.62; p=0.002; effect of genotype F1,30=35.84; p<0.0001).  
However, C2CR.33 mice showed no alterations compared to WT mice in wheel 
running behaviour (Figure 3.8b; interaction F2,30=1.14; p=0.333; genotype 
F1,30=0.15; p=0.703). 
 







3.3 Characterisation of models during backcrossing onto 
C57BL/6 
 
In the process of backcrossing the C2CR lines to C57BL/6, the phenotype of 
different generations was tested. This was to check if the modest increase in anxiety-
like behaviour and hypolocomotion seen in these mice at early backcrosses, would 
remain constant as genetic background can exert a strong influence on behaviour and 
the C2CR lines were on a mixed genetic background (CBA, C3H and C57BL/6).    
 
3.3.1 The increase in anxiety-like behaviour was lost in 
C2CR.33 mice during backcrossing onto C57BL/6 
 
The EPM and OF, tests of anxiety-like behaviour, were carried out over different 
generations during the backcrossing process; at generations 4, 6 and 7 on mice kept 


























































Figure 3.8: Voluntary wheel running in male C2CR.10 and C2CR.33 mice     
Wheel running was reduced in C2CR.10 mice (a) in the dark phase compared to WT mice.  No 
alteration in wheel running was found between C2CR.33 mice and WT mice (a). All mice were 
individually housed males, backcrossed to C57BL/6 for 3 generations and C2CR.33 data 
generated by A.Kimura.  Data are expressed as mean±SEM; C2CR.10 or C2CR.33 mice 
compared to WT littermate control mice by two-way ANOVA with Bonferroni posttests or 
unpaired Student‟s t test; n=6 per group.  *** p<0.001. 




travelled in the exposed regions of the maze were used to assess anxiety-like 
behaviour. Generations 6 and 7 of C2CR.33 mice showed no alteration from WT 
mice in the percentage of time spent in the open arms of the EPM (Table 2; 
interaction F1,35=0.97; p=0.332). This was consistent with the initial experiments 
carried out in this line in the EPM.  In the OF, in the initial characterisation using 
generation 3, a significant reduction in the percentage of time spent in the inner zone 
by C2CR.33 mice compared to WT mice was found (see Figure 3.5b). However, 
following backcrossing to C57BL/6 for 4, 6 and 7 generations there was no 
alteration from WT mice in the percentage of time spent in the inner zone of the OF 
in  (Table 2; interaction F2,64=0.44; p=0.648).  
 
 
Table 3.2: Percentage time (of total time) spent in the open arms of the elevated plus 
maze or inner zone of the open field following backcrossing onto C57BL/6 in male 
C2CR.33 mice 
No alterations between genotypes found in the percentage time spent in the open arms of 
the EPM or inner zone of the OF in male mice backcrossed to C57BL/6 for 4, 6 or 7 
generations. Data expressed as mean±SEM; C2CR.33 mice were compared to WT 
littermate control mice by two-way ANOVA with Bonferroni posttests; n=8-14 per group. 
 Generation 4 Generation 6 Generation 7 
WT C2CR.33 WT C2CR.33 WT C2CR.33 
EPM   28.6 ±5.4 24.19 ±5.63 20.8±2.14 24.06±3.1
6 
OF 18.6±5.71 17.0±4.43 17.4±3.04 13.2±2.67 21.7±4.77 21.1±3.08 
 
 
In the initial characterisation of C2CR.33 mice backcrossed to C57BL/6 for 3 
generations, although C2CR.33 mice had a similar percentage of time spent in the 
open arms compared to WT mice in the EPM, they travelled a significantly lower 
percentage of their total distance in the open arms compared to WT mice. It was 
concluded that C2CR.33 mice were freezing in the open arms due to increased 
anxiety-like behaviour. Following backcrossing to C57BL/6 for 6 and 7 generations, 
C2CR.33 mice did not differ from WT mice in the percentage of their total distance 
they travelled in the open arms in the EPM (Table 3; F1,33=0.00; p=0.959).  In the 




OF, generations 4, 6 and 7 of C2CR.33 mice did not differ from WT mice in the 
percentage of distance travelled in the inner zone of the OF (Table 3; F2,62=0.89; 
p=0.415), consistent with the data from generation 3 mice.  
 
 
Table 3.3: Percentage distance (of total distance) travelled in the open arms of the 
elevated plus maze or inner zone of the open field following backcrossing onto 
C57BL/6 in male C2CR.33 mice                     
No alterations between genotypes found in the percentage distance travelled in the open 
arms of the EPM or inner zone of the OF in male mice backcrossed to C57BL/6 for 4, 6 or 7 
generations. Data expressed as mean±SEM; C2CR.33 mice were compared to WT 
littermate control mice by two-way ANOVA with Bonferroni posttests; n=8-14 per group. 
 Generation 4 Generation 6 Generation 7 
WT C2CR.33 WT C2CR.33 WT C2CR.33 
EPM   23.1±4.3 24.3±4.94 29.53±4.04 31.2±3.85 
OF 25.5±3.5
6 
31±3.81 17.2±2.56 17.1±3.05 21.7±3.95 19.8±1.95 
 
 
Female C2CR.33 mice (backcrossed to C57BL/6 for 7 generations) were also tested 
for anxiety-like behaviour. However, in the EPM, no alteration from WT mice was 
found in either the percentage of time spent (Table 4; p=0.825) or percentage of 
distance travelled in the open arms (Table 4; p=0.473) or in the percentage of time 
spent (Table 4; p=0.832) or percentage of distance travelled in the inner zone (Table 
4; p=0.471) of the OF. In a gender comparison of C2CR.33 male and female mice, 
backcrossed to C57BL/6 for 7 generations, females have a higher percentage of 
distance travelled in the open arms of the EPM (Figure 3.9; F1,34=55.00; p<0.0001) 









Table 3.4: Behaviour in the elevated plus maze and open field test in female C2CR.33 
mice       
No alterations between genotypes found in the percentage of time spent or distance 
travelled in the open arms of the EPM or inner zone of the OF in female mice backcrossed 
to C57BL/6 7 generations. Data expressed as mean±SEM, with percentages representing 
the percentage of total distance or time throughout test; C2CR.33 mice were compared to 
WT littermate control mice by two-way ANOVA with Bonferroni posttests; n=7-9 per group. 






% Distance OF 
WT 37.07 ± 
5.13 
62.72 ± 5.49 20.25 ± 
3.84 
23.64 ± 4.22 
C2CR.33  35.17 ± 
6.92 
68.78 ± 6.11 19.11 ± 
3.37 











































Figure 3.9: Distance in the open arms of the elevated plus maze in C2CR.33 males and 
female mice                            
The percentage of distance travelled in the open arms of the EPM was similar between 
genotypes with female mice having increased percentage distance travelled compared to male 
mice.  Mice were males and females backcrossed to C57BL/6 for 7 generations. Data are 
expressed as mean ±SEM, n=7-12, C2CR.33 compared to WT littermate control mice by two-
way ANOVA with Bonferroni posttests.  




During the initial characterisation of C2CR.33 mice (backcrossed to C57BL/6 for 3 
generations) although no alteration in locomotion was found in C2CR.33 mice 
compared to WT mice in the EPM, a significant reduction in locomotion was found 
in the OF. In C2CR.33 mice, backcrossed to C57BL/6 for 6 (p=0.232) and 7 
generations (p=0.980) the total distance travelled in the EPM throughout the test was 
similar between genotypes (Figure 3.10a), consistent with the previous results. There 
was an effect of the generation of backcrossing onto C57BL/6 with generation 7 
mice travelling a greater distance around the maze than generation 6 (Figure 3.9a; 
F1,33=29.03; p<0.0001 by two-way ANOVA). The hypolocomotion found in 
C2CR.33 mice in the OF during the initial characterisation remained following 4 
generations of backcrossing onto C57BL/6 (Figure 3.10b; p=0.021) but was not seen 
after 6 (Figure 3.10b; p=0.52) or 7 generations (Figure 3.9b; p=0.334), there was a 
significant effect of generation (F1,58=10.77; p=0.0001, two-way ANOVA) and 
interaction with genotype (F1,58=3.08; p=0.05, two-way ANOVA). The loss of 
hypolocomotion in C2CR.33 mice actually appeared due to a reduction in 
locomotion across generations of WT mice (Figure 3.10c; p<0.0001, one-way 
ANOVA), while the locomotion of C2CR.33 mice was unaltered across generations 
(Figure 3.10d; p=0.459, one-way ANOVA).  





Because the initial characterisation showed a difference in locomotion, C2CR.33 
mice backcrossed to C57BL/6 for 6 generations, were tested in the OF for 30 
minutes.  Generation 6 mice were the earliest generation during backcrossing when 
no alteration was found between basal locomotion in this test.  There was no 
difference between genotypes even in this 30 min test (Figure 3.11; p=0.997). 
 
(b) Open Field
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(a) Elevated Plus Maze



































Figure 3.10: Total distance travelled in the elevated plus maze or open field in male 
C2CR.33 mice backcrossed to C57BL/6 for 4, 6 or 7 generations             
The total distance travelled in the EPM was unaltered between genotypes (a) although mice 
backcrossed to C57BL/6 for 7 generations travelled a greater distance than those backcrossed for 
6 generations.  In the OF the total distance travelled (b) was reduced in C2CR.33 mice compared 
to WT mice following backcrossing to C57BL/6 for 4 generations. However, following 6 and 7 
generations of backcrossing, no difference in locomotion was found between genotypes. 
Locomotion in the OF was reduced in WT mice (c) following 6 and 7 generations of backcrossing 
onto C57BL/6.  Distance travelled in the OF by C2CR.33 mice (d) was unaltered by backcrossing.  
All mice were male. Data are expressed as mean±SEM; C2CR.33 mice were compared to WT 
littermate control mice by unpaired Student‟s t test, one-way ANOVA and/or two-way ANOVA with 
Bonferroni posttests; n=8-9 per group. *** p<0.001 for gen 4 vs gen 6 and gen 4 vs gen 7 in c. 
 










Following backcrossing, C2CR.33 female mice were also tested in both the EPM 
and OF to determine if locomotion was altered. However, they did not differ from 
WT mice in either the EPM (Table 5; p=0.234, unpaired Student‟s t test) or OF 
(p=0.505, unpaired Student‟s t test).  In the EPM a significant effect of gender was 
found (F1,34=17.61; p=0.0002, two-way ANOVA) with female mice travelling a 





































Figure 3.11: Total distance travelled during a 30 minute open field test in male C2CR.33 
mice                     
Total distance travelled in the OF for 30 minutes is unaltered between genotypes.  All mice were 
males backcrossed to C57BL/6 for 6 generations. Data are expressed as mean±SEM; C2CR.33 
mice were compared to WT littermate control mice by unpaired Student‟s t tests; n=8-9 per group. 
 




Table 5: Total distance travelled in the elevated plus maze and open field in C2CR.33 
mice backcrossed to C57BL/6 for 7 generations             
Female C2CR.33 mice did not differ from WT control mice in total distance travelled in the 
EPM or OF.  All mice were backcrossed to C57BL/6 for 7 generations. Data are expressed 
as mean±SEM; C2CR.33 mice were compared to WT littermate control mice by unpaired 
Student‟s t tests; n=7-9. 
 Total Distance EPM Total Distance OF 
WT 904.72 ± 54.16 1901.15 ± 185.15 
C2CR.33  1009.23 ± 64.74 2084.27 ± 187.32 
 
 
In summary, the weak anxiety phenotype that had been found in both the EPM and 
OF and the hypolocomotion found in the OF during the initial characterisation of 
C2CR.33 mice was lost during the backcrossing process onto C57BL/6. 
 
 
3.3.2 5-HT2C receptor over-expression in C2CR.33 mice did 
not alter fear responses or depressive-like behaviour in this 
study 
 
The 5-HT2C receptor is implicated strongly in depression, although the literature is 
conflicting with both agonists and antagonists of this receptor having antidepressant 
properties (Dunlop et al., 2006; Millan et al., 2006; Dekeyne et al., 2008). 
Activation of the 5-HT2C receptor is involved in the regulation of the hypothalamic-
pituitary-adrenal (HPA) axis through corticotrophin-releasing hormone (CRH).  5-
HT2C receptor is also implicated in fear responses due to altered influence on HPA 
axis regulation. Although the anxiety-like phenotype previously found in C2CR.10 
and C2CR.33 mice was abolished following backcrossing onto C57BL/6, it is 
possible that other aspects of mood could be altered such as depressive-like 
behaviour. Hence, further tests were carried out. The conditioned avoidance test uses 
memory formation to an aversive stimulus as a measure of fear, with an increase in 
latency to move into the dark chamber following a foot shock indicating an increased 




association and fear response (described in Chapter 2 section 2.3.5). C2CR.33 mice, 
backcrossed to C57BL/6 for 6 generations, showed no difference to WT mice in the 
time delay to enter the dark compartment (Figure 3.12a, p=0.149).  
 
 
In order to test if there was a difference in depressive-like behaviour, a tail 
suspension test was used as described in Chapter 2 (2.3.4). Increased depressive-like 
behaviour is indicated by an increase in the percentage of time spent hanging 
passively during the test. C2CR.33 mice, backcrossed to C57BL/6 for 5 (Figure 
3.12b; p=0.583) and 6 generations (Figure 3.12b; p=0.159), showed no tendency 
toward an alteration in depressive-like behaviour compared to WT mice.   
 
 
These results suggest that over-expression of 5-HT2C receptors in the forebrain does 
not cause either an increased fear response or depressive-like behaviour.    
 
 

























(b) Tail Suspension Test






















Figure 3.12: Behaviour during conditioned avoidance and tail suspension tests in male 
C2CR.33 mice                   
No difference between genotypes was found in the delay in time taken to enter the dark 
compartment between the conditioned avoidance test when a shock is given and the second 
repeat test in male mice backcrossed to C57BL/6 for 6 generations (a; n=20). The percentage of 
time spent passively hanging throughout the tail suspension test was similar in both genotypes in 
male mice backcrossed to C57BL/6 for 5 and 6 generations (B; n=9-11).   Data are expressed as 
mean±SEM; C2CR.33 mice were compared to WT littermate control mice by unpaired Student‟s 
t test. 





3.3.3 Following backcrossing onto C57BL/6, locomotion was 
unaltered in C2CR.10 mice  
 
For the same reasons that anxiety-like behaviour was re examined during 
backcrossing, locomotion was also re-tested in C2CR.10 mice. During the initial 
characterisation C2CR.10 mice (backcrossed to C57BL/6 for 3 generations) showed 
hypolocomotion during the dark phase as well as reduced total daily running 
compared to WT mice. Following backcrossing to C57BL/6, there was no change in 
total wheel running, Figure 3.13; p=0.228) or in the light phase or dark phase (Figure 






























Figure 3.13: Voluntary wheel running behaviour in male C2CR.10 mice backcrossed to 
C57BL/6 for 4 generations                       
No difference between genotypes was found in basal wheel running in individually housed male 
mice backcrossed to C57BL/6 for 4 generations in normal lighting conditions. Data are expressed as 
mean±SEM; C2CR.10 were compared to WT littermate control mice by unpaired Student‟s t test or 
two-way ANOVA with Bonferroni posttests; n=6 per group. 




3.3.4 Overexpression of 5-HT2C receptors in C2CR.33 mice 
did not alter general agility and balance 
 
In order to assess locomotion in more detail, C2CR.33 were subjected to a rotorod 
test to test their general agility and balance. This was carried out to check that the 
presence of the transgene was not impairing their physical ability.  
 
C2CR.33 mice, backcrossed to C57BL/6 for 6 or 7 generations, performed just as 
well as the WT littermate control mice on the rotorod at 6 months of age (Figure 
3.14a; F1,28=0.14; p=0.714).  An effect of generation was found, with generation 7 
mice having reduced agility and balance compared to generation 6 mice (Figure 
3.14a; F1,28=29.68; p<0.0001), although no interaction of genotype and generation 
was found (F1,28=2.36; p=0.136).  C2CR.33 mice, backcrossed to C57BL/6 for 6 
generations, also had similar general agility and balance on the rotorod as WT mice 
at 3 months of age (data not shown, p=0.133).  A comparison of C2CR.33 male and 
female mice showed a significant reduction in agility and balance in both genders 
compared to WT mice (Figure 3.14b, F1,28=4.92;  p=0.035). Female mice had 
increased general agility and balance compared to males (F1,28=10.59; p=0.003) but 
there was no interaction of genotype with sex (F1,28=0.03; p=0.854).   
 
In summary, increased 5-HT2C receptor in the forebrain does not affect general 
agility and balance in C2CR.33 male or female mice, although female mice had 
increased agility and balance than male mice on the whole. 
(a) Rotorod
Effect of Generation









































Figure 3.14: Effect of generation and gender during the rotorod test in C2CR.33 mice      
There was no effect of genotype on the length of time male mice were able to stay on the rotorod 
(a) without circling or falling off, although generation 7 mice were not as agile as generation 6 male 
mice.  Male mice (a) were backcrossed to C57BL/6 for 6 and 7 generations, age 6 months, n=16-
18 per group. Male and female C2CR.33 mice were had reduced agility and balance than WT mice 
(b) and female mice had an increased length of time on the rotorod compared to male mice.  Male 
and female mice (b) were backcrossed to C57BL/6 for 7 generations, age 6 months, n=12-16 per 
group.  Data are expressed as mean±SEM;  C2CR.33 mice were compared to WT littermate 
control mice by two-way ANOVA with Bonferroni posttests.  
 




3.3.5 The pattern of 5-HT2C receptor mRNA over-expression in 
C2CR.33 mice was unaffected by backcrossing to C57BL/6 
 
It can be concluded from the behavioural assessment of the lines that the weak 
hypolocomotion and anxiety-like behavioural phenotypes found in the initial 
characterisation were lost during backcrossing to C57BL/6. There are many possible 
reasons for this that must be investigated in order to determine the underlying cause 
of this. One major possibility sometimes observed in transgenic lines is transgene 
silencing. Accordingly, 5-HT2C receptor mRNA and binding levels were re-assessed 
in generation 7 and 6 mice respectively.     
 
Following 7 generations of backcrossing to C57BL/6, 5-HT2C receptor mRNA levels 
remained elevated in C2CR.33 mice in the same brain regions (the CPu, AcbC, 
AcbSh, primary somatosensory cortex, primary and secondary motor cortex, BLA, 
cortex and dorsal and ventral CA1, CA2, CA3 fields of the hippocampus and DG) 
found in C2CR.33 mice backcrossed to C57BL/6 for 2 generations (Figure 3.15 
compare with Figure 3.3 from generation 2 mice).  The exception to the identical 
pattern between the two C2CR.33 generations is that generation 7 mice had 
increased 5-HT2C receptor compared to WT mice, which shows no alteration in 
generation 2 mice.  
 
Additional regions to those examined in generation 2 mice were examined in 
C2CR.33 mice backcrossed to C57BL/6 for 7 generations. Compared to WT mice, 
no alterations were found in the paraventricular nucleus (PVN), thalamus, SM, raphe 
nulceus or pontine, although a significant increase in 5-HT2C receptor mRNA level 























































































































































































Figure 3.15: 5-HT2C receptor mRNA expression frontal to posterior in adult male C2CR.33 
mice                               
5-HT2C receptor mRNA expression increase is maintained in C2CR.33 mice compared to WT 
littermate control mice in (a) Striatal (b) PVN (c) frontal forebrain, (d) posterior forebrain, (e) ventral 
limbic regions and (f) raphe nulcei. Expression levels were measured by optical densitometry of in 
situ hybridisation autoradiographs. Data are expressed as mean±SEM in males backcrossed to 
C57BL/6 for 7 generations and analysed by unpaired, 2-way ANOVA with Bonferroni posttests; n= 6 
per group. * p=<0.05; ** p=<0.01; *** p=<0.001. Interaction of genotype and region is (a) p=0.0331, 
(b) p=<0.0001, (c) p=0.0528, (d) p=<0.0001, (e) p=<0.0001 
CPu = caudate putamen; AcbN = nucleus accumbens core; AcbSh = nucleus accumbens shell; S1 
= primary somatosensory cortex; M1/M2 = primary/secondary motor cortex; PVN = paraventricular 
nucleus,   CA1, CA2 or CA3 = CA1, CA2 or CA3 field of the hippocampus; DG = dentate gyrus; BLA 
= basolateral amygdaloid nucleus (anterior); CP = choroid plexus; SN = substantia nigra; CORT = 
cortex  MRaphe = median raphe nucleus; DRaphe = dorsal raphe nucleus.  
 





In order to verify that the elevated mRNA levels were still being translated to 
protein, 5-HT2C receptors were measured again using a 
3
H-mesulergine binding 
assay. A two-fold increase in 
3
H-mesulergine binding was found in the forebrain of 
C2CR.33 mice backcrossed to C57BL/6 for 7 generations (Figure 3.16, unpaired 
Student‟s t test p=0.012) indicating increased 5-HT2C receptor number . Similarly to 
the initial characterisation in C2CR.33 mice, no alteration in 
3
H-mesulergine binding 
levels were found in hindbrain membrane preparations (p=0.657).   









































Figure 3.16:  5-HT2C receptor number in adult male C2CR.33 mice determined by 
3
H-
mesulergine binding assay                                                                                
In forebrain membrane preparations from C2CR.33 mice, 5-HT2C receptor number was 
increased compared to WT mice, with no alterations between genotypes in the hindbrain 
membrane preparation.  C2CR.33 mice backcrossed to C57BL/6 for 7 generations.  Data are 
expressed as mean±SEM; C2CR.33 mice compared to WT littermate control mice for each 
region using unpaired Student‟s t test; n=6 per group. * p<0.05 
 





3.4 Response to 5-HT2C receptor ligands in C2CR.10 and 
C2CR.33 mice 
 
When these experiments were undertaken the aim was to examine if the 
hypolocomotor effects of transgene expression could be due to an elevated forebrain 
5-HT2C receptor number, an increased ligand sensitivity of transgene encoded 5-
HT2C receptor (the unedited isoform has a higher constitutive activity and an 
increased ligand sensitivity in vitro) or a combination of both. However, even 
following the loss of behavioural phenotype during backcrossing onto C57BL/6 
experiments where ligands were administered were continued in case this might 
uncover a phenotype.        
 
The behavioural response to 5-HT2C receptor ligands, agonists and antagonists, were 
determined. Increased 5-HT2C receptors in C2CR.33 and C2CR.10 mice may cause a 
response at a much lower dose of agonist compared to WT mice or alternatively no 
effect on Kd might be predicted but a bigger response in C2CR lines at a given dose 
might be found. On the other hand, due to the over-expressed receptor being fully 
unedited it is possible that all of these receptors may be constitutively active and so 
no further response in behaviour may be found upon the injection of agonist. Inverse 
agonists are a useful tool to elucidate whether constitutive activity is present in a 
model. Ligands were administered by intraperitoneal injection 30 minutes prior to 
testing in the OF or 30 minutes prior to the onset of the dark phase in voluntary 












3.4.1 The effect of agonists and antagonists on behaviour in 
novel environment 
 
The open field test was used to assess the acute effect of 5-HT2C receptor agonists on 
both locomotor activity in a novel environment and anxiety-like behaviour. The 
mixed agonist, mCPP, which has been shown to induce anxiety and cause 
hypolocomotion but is preferential for the 5-HT2C receptor (Hackler et al., 2007; 
Stiedle et al., 2007), was administered.  Previously, Dr A. Kimura found a weak 
anxiety-like phenotype in C2CR.33 mice backcrossed to C57BL/6 for 3 generations, 
with a reduction in the percentage time spent in the inner zone of the OF (Figure 
3.17a) following vehicle injection. The significant reduction on the percentage of 
time spent in the inner zone was not seen following the administration of mCPP, due 
to a high level of variation in the WT mice group (Figure 3.17a, interaction between 
genotype and drug F1,15=0.00; p=0.993), and administration of 0.3mg/kg mCPP had 
no effect on the percentage of time spent in the inner zone in either C2CR.33 or WT 
mice (F1,15=0.11; p=0.747). However, a dose of 0.3mg/kg mCPP significantly 
reduced the percentage of distance travelled by C2CR.33 mice in the inner zone 
compared to WT mice (Figure 3.17b; interaction of genotype and drug F1,16=6.87; 
p=0.019). This indicates that C2CR.33 mice have a higher sensitivity to the 
anxiolytic effect of mCPP than WT mice. A strong hypolocomoter phenotype had 
been found in C2CR.33 mice, backcrossed to C57BL/6 for 3 generations, compared 
to WT mice in the OF (Figure 3.17c).  Administration of mCPP to WT mice 
significantly decreased total distance travelled in the OF, but was unable to further 
reduce locomotion in C2CR.33 mice (Figure 3.17c, interaction of genotype and drug 
F1,16=10.32; p=0.005). This suggests that 5-HT2C receptor over-expression is 
maximally inhibiting locomotion under basal conditions. Due to the lack of effect of 
mCPP (compared to saline injection) on the total distance travelled it can be 
concluded that the increased anxiety-like behaviour following mCPP administration 
(suggested by the reduced percentage distance travelled in the inner zone) was not 
attributable to a sedative effect of mCPP.  








Although mCPP has a high affinity for the 5-HT2C receptor, it has also been shown 
to act on other 5-HT receptor subtypes, which can affect behaviour.  Hence, a more 
selective 5-HT2C receptor agonist (RO 60-0175) was administered to determine the 
extent of 5-HT2C receptor contribution on behavioural responses. This experiment 
(a) Open Field





































































































Figure 3.17: Effect of mCPP on behaviour in the open field in male C2CR.33 mice         
0.3mg/kg mCPP given in the OF did not alter the percentage of time spent in the inner zone (a) in 
C2CR.33 or WT mice, reduced the percentage of distance travelled in the inner zone (b) in C2CR.33 
mice but not in WT mice and reduced the total distance travelled (c) in WT mice but was unable to 
further reduce locomotion in C2CR.33 mice.  All mice were males, backcrossed to C57BL/6 for 3 
generations.  Data are expressed as mean±SEM. Data generated by A. Kimura. C2CR.33 mice were 
compared to WT littermate control mice by two-way ANOVA with Bonferroni posttests; n=6 per group. 
* p<0.05, ** p<0.01. 




was undertaken in C2CR.33 mice, backcrossed to C57BL/6 for 6 generations, which 
under basal conditions do not show any altered behaviour compared to WT mice (see 
Figure 3.6b). Accordingly results following RO-60 0175 must be interpreted with 
caution when comparing to those gained from the mCPP injection. RO 60-0175 
significantly reduced total locomotion in the OF in both C2CR.33 and WT mice 
(Figure 3.18; F2,24=8.31; p=0.002), however locomotion in both genotypes was 





To test constitutive activity  of 5-HT2C receptors, an inverse agonist (SB206553) was 
administered. In the OF, both genotypes of mice became almost completely 
immobile following SB206553 administration (Figure 3.19, p=0.464). This was 
unexpected as an inverse agonist should prevent constitutive activity of 5-HT2C 
receptor and so was predicted to increase locomotion. At this point, further tests 































Figure 3.18: Response to RO 60-0175 administration in the open field in male C2CR.33 mice    
Total locomotion travelled in the OF was reduced following IP injection of RO 60-0175 (3mg/kg or 
5mg/kg), in both gentoypes.  All mice were males, backcrossed to C57BL/6 for 6 generations. Data are 
expressed as mean±SEM; C2CR.33 mice were compared to WT littermate control mice by two-way 
ANOVA with Bonferroni posttests; n=9 per group. 
  




be noted that within text freezing was classified as maintaining a rigid, fixed position 
for a period of 10 seconds while a sedation effect would be expected to have the 






3.4.2 Response to 5-HT2C receptor ligands in C2CR.10 mice 
on wheel running behaviour 
 
Effects of 5-HT2C receptor ligands or vehicle on locomotor activity in wheel cages 
were measured in C2CR.10 mice as they showed a hypolocomotion phenotype under 
basal conditions. C2CR.10 mice had reduced activity compared to WT mice (Figure 
3.20, F1,30=5.27; p=0.029). Compared with saline injection, the lower dose of mCPP 







































Figure 3.19: Inhibition of distance travelled in the open field following administration of 
SB 206553 in male C2CR.33 
The total distance travelled in the OF was inhibited (% inhibition represents the difference in 
distance travelled before and after SB206553) in both genotypes in response to the 
administration of inverse agonist (SB206553).  All mice were males, backcrossed to C57BL/6 
for 4 generations. Data expressed as mean±SEM; C2CR.33 mice were compared to WT 
littermate control mice for each region using unpaired Student‟s t test; n=7 per group. 
 




significantly reduced locomotion in both genotypes (Figure 3.20, effect of drug 
F2,30=3.81; p=0.034) but there was no interaction between drug and genotype 








In order to further examine whether the reduced wheel running activity was due to 
higher sensitivity of the receptor to endogenous 5-HT or increased constitutive 
activity, a selective 5-HT2C receptor antagonist (SB242084) or an inverse agonist 
(SB206553) were injected 30 (minutes prior to the onset of the dark phase) and 
activity measured for two hours following dark phase onset. This experiment was 
planned and carried out in parallel with the administration of SB206553 in C2CR.33 

































Figure 3.20: Effect of mCPP administration on voluntary wheel running in C2CR.10 mice 
C2CR.10 mice had reduced locomotion to WT mice following saline administration, 0.3mg/kg 
mCPP had no effect but 3mg/kg mCPP reduced locomotion in WT mice.  All mice were males, 
backcrossed to C57BL/6 for 3 generations.  The effect of mCPP on wheel rotations was 
measured for two hours following IP injection. Data are expressed as mean±SEM; C2CR.10 mice 
were compared to WT littermate control mice by two-way ANOVA with Bonferroni posttests; n=6 
per group.  
 




mice; it was not designed to test the unexpected results in Figure 3.19.  A dose of the 
SB242084 previously shown to antagonise 5-HT2C receptors was chosen. Again, 
locomotion was reduced in C2CR.10 mice compared to WT mice (Figure 3.21; 
effect of genotype F1,10=5.80; p=0.037). However, there was only a trend of effect of 
drug (F1,10=3.64; p=0.085) and there was no interaction between drug administration 
and genotype (F1,10=0.51; p=0.490). This suggests that the hypolocomotion of 
C2CR.10 mice could be partly to constitutive activity of the overexpressed 5-HT2C 
receptor rather than increased ligand activation by endogenous 5-HT however the 




Administration of the inverse agonist reduced locomotion in both C2CR.10 and WT 
mice (Figure 3.22a, effect of drug F2,20=9.48; p=0.001) similar to the response in 
C2CR.33 following administration of SB206553. There was an effect of genotype 
(F1,20=5.14; p=0.047) with a dose-dependent effect of SB206553 on locomotion in 



























Figure 3.21: Effect of SB242084 administration on voluntary wheel running in C2CR.10 
mice                       
C2CR.10 mice had reduced locomotion to WT mice following vehicle (5%DMSO in water) 
administration and there was trend for an effect of antagonist administration.  All mice were 
males, backcrossed to C57BL/6 for 3 generations.  The effect of SB242084 on wheel rotations 
was measured for two hours following IP injection. Data are expressed as mean±SEM; C2CR.10 
mice were compared to WT littermate control mice by two-way ANOVA with Bonferroni 
posttests; n=6 per group. (* p<0.05 by unpaired Student‟s t test)  
 
 




way ANOVA).  It is possible that the inverse agonist is unable to reduce locomotion 
in C2CR.10 mice further than the hypolocomotion caused by over-expression of 5-
HT2C receptor.  These data and the above data (Figure 3.19) suggested that this 
inverse agonist was acting on receptors other than 5-HT2C receptors. Accordingly, 
SB206553 was administered to TetO-2CR mice which show negligible expression of 
the 5-HT2C receptor (see Chapter 5).  Locomotion was reduced in both WT and 
TetO-2CR mice to the same degree (Figure 3.22b; p=0.818. See Chapter 4 for 
further details) indicating that SB206553 administered intraperitoneally is not 

















































































Figure 3.22: Effect of SB206553 administration on wheel running in C2CR.10 or TetO-2CR 
mice                            
Compared to vehicle (5%DMSO in water), administration of 1mg/kg or 5mg/kg inverse agonist 
(SB206553) reduced wheel running (a) in both C2CR.10 and WT mice. Both doses had a similar 
effect in C2CR.10 mice while there was a dose-dependent effect of SB206553 in WT mice.  Male 
mice backcrossed to C57BL/6 for 4 generations (a).  Wheel running was inhibited in both TetO-
2CR and WT mice (b) following administration of 5 mg/kg dose of SB206553. The effect of 
SB206553 on wheel rotations was measured for two hours following IP injection. Data expressed 
as mean±SEM. C2CR.10 mice were  compared to WT littermate control mice by two-way 
ANOVA with Bonferroni posttests and TetO-2CR mice were compared to WT littermate control 
mice by unpaired Student‟s t test; n=6 per group. * p<0.05.   






3.5.1 5-HT2C receptor mRNA and protein levels in brains of 
C2CR.10 and C2CR.33 mice during initial characterisation 
 
5-HT2C receptor mRNA expression was significantly increased in both C2CR.33 
mice (high over-expressor) and C2CR.10 mice (low over-expressor) limbic regions 
and the cerebral cortex (C2CR.33 mice only).  The transgene generated 5-HT2C 
receptor mRNA over-expression pattern is more restricted in C2CR.10 mice than in 
C2CR.33 mice. C2CR.10 mice had over-expression of 5-HT2C receptor in the AcbC, 
dorsal CA1 field of the hippocampus, dorsal and ventral CA3 field of the 
hippocampus and dorsal and ventral DG. In addition to these areas, C2CR.33 mice 
had overexpression in the CPu, AcbSh, primary somatosensory cortex, primary and 
secondary motor cortex as well as the cortex and BLA. C2CR.33 mice had more 
regions with overexpression of 5-HT2C receptor mRNA in the hippocampus 
compared to C2CR.10 mice with elevated levels in the dorsal and ventral CA1, CA2, 
CA3 fields of the hippocampus and DG.  Interestingly, C2CR.10 mice had 
significantly elevated 5-HT2C receptor mRNA levels in the SN compared to WT 
mice, but no alterations were found in this region in C2CR.33 mice. This pattern of 
expression, driven by the calcium-calmodulin-dependent protein kinase IIα promoter 
(CamKIIα), was similar to the observed pattern of endogenous 5-HT2C receptor 
expression.  
 
The increased 5-HT2C receptor mRNA levels were translated into increased receptor 
levels in the forebrain of C2CR.33 mice as demonstrated in the binding study.  In 
C2CR.10 mice, it was not possible to detect an increase in 
3
H-mesulergine binding in 
the membrane preparation containing the forebrain, possibly because the preparation 
also contained the midbrain and the cortex (together constituting a large proportion 
of the forebrain) and 5-HT2C receptor mRNA levels were unaltered in these regions 
in C2CR.10 mice.  In the hindbrain membrane preparation, 5-HT2C receptor protein 
did not differ between C2CR.33 and WT mice. However, in C2CR.10 mice a 
significant increase in binding was found in the hindbrain membrane preparation.  




One contributing factor could be the possibility that a larger portion of the raphe 
nuclei was incorporated into the hindbrain membrane preparation in C2CR.10 
preparations compared to C2CR.33 preparations.  In the raphe nucleus, 5-HT2C 
receptor mRNA levels were unaltered in C2CR.33 mice but it is possible they are 
elevated in C2CR.10 mice, which was not examined in this line due to a lack of 
mice.  A known problem in transgenic models generated using the CamKIIα 
promoter (which is expected to cause alterations in the forebrain) is the expression of 
the transgene in the cerebellum and this is may be the case in C2CR.10 mice.  
Unfortunately due to a shortage of animals, analysis of the cerebellum to assess 5-




3.5.2 Behavioural phenotype in 5-HT2C receptor 




Due to the regions of 5-HT2C receptor over-expression in both C2CR.10 and 
C2CR.33 mice in the limbic system and cortex, an increase in anxiety-like 
behaviour, depressive like behaviour and hypolocomotion were anticipated. 
 
During the initial characterisation a slight increase in anxiety-like behaviour in 
response to novel environments containing a component of stress, was found in both 
C2CR.33 and C2CR.10 mice.  This consistent phenotype seen in both lines suggests 
this was a result of the 5-HT2C receptor over-expression rather than disruption of an 
unknown gene by the random chromosomal insertion of the transgene. The 
behavioural phenotype of C2CR.33 mice was greater than that of C2CR.10 mice 
with greater anxiety-like behaviour than C2CR.10 mice. Hypolocomotion in 
response to a novel environment was observed in C2CR.33 mice only.  
 




The increase in anxiety-like behaviour in the absence of exogenous ligand suggests 
that receptors in C2CR.10 and C2CR.33 mice may be already activated by low levels 
of endogenous ligand or may be constitutively active. Either (or both) could result 
from an altered ratio of unedited to edited 5-HT2C receptor isoforms in these lines as 
the transgene generated receptors are not capable of being edited. Alternatively, as 
the 5-HT2C receptor influences the HPA axis through the regulation of CRF in 
hypothalamic regions (Heisler et al., 2007a), and increased anxiety-like behaviour 
may be caused by altered HPA axis activity. However, as 5-HT2C receptor mRNA 
levels were unaltered in hypothalamic regions and it had previously been shown that 
under both basal and stressed conditions corticosterone levels were similar in both 
C2CR.10 and C2CR.33 mice compared to WT mice (Kimura et al., 2009), therefore 
it is unlikely that the anxiety phenotype results from a hypersensitive HPA axis.  
 
To date, the literature supports the finding that increased 5-HT2C receptor signalling 
elevates anxiety-like behaviour, while antagonists act as anxiolytics (Kennett et al., 
1989, Jenck et al., 1998, Harada et al., 2008). 5-HT2C receptor knock-out (KO) mice 
had an anxiolytic phenotype (Heisler et al., 2007b) which concurs with the literature 
on the effect of antagonists.  
 
Hypolocomotion resulted from forebrain 5-HT2C receptor over-expression, although 
hypolocomotion was dependent on the line of C2CR mice and the behavioural test 
used. Over-expression of 5-HT2C receptors in C2CR.33 mice caused hypolocomotion 
in the novel environment of the OF. However, this was not replicated in C2CR.10 
mice (Kimura et al., 2009). This could be explained by the elevation in 5-HT2C 
receptor mRNA levels in the cortex (responsible for locomotor functions) only being 
present in C2CR.33 mice and not in C2CR.10 mice. 
 
Voluntary wheel running allows locomotion to be examined without the stress of a 
novel environment although it is dependent on the mice voluntarily exercising. No 
difference in total wheel running was found in the C2CR.33 mice (A. Kimura, 
unpublished data) compared to WT mice.  In contrast, a strong hypolocomotor 
phenotype was found in C2CR.10 mice in this test. One possible explanation for this 




difference between the lines is that 5-HT2C receptor protein levels were elevated in 
the hindbrain membrane preparation of C2CR.10 mice, but not C2CR.33 mice. 
Dopamine (DA) is involved in locomotion and the 5-HT2C receptor influences DA 
release. It is believed that an inhibitory control on both the mesolimbic and 
nigrostriatal DA systems by 5-HT occurs through the 5-HT2C receptor (Di Matteo et 
al., 2001; Di Matteo et al., 2002; De Deurwaerdere et al., 2004; Higgins and 
Fletcher., 2003; McMahon et al., 2001). It is well established that DA depletion by a 
gradual degeneration of SN compacta (SNc) cells projecting to the STR results in 
loss of movement in Parkinson‟s disease (Bossy-Wetzel et al., 2004).   Functioning 
of the substantia nigra (SN) is vital as it is one of three regions in the brain 
containing primary DA synthesising cells. 5-HT2C receptor mRNA levels were 
elevated in the SN only in C2CR.10 mice, so it is possible that the increase in 5-
HT2C receptors in the SN may influence DA levels.  The relationship between 5-
HT2C receptor activation in the SN, leading to inhibition of DA release in the nucleus 
accumbens and prefrontal cortex by reduced firing rate and bursting-activity of DA-
containing neurons in the ventral tegmental area (VTA) could be the mechanism by 
which this hypoclocomotion is achieved and this will be discussed in greater detail in 
chapter 5, where aspects of the DA system are examined.  
 
The different behavioural tests used allow different parts of the CNS to be tested. 
Therefore, the increase in 5-HT2C receptor in the SN in C2CR.10 mice (but not 
C2CR.33 mice) may underlie the hypolocomotor phenotype in voluntary wheel 
running cages and the increase in 5-HT2C receptor in the cortex of C2CR.33 (but not 











3.5.3 The effect of strain background on the phenotype of 5-
HT2C receptor over-expressing mice 
 
In order to establish a good model for carrying out behavioural tests it is vital that the 
genetic background of transgenic mice is the same as their WT controls as different 
strains have markedly different behavioural traits. Thus behavioural traits may be 
due to mixed genetic backgrounds in transgenic mice rather than the transgene itself, 
or could reflect the interaction of different backgrounds with the transgene. 
Backcrossing onto the C57BL/6 line was chosen, as this line has been well 
characterised in behavioural tests and is known to breed consistently well. Mouse 
strains which show a high level of physical activity are a good choice for examining 
a putative hypolocomotor phentoype and/or increased anxiety-like behaviour, both of 
which were hypothesised to result from 5-HT2C receptor over-expression in this 
model. C57BL/6 mice show high levels of locomotion (ambulation) in the OF and 
low levels of anxiety-related measures. Following eight generations of backcrossing 
onto C57BL/6 the line is considered to be congenic with C57BL/6 genetic 
background which, as mentioned above, is desirable for behavioural testing so any 
alterations in phenotype found likely due to the transgene instead of a mixed genetic 
background. 
 
During the backcrossing procedure, C2CR mice were retested to confirm the 
behavioural phenotype found in the initial characterisation. However, both the 
anxiety-like phenotype and hypolocomotion of C2CR.33 mice were no longer 
detectable following backcrossing and similarly, the strong hypolocomotion 
phenotype of C2CR.10 mice in wheel running cages disappeared (due to a shortage 
of animals it was not possible to retest this line in the mazes). It remains possible that 
although the previous phenotype was no longer detectable, other similar tests may be 
able to detect a behavioural difference in these lines of mice. However, it is also 
possible that the phenotype may be due to a mixed background. The possibility of 
transgene silencing was ruled out.  
 




The alteration in genetic background must be considered as a major factor in the loss 
of phenotype. Early generations in the backcrossing process will have a mixed 
behavioural phenotype due to the lines used in the production of this model; CBA, 
C3H and C57BL/6. All of these lines have similar characteristics in behavioural tests 
(for example percentage time in open quadrants of elevated zero maze; 12.7% in 
C57BL/6, 23.6% in CBA and 28.4% in C3H, from Mouse Phenome Database, Jax 
Laboratories). In both the novel environment with a component of stress (OF) and in 
voluntary wheel running, the loss of locomotor phenotype is being generated by a 
reduction in total locomotion in the WT mice.  It is unlikely that this reduction is due 
to the increased genetic background of C57BL/6 as a similar reduction would be 
anticipated in C2CR.10 and C2CR.33 mice.  All of the mouse lines used in 
generating C2CR mice have similar locomotor activity, for example horizontal 
movement is around 2513 in C3H, 2889  in CBA and 3226  in C57BL/6 (from 
Mouse Phenome Database, Jax Laboratories) so if anything, an increase in general 
locomotion would have been anticipated with the increased influence from C57BL/6.  
 
 
Additional tests were carried out on the later generations of C2CR.33 mice in case 
another aspect of mood was altered, such as fear responses. 5-HT release and 
activation of 5-HT2 receptors, particularly within the amygdaloid complex, have 
been associated with anxiogenic behaviours and emotional stress (Chaouloff et al., 
2000; Kawahara et al., 1993; Stein et al., 2000) as well as facilitating conditioned 
fear in rodents (Graeff et al., 1997; Mora et al., 1997) and learned fear in humans 
(Graeff et al., 1996).  The 5-HT2C receptor has been shown to have an anxiolytic 
effect in conditioned anxiety (Davis et al., 1986) and activation within the 
basolateral amygdala (BLA) potentiates innate fear responses (Campbell and 
Merchant., 2003). Because C2CR.33 mice have increased 5-HT2C receptor mRNA 
levels in the amygdaloid complex, it was hypothesised that conditioned fear 
responses may be increased. This was not found to be the case. The regulation of 
fear responses is complex and 5-HT2C receptor activation has region-specific 
consequences, with inhibition of innate fear responses in the dorsal periaqueductal 
gray region but potentiation of conditioned fear in the amygdala (Graeff et al., 1997). 




Another point of interest is that the 5-HT2C receptor is expressed on both the 
projection neurones and interneurons in the BLA (Stein et al., 2000) which could 
have opposing actions on GABA release (Rainnie et al., 1999; Stutzmann et al., 
1999). Due to the complex regulation of fear responses and dependency on the 
specific type of anxiety, for example learned or innate fear, further tests would have 
to be carried out to exclude an effect of forebrain over-expression of 5-HT2C 
receptors upon fear responses.  
 
The literature on the effects of 5-HT2C receptor agonists and antagonists upon 
depressive-like behaviour is conflicting. Antagonists, such as the potent 5-HT2C 
receptor antagonist, S32006 (Dekeyne et al., 2008) in addition to being anxiolytic, 
have antidepressive properties (Millan et al., 2006).  DBA/2N mice have lower brain 
5-HT levels and are found to be insensitive to citalopram, a SSRI, but when a 5-
HT2C receptor antagonist is administered in combination with citalopram this 
restores its antidepressant effect (Calcagno et al, 2008). Agomelatine, a 5-HT2C 
receptor antagonist and melatonin receptor agonist, is effective in the treatment of 
major depressive disorder as well as SAD disorder (Millan et al., 2005; Pjerk et al 
2006), and has been found to improve sleep disturbances (Pandi-Perumal et al., 
2009). There is evidence that agonists of the 5-HT2C receptor may also be efficacious 
antidepressants (Dunlop et al., 2006). In C2CR.33 mice, over-expression of 5-HT2C 
receptor in the forebrain did not alter depressive-like behaviour. This result is not 
conclusive as only one test of depressive-like behaviour was used.  Some 5-HT2C 
receptor antagonists are inactive in tests of antidepressant, anti OCD and antipanic 
activity (Jenck et al 1998) indicating that the effects may be due to off-target effects 
of the antagonist or that 5-HT2C receptor involvement is not always picked up in 
behavioural testing. Hence further tests are required to confirm this absence of 
depressive-like behaviour in this model. 
 
The general ability and balance of the mice was tested using the rotorod in order to 
exclude this as a cause for the hypolocomotion previously found.  C2CR.33 mice 
performed just as well as WT mice in this test and no obvious differences in activity 
in home cages were noticed in C2CR.10 or C2CR.33 mice (personal observation). 




This suggests that the hypolocomotion found during the intitial characterisation was 
due to mixed genetic background.  
 
There are many possible reasons for the loss of phenotype following backcrossing, 
the genetic background of the mice has already been discussed. The most easily 
tested is that the transgene may be silenced by mutations or epigenetic silencing 
through generations.  This can be ruled out in C2R.33 mice as the generation 6 
C2CR.33 mice still had increased 5-HT2C receptor mRNA in the same regions as 
found during the initial characterisation as well as increased 5-HT receptor levels in 
the forebrain. 
 
One major factor to consider is that there was a move in animal facilities at the time 
when the phenotype was lost. The new facility is much bigger, busier and noisier 
than the previous one, possibly stressful for the mice, with consequent effects on 
behaviour. To assess whether the business of the holding rooms was causing the loss 
of phenotype, following weaning animals were moved to a secluded quiet room 
where access was restricted. This did not restore the phenotype, even after several 
months.  In addition, breeding of the mice in the quiet area of the unit (to eliminate 
any possibility of stress caused by moving animals within the unit) had no impact on 
the behavioural phenotype. 
 
The area to consider in this alteration in WT locomotion is the HPA axis which is 
influenced by the 5-HT2C receptor as previously mentioned. The decreased 
locomotion in the OF in WT mice over generations could be due to alterations in the 
HPA axis resulting from backcrossing onto the C57BL/6 background. However, in 
all lines involved in the generation of this model (C57BL/6, CBA and C3H) adrenal 
weights and corticosterone secretion are similar and therefore altering the genetic 
background of the mice by backcrossing onto C57BL/6 would not be expected to 
alter either adrenal weights or corticosterone secretion. Effects of transgenes can 
greatly depend on the genetic background of the strain with some non sense 
mutations being lethal on one strain but not on another (for example, 11βHSD2 KO 
mouse). In the OF the total locomotion in C2CR.33 mice remained constant across 




generations while WT mice locomotion altered. It would be expected that a similar 
alteration in locomotion would be found in both C2CR.33 and WT mice would be 
expected if the change was due to backcrossing onto the C57BL/6 background. It is 
possible that the transgene is maintaining locomotion regardless of the genetic 
background across generations in C2CR.33 mice. Voluntary wheel running has been 
shown to have an antidepressant effect and alters both adrenal weight and HPA axis 
responses initially and it is possible that these potential alterations in could affect 
wheel running behaviour in C2CR.10 and WT mice. 
 
There may have been compensation for the increase in 5-HT2C receptor within the 
serotonin system which occurred over the generations during backcrossing. For 
example, a reduction or increase in another 5-HT receptor could normalise the 
behavioural phenotype. This will be discussed in Chapter 5, where both the 5-HT 
and DA systems were examined. 
 
 
3.5.4 Response to 5-HT2C receptor agonist and antagonist 
administration in C2CR.10 and C2CR.33 
 
The injection procedure for ligand administration is a stressful one in for mice and 
vehicle injection caused hypoactivity in C2CR.10, C2CR.33 and WT mice, in both 
the OF and voluntary wheel running tests. The stress of removing mice from their 
wheel cages and the injection inhibited their previously consistent activity patterns. 
The extent of this hypoactivity varied and, in some cases, was so severe that no 
further inhibition of activity could be observed following agonist administration. The 
acute nature of the effect (under thirty minutes) excluded a genomic action of, for 
example, corticosterone (which would most probably take over forty minutes). The 
hypolocomotion response plausibly results from a direct effect of 5-HT release, or 
other neurotransmitter pathways, rather than the transgene, as C2CR.10. C2CR.33 
and WT mice were equally affected. 
 
 




3.5.4.1 Response to 5-HT2C receptor agonists in C2CR.33 
mice in a novel environment 
 
The mixed 5-HT2C receptor agonist, mCPP, administered at levels previously shown 
to reduce locomotion in mice, reduced activity in both voluntary wheel running and 
in a novel environment (OF). In the novel environment, although effective in 
reducing locomotion in WT mice, mCPP was ineffective in C2CR.33 mice. This 
suggests that mCPP is unable to further decrease locomotion below that seen with 
vehicle in this line. In 5-HT2C receptor KO mice, mCPP actually elicits hyperactivity 
(Heisler & Tecott., 2000; Dalton et al., 2004) which could be due to activation of 5-
HT1B and 5-HT2A receptors which is unmasked in the absence of 5-HT2C receptors. 
Hence the more specific 5-HT2C receptor agonist, RO 60-0175, was used in the next 
experiment. A sedative-like effect of RO 60-0175, with no effect on anxiety, has 
been reported (Kennett et al 2000). RO 60-0175 administration reduced locomotion 
of WT and C2CR.33 mice. It is possible that a sedative like effect could be the 
reason for the reduced locomotion of C2CR.33 mice but in order to determine this, a 
dose-response should be carried out. It is possible that hypolocomotion is not a 
sensitive measure in this test and so an antagonist should be administered to block 
the effect of the agonist. The administration of 5-HT2C receptor agonists reduced 
locomotion in both WT and transgenic mice to some extent, therefore there is no 
evidence in these experiments for altered sensitivity of 5-HT2C receptor.   
 
 
3.5.4.2 Response to 5-HT2C receptor ligands in C2CR.10 mice 
in voluntary wheel running cages 
 
At the higher dose, the mixed 5-HT receptor agonist, mCPP, reduced wheel-running 
activity equally in both C2CR.10 and WT mice although interestingly the level of 
agonist inhibition of activity did not differ between the genotypes regardless of the 
different receptor expression levels. The antagonist (SB242084) failed to elevate 
activity levels in both C2CR.10 and WT mice at a dose previously shown to be 




inhibitory in vivo (Kennett et al., 1997; Nonogaki et al., 2007). This suggests that the 
hypoactivity of C2CR.10 mice could be due to constitutive 5-HT2C receptor activity 
and not to ligand activation by the low levels of endogenous 5-HT present. In order 
to assess the constitutive activity element an inverse agonist can be used which 
antagonises both the ligand-activated receptor activity in addition to reversing 
constitutive activity. The inverse agonist SB206553 had previously been used in vivo 
successfully in rat, human and frog (Berg et al 1999; Chanrion et al 2007).  
Surprisingly, instead of restoring activity levels, administration of SB206553 
virtually abolished all movement in wheels or a novel environment, regardless of 
genotype.  In rats the standard dose of SB206553 used is 5mg/kg, due to the non-
specific effect found by the 5mg/kg dose in these mice it was possible that 
(considering the bell-shaped dose response curve) too high a dose had been given. 
However, a lower dose of SB206553 (1mg/kg) also reduced locomotion. Notably, a 
similar effect was found in 5-HT2C receptor-deficient mice (TetO-2CR mice; Chapter 
4) suggesting that in mice, this effect of SB206553 is independent of 5-HT2C 
receptor. This inverse agonist also binds to 5-HT2B receptor which in the brain has 
similar effects to 5-HT2C receptor. However, the 5-HT2B receptor is also expressed in 
the periphery where it is found is on motor neurones. It could therefore affect 
movement through a peripheral action due to administration intraperitoneally. It 
might also be acting on 5-HT2A receptors in the mouse brain due to large 
homologous regions with the 5-HT2C receptor, predicted to reduce movement.  
 
Because SB206553 is not a specific 5-HT2C receptor inverse agonist in mice, this 
experiment was unable to determine if the hypolocomotion is due to increased 
constitutive activity or enhanced sensitivity to endogenous ligand.  It is likely that a 
combination of constitutive activity and enhanced endogenous ligand sensitivity will 










3.5.7 Concluding Remarks 
 
The transgene resulted in 5-HT2C over-expression in a restricted region-specific 
manner in C2CR.10 compared to C2CR.33 mice which had over-expression in most 
brain regions examined. C2CR.33 mice had higher over-expression of 5-HT2C 
receptor compared to C2CR.10 mice.  5-HT2C receptor binding sites were increased 
in the forebrain of C2CR.33 mice and in the hindbrain of C2CR.10 mice.  Both 
C2CR.10 and C2CR.33 lines of mice showed anxiety-like behaviour and 
hypolocomotion; an effect that was lost on subsequent backcrossing to C57BL/6 and 
there was no indication of altered depressive-like or fear behaviour.  This loss of 
behavioural phenotype was not due to transgene turn off as 5-HT2C receptor mRNA 
and binding sites were still elevated in C2CR.33 mice following backcrossing to 
C57BL/6 for 7 or 6 generations. The reason for the loss of phenotype is therefore 





























CHAPTER 4:  
CHARACTERISATION OF A MOUSE  
DEFICIENT IN THE 5-HT2C RECEPTOR   















This experimental chapter examines the 5-HT2C receptor under-expressing mouse 
line and has the following aims: 
1. To determine the extent of the deficiency in 5-HT2C receptors in the TetO-
2CR mouse line 
2. To establish any behavioural phenotype that may be present as a result of the 
5-HT2C receptor deficiency and examine functionality of the 5-HT2C receptor 
using ligand studies 
3. To consider if the deficiency in the 5-HT2C receptor could alter the regulation 
of either the food entrainable oscillator or the light entrainable oscillator 
It was hypothesised that 5-HT2C receptor would be decreased causing 




















5-HT2C receptors have been implicated in many behaviours including the regulation 
of mood, food intake and locomotion (Gleason et al., 2001; Schuhler et al., 2005; 
Harada et al., 2008).  Mice that lack 5-HT2C receptors (5-HT2C receptor KO mice) 
are hyperphagic, developing obesity in later life (Tecott et al., 1995), have an 
anxiolytic phenotype (Heisler et al., 2007b), show hyperlocomotion (Heisler & 
Tecott., 2000; Dalton et al., 2004) and obsessive compulsive behaviour (Chou-Green 
et al., 2003).  In many cases creating a knockout model of a particular receptor 
provides an indispensible tool to elucidate its pathophysiological function. This 
study uses mice, termed TetO-2CR mice (developed by McColl, Chapman, Homes 
and Melton, see Chapter 2), in which the 5-HT2C receptor has been targeted using a 
construct containing a tetracycline activator (TetA) hence nomenclature of TetO-
2CR but in this case being used as an under-expressing model. In TetO-2CR mice, 
the expression of the 5-HT2C receptor is driven by the normal 5-HT2C receptor 
promoter and, unexpectedly, a deficiency in the 5-HT2C receptor was produced 
throughout the brain. This model has the advantage of having low levels of the 
receptor throughout development as opposed to no 5-HT2C receptors which can be a 
potential problem in knockout models (KO). This is the case in the 5-HT2C receptor 
KO mice as a percentage of these animals suffer from spontaneous seizures and 
death (Tecott et al., 1995). TetO-2CR mice are novel as they are resistant from 
spontaneous seizures.  The first aim of this chapter was to establish the extent of this 
deficiency and the effect this has on behaviour.  Secondly, the loss of receptor 
expression may result in compensatory alterations in other systems and this will be 
considered.  The final part of this chapter considers whether a deficiency in 5-HT2C 
receptor could alter the regulation of the light entrainable oscillator (LEO) and/or the 
food entrainable oscillator (FEO).    
 
 




4.2 Basic Analysis of model 
The construct used to create the TetO-2CR mice was targeted to the 5-HT2C receptor 
gene. The targeting cassette was found to be passed through the generations with a 
ratio of 2 WT: 1 TetO-2CR mice per litter, with the average litter size being 9 pups.  
Basic analysis of model had been carried out by A. Kimura which showed that until 
23 weeks of age TetO-2CR mice had a similar BW growth curve to WT mice 
(Figure 4.1a) after which  BW diverged and TetO-2CR mice became significantly 
heavier than WT mice (Figure 4.1b; p=0.005). TetO-2CR males were also shown to 
have a greater food intake (Figure 4.1c; p=0.003).   












































































(a) BW Growth Curve
(b) Body Weight (c) Food Intake
 
Figure 4.1: Body weight and food intake in TetO-2CR males                                                  
Effect of genotype on (a) Body weight growth curve (WT = black; TetO-2CR = red), (b) body 
weight at 24 weeks and (c) average hourly food intake in 24 week old TetO-2CR males, 
generation 2 of backcrossing onto C57BL/6. Data are expressed as mean±SEM and TetO-2CR 
males are compared to WT littermate controls by unpaired Student‟s T-test; n=6-19 per group. ** 
p <0.01.  




4.2.1: Tetracycline activator (tTA) mRNA is present in TetO-
2CR mice 
In the TetO-2CR mice the tetracycline activator (tTA) protein is encoded by the 
targeting construct and transcription of tTA protein is driven by the 5-HT2C receptor 
promoter.  The principle behind this model is that the tTA protein produced binds to 
the tetracycline (Tet) operon and amplifies promotion of 5-HT2C receptor production.  
In TetO-2CR mice although tTA is expressed, unexpectedly the result of this 
targeting was reduced expression of the 5-HT2C receptor.  The presence of tTA 
mRNA can, however, be used to indicate the regions where alteration in the 5-HT2C 
receptor levels would be anticipated due to the fact that tTA protein is not normally 
present in mouse brain. tTA mRNA was found in TetO-2CR mice with only 
nonspecific levels being found in WT mice in regions where the 5-HT2C receptor is 
expressed (Figure 4.2; F1,30=545.96; p<0.0001) and there was an interaction between 
genotype and region (Figure 4.2; F4,30=6.55; p=0.0007).   
 
 






























Figure 4.2: Tetracycline activator (tTA) mRNA expression in adult male TetO-2CR mice                                                                                                                                      
tTA mRNA was present in TetO-2CR mice indicating the presence of the targeting cassette while 
only a nonspecific signal was found in WT mice. Expression levels were measured by optical 
densitometry of in situ hybridisation autoradiographs. Data are expressed as mean±SEM in 
males backcrossed to C57BL/6 for 3 generations. TetO-2CR mice compared to WT littermate 
control mice by two-way ANOVA with Bonferroni posttests; n=6 per group.  SN = Substantia 
Nigra; SMN = Supramammillary nucleus. *** p<0.001.  
 
 





4.2.2 TetO-2CR mice show reduced expression of 5-HT2C 
receptor mRNA throughout the brain 
 
In situ hybridisation was used to establish whether 5-HT2C receptor mRNA 
expression was altered as a result of the gene targeting in TetO-2CR mice. This 
technique allows gene quantification of 5-HT2C receptor mRNA levels in brain 
sections and clearly shows the expression pattern within these sections. TetO-2CR 
mice had significantly reduced 5-HT2C receptor mRNA levels compared to WT mice 
in all regions of the brain examined with the exception of the primary somatosensory 
cortex, primary and secondary motor cortex and the CA1 field of the dorsal 
hippocampus where the decrease did not reach significance probably because levels 
of 5-HT2C receptor mRNA expression in these regions is low in WT mice (Figure 
4.3).  Firstly, in regions of the frontal forebrain such as the caudate putamen (CPu) 
and nucleus accumbens core (AcbC) and shell (AcbSh) TetO-2CR mice were found 
to have significantly reduced 5-HT2C receptor mRNA levels with a significant 
interaction of genotype and region (Figure 4.3a; F4,25=8.2; p=0.0002). In more 
posterior forebrain regions such as the dorsal hippocampus (CA1), amygdala and 
choroid plexus (CP) 5-HT2C receptor mRNA levels were reduced in TetO-2CR mice 
with a significant effect of the genotype of the mouse and its interaction with the 
regions tested (Figure 4.3b; F5,36=6.56; p=0.0002). Finally in midbrain regions such 
as the substantia nigra (SN) although no significant interaction of genotype and 
region was found (Figure 4.3c; F4,35=2.44; p=0.0653) there was a significant effect of 
genotype (Figure 4.3c; F1,35=98.62; p<0.0001).   
 
































































































(a) 5-HT2C receptor mRNA
           Frontal Forebrain
(b) 5-HT2C receptor mRNA
       Posterior Forebrain
(c) 5-HT2C receptor mRNA
                Midbrain
 
Figure 4.3: 5-HT2C receptor mRNA expression frontal to posterior in adult male TetO-2CR 
mice                                                                                                                                                   
5-HT2C receptor mRNA expression is reduced in TetO-2CR mice compared to WT littermate 
controls in (a) frontal forebrain, (b) posterior forebrain and (c) midbrain. Expression levels were 
measured by optical densitometry of in situ hybridisation autoradiographs.  Data are expressed 
as mean±SEM in males backcrossed to C57BL/6 for 2 generations and analysed by unpaired, 2-
way ANOVA with Bonferroni posttests; n=5 per group.  * p<0.05; ** p<0.01; *** p<0.001.  
CPu = caudate putamen; AcbN = nucleus accumbens core; AcbSh = nucleus accumbens shell; 
S1= primary somatosensory cortex; M1/M2 = primary/secondary motor cortex; CA1 = CA1 field 
of the dorsal hippocampus; BLA = basolateral amygdaloid nucleus (anterior); MDL = mediodorsal 
thalamic nuclei (lateral); MDM = mediodorsal thalamic nuclei (med); IMD = intermediodorsal 
thalamic nuclei; SN = Substantia nigra; Gen = geniculate; Post Thal = posterior thalamus; CP = 
choroid plexus.   





4.2.3: 5-HT2C receptor binding sites are decreased in TetO-
2CR mice 
 
It is vital to establish if the decrease in 5-HT2C receptor mRNA in TetO-2CR mice 
found by in situ hybridisation (section 4.2.2) is translated to the protein level. In 
order to assess this, 5-HT2C receptor number was measured with a [
3
H]-mesulergine 
binding assay in membrane preparations from the midbrain.   Consistent with 
reduced 5-HT2C receptor mRNA level in Teto-2CR mice, [
3
H]-mesulergine binding 
was found to be significantly reduced (80%) in TetO-2CR mice compared to WT 




























Figure 4.4: 5-HT2C receptor number in the midbrain of adult male TetO-2CR mice  5-HT2C 
receptor number was reduced in TetO-2CR mice compared to WT mice, determined using [
3
H]-
mesulergine binding in membrane preparation from midbrain homogenates.  Data are expressed 
as mean±SEM in males backcrossed to C57BL/6 for 5 generations and analysed by unpaired 
Student‟s t test; n=3 per group. * p<0.05  
 




4.2.4: Body Weight and Food Intake are increased in TetO-
2CR mice 
The 5-HT2C receptor is involved in the regulation of food intake (FI) with 5-HT2C 
receptor agonists being appetite suppressants (Schuhler et al., 2005).  TetO-2CR 
mice had significantly increased food intake compared to WT mice (Figure 4.5a; 
p=0.0001 average intake/day corrected for BW measured over 7 days) and were 
heavier than WT mice by 7 months of age (Figure 4.5b; p=0.006). 
 
4.2.5: 5-HT2C receptor deficiency in TetO-2CR mice causes no 
alteration in anxiety-like behaviour or depressive-like 
behaviour in this study 
 
The 5-HT2C receptor has been implicated in the control of mood and anxiety, with 
agonists reported to be anxiogenic while antagonists are anxiolytic (see Chapter 1).  
Accordingly the elevated plus maze (EPM) and the open field (OF) tests were used 























































(a) Food Intake (b) Body Weight
 
Figure 4.5:  Food intake and body weight in male TetO-2CR mice                                      
TetO-2CR 7 month old mice have increased average food intake and body weight compared to 
WT littermate control mice following backcrossing to C57BL/6 for 3 generations. Data are 
expressed as mean±SEM and analysed using an unpaired Student‟s  t test; n=14-24 per group. ** 
p<0.01; *** p<0.001. 




established tests of anxiety-like behaviour in mice and test the natural instinct of 
rodents to avoid brightly light exposed regions of the mazes. In the EPM increased 
anxiety-like behaviour is indicated by a decrease in exploration, time and/or distance 
travelled in the elevated and exposed light open arms. The OF works on a similar 
principle with decreased time and/or distance travelled in the exposed, brightly lit 
central region of the maze indicating increased anxiety-like behaviour.  Both of these 
measures, percentage time and percentage distance travelled, must be considered 
before a conclusion can be drawn for both the EPM and the OF.  In the EPM, both 
genotypes spent a similar percentage of time (Figure 4.6a; p=0.612) and travelled a 
similar distance (Figure 4.6b; 0.525) in the open arms and travelled a similar total 
distance around the maze (Figure 4.6c; p=0.659). The behaviour of mice in the maze 
(stretch attend and rearing) was similar between TetO-2CR and WT mice (Figure 
4.6d; effect of genotype F1,60=2.48; p=0.121), indicating that there is no alteration in 
anxiety-like behaviour in this test. Unexpectedly TetO-2CR mice showed a trend 
toward spending less time in the inner zone of the OF compared to WT mice (Figure 
4.6e; p=0.0995).  However, both TetO-2CR and WT mice travelled a similar 
distance in the inner zone (Figure 4.6f; p=0.541), although TetO-2CR mice have a 
trend to reduced total distance travelled around the maze compared to WT mice 
(Figure 4.6g; p=0.073).  During the OF test, a significant interaction of the genotype 
and behaviour was found (Figure 4.6h; interaction of genotype and behaviour 
F2,48=6.46; p=0.003) with TetO-2CR mice showing significantly less rearing which 
could indicate reduced exploratory or escape behaviour, but similar grooming levels 
compared to WT mice. Taken together, the reduction in 5-HT2C receptor throughout 
the brain did not significantly alter anxiety-like behaviour or locomotion in a novel 
environment with a component of stress in these tests.    
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Figure 4.6:  Behaviour in the elevated plus maze and open field test in male TetO-2CR mice                                                                                                                                                       
No alterations were found in the time (a) or distance travelled (b) in the open arms, total distance (c) or 
behaviour (d) in the EPM.  TetO-2CR mice showed trend to reduced time (e) but no alteration in the 
distance travelled (f) in the inner zone of the OF, with a trend to reduced total locomotion (g) and 
significantly less rearing behaviour (h) in TetO-2CR mice compared to WT littermate controls. All mice 
were 12 month old males, backcrossed to C57BL/6 for 5 generations. Data are expressed as 
mean±SEM and analysed by unpaired Student‟s t test or 2-way ANOVA with Bonferroni posttests; n=9-
12 per group. *** p<0.001  
 




The 5-HT2C receptor is implicated in depression, although the literature is conflicting 
with both agonists and antagonists of this receptor reported to have antidepressant 
properties (Dunlop et al., 2006; Millan et al., 2006; Dekeyne et al., 2008). One 
symptom present in many mood disorders, including depression and schizophrenia, 
is anhedonia, an inability to experience pleasure from normally pleasurable events 
such as eating (Pelizza & Ferrari., 2009). Sucrose has a natural hedonic effect and 
reduced consumption of (or preference for) sucrose could be said to indicate an 
increase in depressive-like behaviour.  To test if anhedonic behaviour was altered by 
5-HT2C receptor deficiency, the sucrose preference test was used.  
 
The sucrose preference test consists of three sections all with ad libitum access to 
two water bottles.  In the first section, both bottles are filled with water (w/w).  In the 
second, both bottles are filled with a sucrose solution (s/s) and during the third 
section, which is the preference stage, mice are given one bottle filled with water and 
one filled with the sucrose solution (w/s).  
 
The total volume of liquid drunk differed significantly depending on the stage of the 
test, with both TetO-2CR and WT mice drinking more during the stage with two 
sucrose (s/s) bottles (Figure 4.7a: F2,27=4.72; p=0.017) but there was no alteration in 
liquid intake between genotypes (Figure 4.7a: effect of genotype F1,27=0.80; 
p=0.380) or an interaction between the genotype and stage of test (Figure 4.7a: 
F2,27=1.08; p=0.355).  TetO-2CR mice did have a significantly greater water intake 
compared to WT mice (Figure 4.7b; p=0.011) but there was no difference between 
genotypes in sucrose intake during the preference (w/s) stage (Figure 4.7c; p=0.19).   
 
The preference for sucrose over water is tests hedonic behaviour. Consistent with 
this no difference in sucrose preference was found between genotypes (Figure 4.7d; 
p=0.24) suggesting that the deficiency in 5-HT2C receptor in TetO-2CR mice does 






























































































































Figure 4.7: Volume drunk and sucrose preference in male TetO-2CR mice during the 
sucrose preference test                                                                                                        
Total volume drunk increases in both genotypes in the s/s stage of the sucrose preference test 
(a). TetO-2CR mice drink significantly more water than WT during the preference (w/s) stage of 
the test (b) but both genotypes drink a similar volume of sucrose during the w/s stage if the test 
(c).  There was no difference in sucrose preference between genotypes during w/s stage (d; 
values calculated by: (vol sucrose/total volume drank)*100).   All data is corrected for body weight 
(BW) and is in TetO-2CR males backcrossed to C57BL/6 for 5 generations.  Data are expressed 
as mean±SEM, , TetO-2CR mice are compared to WT littermate control mice by either 2-way 
ANOVA with Bonferroni posttests or unpaired Student‟s t tests; n=6 per group. * p<0.05. Two 









4.2.6: 5-HT2C receptor deficiency causes hyperlocomotion 
and increases agility and balance in TetO-2CR mice 
 
Another phenotype regulated by 5-HT2C receptor is activity/locomotion, with 
agonists such as mCPP causing hypolocomotion (Gleason et al., 2001).  Voluntary 
wheel running was used to examine the effect of 5-HT2C receptor deficiency in 
TetO-2CR mice.  This allows monitoring of the locomotion of an individual mouse 
over an indefinite period of time, providing data on the total activity as well as the 
pattern of wheel running throughout the experiment. During the initial 
characterisation of the TetO-2CR line, TetO-2CR males showed a trend toward 
increased wheel running behaviour compared to WT controls although this did not 
achieve significance (Figure 4.8a; Kimura, Chapman & Holmes unpublished 
observation; p=0.094), and no alteration in wheel running was found in TetO-2CR 
mice compared to WT mice following backcrossing to C57BL/6 for 4 generations.  
However TetO-2CR mice backcrossed for 5 generations appeared to be hyperactive 
compared to WT mice (Figure 4.8b; genotype F1,19=9.69; p=0.006; generation 
F1,19=6.20; p=0.022). There was also an interaction between genotype and the 
generation of backcrossing (Figure 4.8b; F1,19=4.38; p=0.05).  This variability in the 
hyperlocomotor phenotype is primarily due to altered behaviour in WT mice as the 
strain background changes towards C57Bl/6, with consistent behaviour seen in 
TetO-2CR mice independent of strain (Figure 4.8b).  However, TetO-2CR mice did 
show a consistent difference in running pattern to WT littermates, with TetO-2CR 
mice having a consistently later offset (the time at which running stops each day) of 
running time (Figure 4.8c; genotype F1,25=19.58; p=0.0002) in both generation 4 and 
5 (effect of generation F1,25=0.01; p=0.928) and no interaction of genotype and 
generation (F1,25=0.38; p=0.541) was found.   
 



































































































(a) Average daily wheel
running (backcrossed to
C57BL/6 for 2 generations)
  (b) Average daily wheel
running in later generations
  (c) Average daily
running offset time
 
Figure 4.8:  Behaviour in wheel cages in male TetO-2CR mice                                           
Following backcrossing to C57BL/6 for 2 generations a trend to increased wheel running was 
found by A. Kimura in TetO-2CR mice compared to WT mice (a).  Following re-derivation at a 
new animal facility there was no alteration between genotypes backcrossed to C57BL/6 for 4 
generations, however a significant increase in wheel running was found in TetO-2CR mice 
compared to WT mice (b).  TetO-2CR mice had a consistently later offset of running time 
compared to WT mice (c).  All mice were individually housed in wheel running cages. Data are 
expressed as mean±SEM and TetO-2CR mice are compared to WT littermate control mice by 
unpaired Student‟s t test (A) and by two-way ANOVAs (B and C); n=6 per group. * p<0.05, ** 
p<0.01, *** p<0.001. 
 
 





In order to assess the general agility and balance of mice a rotorod test was 
undertaken. TetO-2CR mice had increased agility and balance compared to WT mice 




4.2.7 Altered activation of 5-HT2C receptor ligands in TetO-
2CR mice 
To test the effect of 5-HT2C receptor ligands upon locomotion, male mice were 
singly housed in cages with wheels. 
 
RO 60-0175, an agonist selective for the 5-HT2C receptor, was administered by 
intraperitoneal (IP) injection, 30 min prior to the onset of the dark phase (7pm). 
Injection of 5mg/kg agonist inhibited wheel running behaviour slightly in TetO-2CR 




















Figure 4.9: Length of time on the rotorod in male TetO-2CR mice                                   
TetO-2CR mice are able to stay on the rotorod (without circling or falling off) longer than WT 
littermate control mice, indicating increased agility and balance in TetO-2CR males, 
backcrossed to C57BL/6 for 5 generations. Data are expressed as mean±SEM and analysed by 
unpaired Student‟s t test; n=12 per group. * p<0.05. 




wheel running (Figure 4.10; p=0.002). This slight inhibition in TetO-2CR mice 




SB206553 is a selective 5-HT2C receptor inverse agonist in rats, however when 
tested in 5-HT2C receptor over-expressing transgenic mice (C2CR.10 and C2CR.33; 
Chapter 3) it caused an inhibition of locomotor activity rather than the anticipated 
increase.  When SB 206553 was administered intraperitoneally to TetO-2CR and 
WT mice in wheel cages 30 min prior to onset of dark phase (7pm), there was 
inhibition of wheel running in both genotypes with no difference in response 















































Figure 4.10: Inhibition of voluntary wheel running following administration of RO 60-
0175 in male TetO-2CR mice                                                                                                     
Inhibition of wheel running is greater in WT mice compared to TetO-2CR mice following IP 
injection of 5mg/kg RO 60-0175. All mice were backcrossed to C57BL/6 for 3 generations. 
Data are expressed as mean±SEM and TetO-2CR mice are compared to WT littermate 
control mice by unpaired Student‟s t test; n=6. ** p<0.01.   
 




solely on the 5-HT2C receptor (TetO-2CR mice having significantly reduced receptor 




4.2.8 Altered response to a novel environment in TetO-2CR 
mice 
 
TetO-2CR mice, when they were about to be handled, would twirl their tails rapidly 
and become defensive. Their behaviour made them hard to handle for injections.  
During voluntary wheel running experiments TetO-2CR mice would also need a 
longer acclimatisation period to settle into a consistent wheel running rhythm than 















































Figure 4.11:  Inhibition of voluntary wheel running following administration of SB 206553 in 
male TetO-2CR mice                                                                                            
Wheel running was inhibited in both genotypes following IP administration of a 5 mg/kg dose of 
inverse agonist (SB206553).  All mice were backcrossed to C57BL/6 for 3 generations. Data 
expressed as mean±SEM and TetO-2CR mice are compared to WT littermate control mice by 
unpaired Student‟s t test; n=6 per group. 
 
 





4.3 Effect of 5-HT2C receptor deficiency on LEO and FEO 
regulation in TetO-2CR mice 
 
4.3.1: 5-HT2C receptor deficiency causes no alteration in 
circadian food or water consumption in TetO-2CR mice 
 
As mentioned previously, the 5-HT2C receptor is expressed in a circadian manner in 
rat (Holmes et al., 1997) and plays a role in regulating food intake with 5-HT2C 
receptor KO mice being hyperphagic (Tecott et al., 1995), with the deficiency in 5-
HT2C receptor in TetO-2CR mice causing hyperphagia. To investigate if TetO-2CR 
mice have a different circadian eating pattern to WT mice, food and drink intake 
were monitored continuously over a 24 hr period. The influence of the LEO on food 
intake was also examined by monitoring under normal lighting conditions (LD, 
lights on 0700, off 1900) and in constant darkness (DD). 
 
Although TetO-2CR mice consumed more calories than WT mice in both lighting 
conditions (Figure 4.12a; effect of genotype F1,140=8.80; p=0.004; effect of lighting 
condition F1,140=0.65; p=0.421), their circadian pattern of eating was similar to WT 




























































































































































































(a) Total food intake
    (b) Circadian food intake
during lights on 0700 off 1900
 (c) Circadian food intake
during constant darkness
 
Figure 4.12: Circadian food intake in male TetO-2CR mice                                                               
Total food intake per day (corrected for BW) was increased in TetO-2CR mice compared to WT 
mice during LD (lights on 0700 off 1900) with a significant effect of genotype but no effect of the 
lighting condition (a). No alteration in circadian eating pattern (g/30 minute not corrected for BW) 
was found between genotypes in LD conditions (b) or DD condition (c; lights continuously off). All 
data were collected in male mice backcrossed to C57BL/6 for 4 generations, aged 3 months. 
Lights on represented by white box and lights off represented by black box.  Data are expressed 
as mean±SEM and TetO-2CR mice compared to WT littermate control mice by two-way ANOVA 
with Bonferroni posttests; n=6 per group.   * p<0.05. 
 




During In LD conditions both genotypes have similar water consumption (Figure 
4.13). During DD conditions WT mice drank more compared to LD (effect of 
lighting condition F1,92=4.91; p=0.029) and so in DD conditions TetO-2CR mice 





4.3.2 5-HT2C receptor deficiency does not alter regulation of 
the food entrainable oscillator (FEO) in TetO-2CR mice 
 
The food entrainable oscillator (FEO), although its location is still unknown, enables 
the animal to entrain to food availability.  When animals are fed at one time point 




































Figure 4.13: Water intake in altered lighting conditions in male TetO-2CR mice                                                    
Total water intake (corrected for BW) was similar between genotypes in LD conditions (lights on 
at 0700 and off at 1900).  WT mice drink more during DD (constant darkness) than during LD 
conditions and so in DD conditions WT mice drink more than TetO-2CR mice.  All mice are 
males, backcrossed to C57BL/6 for 4 generations.  Data are expressed as mean±SEM and 
TetO-2CR mice are compared to WT littermate control mice by two-way ANOVA with Bonferroni 
posttests; n=6 per group. 




behaviour prior to food presentation, even when the SCN is lesioned.  When food is 
presented outside the normal activity period the circadian rhythm regulated by the 
LEO and that of the FEO are dissociated.  This results in two distinct behavioural 
components which can be monitored; the normal nocturnal activity regulated by the 
master clock and entrained by the LEO and food anticipatory running behaviour 
regulated by the FEO.  
 
To test the regulation of the FEO in TetO-2CR mice, food availability was gradually 
reduced over a week to a period of 6 hrs during the light phase.  Throughout the 
experiment, TetO-2CR mice maintained a higher body weight (Figure 4.14a; 
F1,30=68.22; p<0.0001) as well as an increased food intake (Figure 4.14b; F1,30=9.49; 
p=0.004) compared to WT mice which doesn‟t reach significance during LD 


















































(a) Body Weight (b) Food Intake
 
Figure 4.14: Body weight and food intake in male TetO-2CR mice during food restriction in 
wheel cages                                                                                                                                   
TetO-2CR mice are heavier than WT mice during food restriction in both LD and DD conditions 
(a).   Total food intake per day (corrected for BW) TetO-2CR mice have increased daily food 
intake (corrected for BW) during food restriction (b; food available 11am to 5pm). All results 
generated using males, backcrossed onto C57BL/6 for 3 generations, 10 months of age. Data are 
expressed as mean±SEM and TetO-2CR mice are compared to WT littermate control mice using 
2-way ANOVA with Bonferroni posttests; n=6 per group. * p<0.05, *** p<0.001. 
 




Both WT and TetO-2CR mice exhibited food anticipatory running behaviour (Figure 
4.15a and b).  Imposition of constant darkness (DD) causes the onset of running to 
drift slightly each day as the mice are no longer able to entrain their running pattern 
to light cues and this is termed a free-running rhythm.  As would be anticipated WT 
showed a strong free running rhythm, but TetO-2CR mice running did not and ran 
more sporadically.  Interestingly in DD conditions, three of the TetO-2CR mice ran 
throughout the period of time when food was available, however they managed to 
maintain their body weight (Figure 4.15b, Tet 2 is a typical example).  Throughout 
the test a trend to increased wheel running is found in TetO-2CR mice compared to 
WT mice regardless of light condition during the food restriction (Figure 4.15c; 
F1,20=3.65; p=0.07).  Running during Light phase of LD conditions similar between 
TetO-2CR and WT mice indicating similar levels of food anticipatory running 
behaviour (Figure 4.15d; p=0.91). 
 




















(c) Total running during




















(d) Total running during
































Figure 4.15: Behaviour during food restriction in wheel cages in male TetO-2CR mice  
Example of typical WT (a) and TetO-2CR mice (b) double plotted actograms (2 cycles per 
line with the second cycle on a line being the same as the first cycle on the next line) during 
food restriction experiment. Grey shading represents periods when lights are off and pink 
shading representing times when food was available.  Total running per day during food 
restriction is slightly increased in TetO-2CR mice compared to WT mice in both LD and DD 
conditions (c).  Daily running during the light phase of LD was unaltered between 
genotypes (d).  All mice were males, backcrossed to C57BL/6 for 5 generations. Data are 
expressed as mean±SEM and TetO-2CR mice compared to WT littermate control mice by 
two-way ANOVA with Bonferroni posttests; n=6 per group. 
 




It was concluded that deficiency in the 5-HT2C receptor does not alter the regulation 
of the FEO, although there was an indication that alterations may be found in the 
LEO regulation due to the lack of a strong free running rhythm in DD conditions in 
TetO-2CR mice. An addition to this experiment should be a comparison of food 
consumption in both lighting condition during ad lib and food restriction. 
 
 
4.3.3 Effect of 5-HT2C receptor deficiency on the light 
entrainable oscillator (LEO) 
 
The LEO is located within the SCN and synchronises the endogenously generated 
circadian rhythm with the exogenous light dark cycle.  A role for the 5-HT2C 
receptor in regulating the LEO has recently been suggested as 5-HT2C receptor 
agonists given in the first half of the dark phase induced clock gene expression of 
Per1 and Per2 which are essential for rhythm responses to external stimuli such as 
light.  It is already established that the SCN receives serotonergic input from the 
raphe nucleus and that 5-HT2C receptor is expressed in the SCN (Varcoe & 
Kennaway., 2008).   
 
In order to assess if the 5-HT2C receptor plays a role in the regulation of the LEO, 
individual wheel running activity was monitored in different light conditions (Figure 
4.16). Following a period of acclimatisation, lighting was altered from normal LD 
(on at 0700, off at 1900) to 3-3 (on at 0300, off at 1500) to asses ability to entrain 
and finally mice were put into constant darkness (DD) to examine free running 
rhythm before reimposition of the normal LD conditions.  
 





TetO-2CR mice (backcrossed to C57BL/6 for 3 generations) ran more than WT mice 
during LD and DD conditions, although following a phase advance to 3-3 conditions 
there was no difference between genotypes (Figure 4.17a; genotype F1,60=4.97; 
p=0.03) and no effect of lighting condition (F2,60=0.40; p=0.669) or an interaction 
between genotype and lighting condition  was found (F2,60=0.72; p=0.49).  TetO-
2CR mice (backcrossed to C57BL/6 for 5 generations) ran more than WT mice in 3-
 
 
Figure 4.16:  Effect of light alterations on voluntary wheel running behaviour in male TetO-
2CR mice                                                                                                                                                
Example of a typical WT mouse (a) and the two typical running patterns generated by TetO-2CR 
mice (b) in double plotted actograms (2 cycles per line with the second cycle on a line being the 
same as the first cycle on the next line).  All mice are males, backcrossed to C57BL/6 for 4 
generations. Grey shading represents when lights are switched off. LD (on at 0700, off at 1900) to 
3-3 (on at 0300, off at 1500) and finally constant darkness (DD). 
 




3 condition but no differences were found between genotypes in LD or DD 
conditions (Figure 4.17b; F1,16=3.92; p=0.065) and no effect of lighting condition 
(F2,16=1.19; p=0.331) or an interaction of genotype with lighting condition was found 
(F2,16=0.65; p=0.538).   
 
The offset time of running was significantly later in TetO-2CR mice compared to 
WT mice backcrossed to C57BL/6 for 3 generations in all lighting conditions with a 
significant effect of genotype (Figure 4.17c; F1,203=315.72; p<0.0001), lighting 
condition (F2,203=178.60; p<0.0001) and the interaction of genotype with lighting 
condition (F2,203=240.11; p<0.0001).  Following backcrossing to C57BL/6 for 5 
generations the offset in TetO-2CR mice was still later than WT mice in LD and 3-3 
conditions although no difference was found between genotypes in DD conditions 
(Figure 4.17d; genotype effect F1,156=14.61; p=0.0002) and a significant effect of 
lighting condition (F2,156=105.91; p<0.0001) and the interaction of genotype and 
lighting condition were found (F2,156=39.46; p<0.0001).  Interestingly when lighting 
conditions were phase advanced to the 3-3 condition TetO-2CR mice maintained 
their original offset time from the LD conditions, while WT mice moved their offset 
time dependent on the lighting conditions in both generation 3 and 5. Generation 3 
TetO-2CR mice maintained this pattern of running following imposition of constant 
darkness, with their offset time remaining around 7am (Figure 4.17c).  The offset 
time in generation 5 TetO-2CR mice shifted to being similar to WT mice in constant 



























































(a) Generation 3 Total Running (b) Generation 5 Total Running





















































Figure 4.17: Effect of light alterations on voluntary wheel running and running offset time 
in male TetO-2CR mice                                                                                                                  
TetO-2CR mice have increased wheel running compared to WT mice in LD conditions following 
backcrossing to C57BL/6 for 3 generations (Figure 5.22a) but no difference was found between 
genotypes following backcrossing to C57BL/6 for 5 generations (Figure 5.22b).  Running was 
similar between genotypes in generation 3 but increased in TetO-2CR mice in generation 5 during 
3-3 conditions.  In response to the imposition of constant darkness generation 3 and 5 TetO-2CR 
mice ran slightly more than WT mice. The offset of running time was significantly later in TetO-
2CR mice compared to WT mice during LD and 3-3 conditions following backcrossing to C57BL/6 
for 3 and 5 generations (c, d).  Mice were individually housed in wheel cages and their activity 
monitored following an acclimitisation period under three different lighting conditions, LD (lights on 
0700 and off 1900), 3-3 (lights on 0300 and off 1500) and DD (constant darkness).  Data are 
expressed as mean±SEM and TetO-2CR mice are compared to WT littermate control mice by 
two-way ANOVA with Bonferroni posttests; n=6 per group. ** p<0.01, *** p<0.001. 
 
 





Increased number of running bouts were found in TetO-2CR mice backcrossed to 
C57BL/6 for 3 generations compared to WT mice in LD and DD conditions but not 
in 3-3 conditions (Figure 4.18a; effect of genotype F1,295=27.42; p<0.0001), there 
was a trend of an effect of lighting condition (F2,295=2.94; p=0.055) and a significant 
interaction between genotype and lighting condition (F2,295=4.04; p=0.019).  In 
TetO-2CR mice backcrossed to C57BL/6 for 5 generations, increased running bouts 
were also found in LD and DD condition compared to WT mice but not in 3-3 
conditions (Figure 4.18b; effect of genotype F1,306=86.31; p<0.0001), there was no 
effect of lighting condition (F2,306=1.58; p=0.209) but there was an interaction of 





















































































(a) Generation 3 (b) Generation 5
 
Figure 4.18:  Effect of light alterations on the number of wheel running bouts in male TetO-
2CR mice                                                                                                                                          
The number of running bouts each day were higher in TetO-2CR mice compared to WT mice in LD 
conditions and DD conditions but no difference was found between genotypes in 3-3 conditions 
after backcrossing to C57BL/6 for 3 and 5 generations (a, b).  Mice were individually housed in 
wheel cages and their activity monitored following an acclimitisation period under three different 
lighting conditions, LD (lights on 0700 and off 1900), 3-3 (lights on 0300 and off 1500) and DD 
(constant darkness).  Data are expressed as mean±SEM and TetO-2CR mice are compared to WT 
littermate control mice by two-way ANOVA with Bonferroni posttests; n= 6 per group. *** p<0.001. 
 




To further investigate if 5-HT2C receptor deficiency was able to effect the regulation 
of the LEO a series of light pulses were given in the first half of the dark phase on 
intermittent days. The average inhibition of wheel running caused by the light pulses 
was significantly reduced in TetO-2CR mice compared to WT mice (Figure 4.19; 
effect of genotype; F1,24=4.81; p=0.038) and the time the light pulse was given was 























































Figure 4.19: The percentage of  inhibition on wheel running during light pulses         
There were indications that wheel running in TetO-2CR mice was less affected by light pulses than 
WT mice (pulse 1 = 2000 to 2200, pulse 2= 2100 to 2200, pulse 3 = 2100 to 2300). All mice were 
males, backcrossed to C57BL/6 for 5 generations.  Data are expressed as mean±SEM; TetO-2CR 
mice were compared to WT littermate control mice by two-way ANOVA with Bonferroni posttests 
and an unpaired Student‟s Ttest; n=5-6 per group.  
 






Complete loss of 5-HT2C receptor function leads to a lowered seizure threshold and a 
more rapid progression of seizure activity, with 5-HT2C receptor knock-out mice (5-
HT2C receptor KO mice) suffering from spontaneous seizures from the fifth postnatal 
week, resulting in death in hemizygous mutant male mice, with a 60% survival rate 
by 25 weeks (Tecott et al., 1995). In TetO-2CR mice no evidence of seizure activity 
was found, indicating that the low levels of 5-HT2C receptor present during 
development were sufficient to prevent lowering of seizure threshold. The fact that 
the TetO-2CR model does not suffer from spontaneous seizures, possibly due to 
residual function, provides an advantage over the complete 5-HT2C receptor KO 
mouse. 
 
Quantification showed that 5-HT2C receptor mRNA levels were significantly reduced 
throughout the brain in TetO-2CR mice compared to WT mice. As the expression of 
this receptor is driven by the normal 5-HT2C receptor promoter in TetO-2CR mice, 
they are deficient in 5-HT2C receptor in all regions that the 5-HT2C receptor would 
normally be found and this reduction is in a region specific manner. The decrease 
found in 5-HT2C receptor mRNA levels will cause a decrease at the protein level in 
this model and this has been confirmed using the 
3
H-mesulergine binding assay to 
detect 5-HT2C receptor binding. Due to the decreased expression of the 5-HT2C 
receptor in hypothalamic and limbic regions of TetO-2CR mice, an alteration in food 
intake, mood and locomotion were anticipated. 
 
The 5-HT2C receptor has been implicated in the regulation of food intake (Chapter 1) 
with non-selective agonists, such as mCPP, causing advancement in satiety and 
reducing food intake while specific 5-HT2C receptor antagonists are able to block 
these anorectic effects (Clifton et al., 2000 256-267; Kennett & Curzon., 1988 93-
100; Hewitt et al., 2002; Samanin 1979 159-163).  5-HT2C receptor KO mice were 




found to be hyperphagic and both plasma glucose levels and insulin were similar in 
KO compared to WTs when on a standard paired feeding analysis (Tecott et al., 
1995).  Due to larger white fat stores, 5-HT2C receptor KO mice develop obesity in 
later life but no alteration in the level of brown adipose tissue was found compared 
to WT. This hyperphagia and obesity is due to behavioural abnormalities as opposed 
to metabolic defects (Tecott et al., 1995).  Similar to the 5-HT2C receptor KO mice, 
TetO-2CR mice were hyperphagic and heavier than WT mice by twenty-four weeks 
of age.  
 
Because food intake is increased by 5-HT2C receptor deficiency and the 5-HT2C 
receptor is expressed in a circadian manner (Holmes et al., 1997) it was considered 
that the increased food intake may be a consequence of altered regulation of the food 
entrainable oscillator (FEO). This was, however, not the case as TetO-2CR mice had 
a similar pattern of food consumption (over a 24 hr period) to WT mice but with 
increased food intake at each meal.  In addition TetO-2CR mice showed food 
anticipatory running behaviour during a food restriction experiment although moving 
into constant darkness did increase the difference in food intake between genotypes.  
I therefore concluded that in this model 5-HT2C receptor deficiency does not alter the 
regulation of the FEO.  
 
It was hypothesised that anxiety-like behaviour would be decreased in TetO-2CR 
mice compared to WT mice as the 5-HT2C receptor mRNA levels were decreased 
throughout limbic regions of the brain which are involved in the alteration of mood. 
The 5-HT2C receptor plays an important role in the regulation of anxiety-like 
behaviour with agonists increasing anxiety and antagonists being anxiolytic (Kennett 
et al., 1989; Jenck et al., 1998; Harada et al., 2008).  It has been shown that 
transgenic mice over-expressing the 5-HT2C receptor in the forebrain showed a slight 
increase in anxiety-like behaviour (Chapter 3; Kimura et al., 2009) while 5-HT2C 
receptor KO mice had an anxiolytic phenotype (Heisler et al., 2007b). Another 
aspect of mood examined was depressive-like behaviour. The literature on the effects 




of agonists and antagonists is conflicting with the majority of papers finding that 
antagonists have antidepressant properties (Millan et al., 2006; Calcagno et al., 
2008; Dekeyne et al., 2008) but there is evidence that 5-HT2C receptor agonists may 
also be efficacious antidepressants (Dunlop et al., 2006).  In TetO-2CR mice, 
however, no strong phenotype was found in tests of anxiety-like or depressive-like 
behaviour.  Following backcrossing of the 5-HT2C receptor over-expressing 
transgenic mice to C57BL/6, the anxiety-like phenotype was lost and similarly, 5-
HT2C receptor KO mice investigated more recently show no difference in anxiety-
like or depressive-like behaviours (Hill et al., 2010).  This indicates that alterations 
in 5-HT or other systems may have occurred, to compensate for the increased or 
decreased 5-HT2C receptor levels, and normalise behaviour.  The first anxiety tests 
were undertaken in TetO-2CR mice following several more generations of 
backcrossing onto C57BL/6 compared to the first tests carried out in the 5-HT2C 
receptor over-expressing mice and so if TetO-2CR mice had been tested earlier in 
the backcrossing process it is possible that anxiety-like behaviour might have been 
altered. It is possible that on the C57BL/6 genetic background anxiety traits are 
undetectable in both the 5-HT2C over-expressing mice and TetO-2CR mice.  
Interestingly TetO-2CR mice appear to be hyper-sensitive to novel environments as 
they took longer to acclimatise to wheel cages compared to WT mice and behaved in 
a more aggressive manner when handled, particularly when being scruffed. This 
contradicts the hypothesis that reduced 5-HT2C receptor expression would reduce 
anxiety-like behaviour.    
 
It will be important to examine BNDF levels in TetO-2CR mice as both the 
production (Alter 1992) and expression (Nibuya et al., 1995) of BDNF in the brain 
are altered in response to antidepressant treatment.  In addition BDNF infusions in 
rats produce antidepressant effects (Siuciak et al., 1997; Shirayama et al., 2002) 
possibly through altering activity of 5-HT, DA and/or NA pathways (Siuciak et al., 
1997) which are known to be altered in depression. In 5-HT2C receptor KO mice, 
BDNF levels were elevated possibly contributing to the loss of the anxiety-like and 
depressive-like phenotype (Hill et al., 2010).  This is an important area to examine in 




TetO-2CR mice as BDNF levels could be elevated and could be a possible 
mechanism to normalise mood-related behaviours. 
 
The role of 5-HT2C receptor, in regulation of locomotion is well established, with 
agonists such as mCPP causing motor depression (Fone et al., 1998; Gleason et al., 
2001) and hypolocomotion occurring in transgenic mice over-expressing 5-HT2C 
receptors in the forebrain (Kimura et al., 2009).  Similar to 5-HT2C receptor KO 
mice, which are hyperactive, TetO-2CR mice were more active than WT mice, and 
consistently showed a later offset time of running in wheel cages.  TetO-2CR mice 
also had increased agility and balance on the rotorod concurring with the 
hyperlocomotor phenotype.  There may be alterations in the DA system which could 
play a role in the locomotor phenotype and will be discussed in Chapter 5.  
 
One possible candidate to consider is brain-derived neurotrophic factor (BDNF) as it 
has been linked to locomotor activity (Kernie et al., 2000) although data are 
conflicting regarding whether increased BDNF levels (Sauer et al., 1993; Li et al., 
2007) or decreased levels in BDNF KO mice, (Rios et al., 2001; Monteggia et al., 
2004) account for hyperlocomotor activity while another study reports no alteration 
in locomotion following selective loss of BDNF in the CA1 or DG (Adachi et al., 
2008).  It is possible that BDNF levels may be altered in TetO-2CR mice as BDNF 
levels have recently been shown to be elevated in the hippocampus of 5-HT2C 
receptor KO mice (Hill et al., 2010).   
 
 
5-HT2C receptors are important in sleep regulation with 5-HT2C receptor KO mice 
having disrupted sleep-wake periods and longer periods of wakefulness (Frank et al., 
2002). Treatment with agomelatine, a melatonin agonist and 5-HT2C receptor 
agonist, improves sleep disturbances and is a potential treatment for SAD (Millan et 
al., 2005; Pandi-Perumal et al., 2009).  Melatonin regulates circadian behaviour and 




C57BL/6 mice do not have active melatonin. As previously mentioned the 5-HT2C 
receptor is involved in depression and the internal clock is profoundly disturbed by 
depression (Mendlewicz., 2009).  It is possible that 5-HT2C receptors could influence 
the circadian control of sleep through regulation of the LEO. It is already established 
that 5-HT is one of the neurotransmitters with the ability to phase-advance the LEO 
via non-photic input pathways (Prosser et al., 1990; Kohler et al., 1999; Kalkowski 
& Wollnik., 1999), with various 5-HT receptors suggested to be involved 
(Kennaway et al., 1996; Gannon et al., 2009).  A role for the 5-HT2C receptor in 
regulating the LEO has been suggested as 5-HT2C receptor agonists given in the first 
half of the dark phase (Varcoe et al., 2003) induced clock gene expression of Per1 
and Per2 which are essential for rhythm responses to external stimuli such as light 
(Albrecht et al., 1997; Miyake et al., 2000; Asai et al., 2001; Yan & Silver., 2002). 
The lack of a free running rhythm in TetO-2CR mice during the DD phase of the 
food restriction experiment indicated that regulation to the LEO may be altered by 
the deficiency in 5-HT2C receptors.  However, both TetO-2CR mice and WT mice 
altered their running behaviour similarly in response to alterations in the lighting 
condition. In one of the trials the offset of running time in TetO-2CR mice did not 
alter as much as WT mice during a phase advance in lighting condition.  The 
deficiency in 5-HT2C receptors also caused a more “broken-up” pattern of running in 
TetO-2CR mice compared to WT mice with running becoming more disjointed as 
lighting conditions progressed to DD. This could be due to a more disrupted sleep 
wake-cycle, similar to that found in 5-HT2C receptor KO mice.  
 
The 5-HT2C receptor deficiency in TetO-2CR mice may generate differences in 
behaviour during light alterations that were too subtle to be detected as it has been 
suggested that the 5-HT2C receptor may regulate the LEO via a secondary pathway 
(Varcoe et al., 2003).  This suggested secondary pathway is proposed to project from 
the retina to raphe nucleus (Shen et al., 1994; Fite et al., 1999) and then to the SCN.  
5-HT is the neurotransmitter that is thought to be utilised in this secondary pathway 
as 5-HT inputs into the SCN from the raphe nucleus (Moga & Moore., 1997; Hay-
Schmidt et al., 2003), and 5-HT2C receptors are proposed to be involved as they are 




present postsynaptically in the SCN (Moyer & Kennaway., 1999; Clemett et al., 
2000; Varcoe & Kennaway., 2008).  The retinohypothalamic tract (RHT), which 
utilises glutamate, is the main pathway that enables photic stimuli to be relayed to 
the SCN (Abe et al., 1991).  Following blockade of NMDA receptors (therefore 
blocking the actions of glutamate and the RHT) rats were able to respond to light 
alterations only in the first half of the dark phase (Rowe et al., 1996; Kennaway et 
al., 2001).  The RHT could be utilizing another transmitter.  However, it is also 
possible that the system is responding through the secondary pathway (retina to 
raphe nucleus to SCN), involving 5-HT and the 5-HT2C receptor.  Expression of 5-
HT2C receptors is on the outer layer of the SCN which puts it in a position to 
potentially influence circadian entrainment (Moyer & Kennaway., 1999). As 
previously mentioned a 5-HT2C receptor agonist induced Per1 and Per2 expression 
only in the first half of the dark phase (Varcoe et al., 2003).  There is a suggestion 
that TetO-2CR mice are less responsive to light exposure in the first half of the dark 
phase due to the failure of a light pulse given between 2100 and 2300 hours to 
inhibit running in TetO-2CR mice to the same extent to that found in WT mice.  
There was also a difference in the response in TetO-2CR mice, compared to WT 
mice, in running behaviour following administration of the selective 5-HT2C receptor 
agonist, RO 60-0175. It is suggested that the RHT would need to be blocked in order 
to establish if a deficiency in the 5-HT2C receptor alters the effectiveness of the 
suggested secondary pathway.  
 
4.4.1 Concluding remarks 
Similar to 5-HT2C receptor KO mice, TetO-2CR mice were hyperphagic and heavier 
than WT mice in later life.  However, TetO-2CR mice have an advantage in that they 
do not suffer from the spontaneous seizures seen in 5-HT2C receptor KO mice.  No 
alterations were found in anxiety-like or depressive-like behaviour, and in later 
generations of 5-HT2C receptor KO mice no alterations were found in anxiety-like or 
depressive-like behaviour. A hyperactive phenotype has been shown in TetO-2CR 
mice. BDNF is a possible candidate which could normalize behaviours associated 




with mood and could have a role in locomotor control and it has recently been shown 
to be elevated in 5-HT2C receptor KO mice.  No alteration in regulation of the FEO 
was found in TetO-2CR mice however, it is possible that there is an alteration in the 



































COMPENSATORY ALTERATIONS IN  
THE 5-HT SYSTEM  











This experimental chapter examines whether there are compensatory alterations in 
response to altered 5-HT2C receptor expression levels in both the over- and under-
expressing mouse lines.  The chapter aims were to determine: 
1. Compensatory alterations in other 5-HT receptor subtypes 
2. Alterations in 5-HT levels in different brain regions 
3. Alterations in catecholamine levels 
It was hypothesised that compensatory alterations within the 5-HT system may be 
present in response to altered 5-HT2C receptor levels. A second hypothesis was that 
the levels of DA would be altered due to increased or reduced inhibition on DA 




















A phenotype of anxiety and hypolocomotion was initially found in C2CR.10 and 
C2CR.33 mice which over-express 5-HT2C receptors in the forebrain (see Chapter 3).  
This behavioural phenotype may have been due to the mixed genetic background of 
the mice during the initial characterisation (C57BL/6, CBA and C3H) because as the 
genetic background moved towards congenic C57BL/6, during the backcrossing 
process, the phenotype disappeared.  Another possibility to consider is that aspects 
of the 5-HT and/or another neurotransmitter system, such as catecholamines, 
changed to compensate for the increased 5-HT2C receptors, which could normalise 
behaviour.   
 
5-HT2C receptor agonists increase anxiety-like and depressive-like behaviour and 
reduce locomotion (Chapter 1 and 3). The regulation of these behaviours is complex 
and involves a number of other 5-HT receptor subtypes. 5-HT1A receptors and 5-
HT2A receptors are two such subtypes which are involved in mood regulation (Gross 
et al., 2000; Millan 2003 70).  Alterations in the 5-HT1A receptor can influence 5-HT 
levels due to its role as an autoreceptor. Changes in 5-HT levels play a role in mood 
with selective serotonin reuptake inhibitors (SSRIs) used as a treatment for major 
depression (Deshauer et al., 2008). Increased 5-HT levels are associated with 
decreased locomotor activity.   
 
5-HT2C receptor agonists suppress both dopamine (DA) and noradrenaline (NA) 
pathways in the frontal cortex (Millan et al., 1998; Gobert et al., 2000; Di Matteo et 
al., 2001). The DA system plays a role in locomotion, with DA depletion in 
Parkinson‟s disease resulting in a loss of movement (Bossy-Wetzel et al., 2004).  
The DA system is implicated in mood disorders with DA system over-activity 
associated with schizophrenia and 5-HT and NA reuptake inhibitors (SNRIs) are 
used in the treatment of some anxiety disorders (Dell‟Ossoet al., 2010).  





To adapt to alterations in a system (eg. in a KO model), levels of other receptors or 
neurotransmitters are sometimes found to be altered in order to compensate for lost 
function and to regain behaviour.  It is important to ascertain if altering 5-HT2C 
receptor levels caused compensatory alterations in the 5-HT and DA systems, which 
may contribute to any behavioural responses found.  The aims of this chapter were 
therefore to determine if 5-HT2C receptor over-expression or under-expression 
resulted in (1) compensatory alterations in other 5-HT receptor subtypes; (2) 
alterations in 5-HT levels in different regions of the brain; and (3) if there was an 
effect on other catecholamine levels using the 5-HT2C receptor over-expressing 
(C2CR.10 and C2CR.33 mice; discussed in Chapter 3) and under-expressing mice 
(TetO-2CR mice; discussed in Chapter 4).    

















5.2.1 The Serotonergic System: 5-HT1A receptor mRNA levels 
 
To assess whether expression of other 5-HT receptor subtypes were affected by 5-
HT2C receptor over-expression in situ hybridisation was used.  This technique 
allowed quantification of 5-HT1A and 5-HT2A receptor mRNA levels in brain 
sections. The 5-HT1A receptor was chosen due to its roles in anxiety-like behaviour 
and its role as an autoreceptor of the 5-HT system.  Compared to WT mice, C2CR.10 
mice had reduced 5-HT1A receptor mRNA which reached significance in the CA1 
field of the dorsal hippocampus (Figure 5.1a; effect of genotype F1,30=17.61; 
p=0.0002).  C2CR.33 mice had reduced 5HT1A receptor mRNA levels compared to 
WT mice (Figure 5.1b; effect of genotype F1,40=5.41; p=0.025).  Interestingly, 5-
HT1A receptor mRNA levels were increased in dorsal hippocampus (all regions) as 
well as amygdala in TetO-2CR mice compared to WT mice (Figure 5.1c; genotype: 
F1,35=25.12;   p<0.0001; region: F4,35=25.09; p<0.0001) but there was no interaction 
of the genotype with the region (Figure 5.1c; F4,35=1.66;  p=0.182).  
 
The 5-HT1A receptor mRNA levels were also examined in the raphe nucleus due to 
its role as an autoreceptor of the 5-HT system in this region (Figure 5.1d).  No 
alterations between C2CR.33 and WT mice were found in the dorsal or medial raphe 


































































































































Figure 5.1: 5-HT1A receptor mRNA expression                  
5-HT1A receptor mRNA levels were decreased in C2CR.10 mice compared to WT mice (a), 
achieving significance in the CA1 of the dorsal hippocampus.  C2CR.33 mice also had reduced 5-
HT1A receptor mRNA levels (b) compared to WT mice. 5-HT1A receptor mRNA levels were 
increased in the dorsal hippocampus (CA1, CA3 and DG), cortex and amygdala (BLA) in TetO-
2CR mice (c) compared to WT mice.   In the raphe nucleus or cortex (d) there was no difference in 
5-HT1A receptor mRNA levels between C2CR.33 and WT mice.  Expression levels were measured 
by optical densitometry of in situ hybridisation autoradiographs. All mice were males; C2CR.10 and 
TetO-2CR mice were backcrossed to C57BL/6 for 2 generations and C2CR.33 mice were 
backcrossed to C57BL/6 for 7 generations. Data are expressed as mean±SEM; C2CR.10, 
C2CR.33 or TetO-2CR mice were compared to WT littermate control mice by 2-way ANOVA with 
Bonferroni posttests; n=5-6 per group. ** p<0.01. 
 CA1 = CA1 field of the hippocampus; CA3 = CA3 field of the hippocampus; DG = dentate gyrus; 
BLA = basolateral amygdala; DRaphe = dorsal raphe nucleus; MRaphe = median raphe nuclei 





5.2.2 5-HT2A receptor mRNA levels 
 
The 5-HT2A receptor is the sister receptor to the 5-HT2C receptor and due to their 
similarities in structure and due to its involvement in anxiety-like behaviour 
alterations in this receptor were possible.  5-HT2A receptor mRNA levels in ventral 
hippocampal regions were unaltered in C2CR.10 mice compared to WT mice (Figure 
5.2a; effect of genotype F1,27=2.16; p=0.153; interaction of genotype and region 
F2,27=0.17; p=0.846), although levels were higher in the ventral CA3 field of the 
hippocampus in both genotypes (effect of region F2,27=173.91; p<0.0001).  C2CR.33 
mice had lower 5-HT2A receptor mRNA levels than WT mice (Figure 5.2b; effect of 
genotype F1,9=13.17; p=0.006) generated by a significant decrease in the CA1 field 
of the ventral hippocampus.  In both genotypes, 5-HT2A receptor mRNA levels were 
increased in the CA3 field of the ventral hippocampus (effect of region F2,9=240.06; 
p<0.0001) but there was no interaction of genotype with region (F2,9=1.25; p=0.331). 
In TetO-2CR mice, 5-HT2A receptor mRNA levels did not differ compared to WT 
mice in ventral hippocampus or cortex (Figure 5.2c; F1,15=1.94;  p=0.184), although 
in both genotypes, levels were higher in ventral CA3 than in ventral CA1 or cortex 














   
(a) C2CR.10































































































Figure 5.2: 5-HT2A receptor mRNA expression                   
5-HT2A receptor mRNA levels were unaltered between C2CR.10 and WT mice (a). Mice were males 
backcrossed to C57BL/6 for 2 generations.  C2CR.33 mice had reduced levels of 5-HT2A receptor 
compared to WT mice (b) reaching significance in the CA1 field of the hippocampus. Mice were 
males backcrossed to C57BL/6 for 7 generations. 5-HT2A receptor mRNA levels were similar 
between TetO-2CR and WT mice (c) in ventral hippocampus and cortex with higher levels found in 
the CA3 of both genotypes. Mice were males backcrossed to C57BL/6 for 2 generations. 
Expression levels were measured by optical densitometry of in situ hybridisation autoradiographs. 
Data expressed as mean±SEM..  C2CR.10, C2CR.33 or TetO-2CR mice compared to WT littermate 
control mice by 2-way ANOVA with Bonferroni posttests; n=5-6. * p<0.05. 
CA1 = CA1 field of the hippocampus; CA3 = CA3 field of the hippocampus 
 




5.2.3 Tryptophan Hydroxylase 2 and 5-HT transporter mRNA 
levels 
 
Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the production of 5-
HT with TPH type 2 (TPH2) being the relevant form of the enzyme in the brain. 
Alterations in the mRNA levels of TPH2 could indicate altered activity of this 
enzyme which could alter the production of 5-HT.  In mice backcrossed to C57BL/6 
for 7 generations a significant effect of genotype was found with C2CR.33 mice 
having lower levels of TPH2 compared to WT mice (Figure 5.3a; F1,16=4.75; 
p=0.0447).  No alterations in the 5-HT transporter (5-HTT) mRNA levels were 
found in C2CR.33 mice compared to WT mice, backcrossed to C57BL/6 for 7 
generations (Figure 5.3b; effect of genotype F1,12=0.01; p=0.9173) indicating that the 
transportation of 5-HT is similar between C2CR.33 and WT mice. 
 
(a) Tryptophan Hydroxylase 2


















































Figure 5.3: Tryptophan hydroxylase 2 and 5-HT transporter in male C2CR.33 mice    
Compared to WT mice, C2CR.33 mice had reduced TPH2 (a) but no alteration in the 5-HT 
transporter was found between genotypes (b).  All mice were male, backcrossed to C57BL/6 for 7 
generations. Expression levels were measured by optical densitometry of in situ hybridisation 
autoradiographs. Data are expressed as mean±SEM; C2CR.33 mice were compared to WT 
littermate control mice by 2-way ANOVA with Bonferroni posttests; n=5-6 per group.  
 




5.2.4 Effect of 5-HT2C receptor over- or under-expression on 
brain 5-HT and its metabolites 
 
Compensatory changes in the 5-HT system could occur in levels of 5HT itself, levels 
of 5-HT metabolites, or in expression of the various 5-HT receptors in response to 5-
HT2C receptor over-expression or deficiency.  Levels of 5-HT and its main 
metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were measured in four brain 
regions (cortex, hippocampus, cerebellum which includes the hindbrain and the 
remainder of the brain which includes thalamic regions) by high performance liquid 
chromatography (HPLC).  
 
Compared to WT mice, 5-HT levels were reduced in the hippocampus in C2CR.33 
mice, with a significant interaction of the genotype and region (Figure 5.4a; 
F2,25=3.94; p=0.033).  In both genotypes, 5-HT levels were higher in the hippocampus 
compared to the other brain regions tested (effect of region F2,25=72.46; p<0.0001).  5-
HIAA levels were reduced in the hippocampus in C2CR.33 mice compared to WT 
mice, with a significant interaction of the genotype and region (Figure 5.4a; 
F2,25=3.28; p=0.05).  In both genotypes, 5-HIAA levels were higher in the 
hippocampus compared to the other brain regions tested (effect of region F2,25=93.79; 
p<0.0001). To estimate 5-HT breakdown the ratio of 5-HT to 5-HIAA was calculated 
and was unaltered between C2CR.33 and WT mice suggesting that in the 




















































































































Figure 5.4:  Higher performance liquid chromatography (HPLC) in male C2CR.33 mice for      
5-HT and its metabolites          
5-HT levels were reduced in the hippocampus of C2CR.33 mice (a) compared to WT mice.  
Compared to WT mice, 5-HIAA levels were reduced in the hippocampus (b) in C2CR.33 mice.  The 
5-HT to 5-HIAA ratio was unaltered between genotypes (c).  High performance liquid 
chromatography (HPLC) analysis was used to analyse brain regions (Cx = cortex, Hi = 
hippocampus, Cb = cerebellum and Re = remainder of brain including thalamic and hypothalamus 
regions) in C2CR.33 mice backcrossed to C57BL/6 for 7 generations.  Data are expressed as 
mean±SEM; C2CR.33 mice were compared to WT littermate control mice by 2-way ANOVA with 
Bonferroni posttests; n=5-6. * p<0.05. 
 
   





Measurement of 5-HT levels in four brain regions (cortex, hippocampus, cerebellum 
and the remainder of the brain which includes thalamic regions) showed no 
difference between TetO-2CR and WT mice in each brain region examined (Figure 
5.5a; interaction: F3,32=1.18; p=0.334), although levels of 5-HT differed between 
brain regions (F3,32=28.46; p<0.0001) with the hippocampus and the “remainder” 
(which includes the raphe nucleus) having higher levels than the cortex and 
cerebellum.  5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of 5-HT, 
was higher in the hippocampus of TetO-2CR mice than in WT mice (Figure 5.5b) 
suggesting an increase in 5-HT breakdown and possibly release. Moreover, in both 
genotypes levels of this metabolite were higher in the hippocampus than in other 
regions examined with a significant interaction between genotype and region being 
found (Figure 5.5b interaction: F3,32=3.06; p=0.042; genotype: F1,32=0.78; p=0.383; 
region F3,32=53.57; p<0.0001).  To estimate 5-HT breakdown the ratio of 5-HT to 5-
HIAA was calculated and was unaltered between TetO-2CR and WT mice 
suggesting that in the hippocampus more 5-HT must be released and broken down 
(Figure 5.5c; F1,32=0.54; p=0.467). 
 

















































































































(a) 5-HT (b) 5-HIAA
(c) 5-HT:5-HIAA
 
Figure 5.5:  High performance liquid chromatography (HPLC) in male TetO-2CR mice for 5-HT 
and its metabolites                                                                                                                                         
5-HT levels was higher in the hippocampus and “remainder” in both genotypes but no alterations 
were found between genotypes (a).  5-HIAA is increased in the hippocampus of TetO-2CR mice 
compared to WT mice (b). 5-HT breakdown was unaltered between genotypes (c).  High 
performance liquid chromatography (HPLC) was used to analyse brain regions (Cx = cortex, Hi = 
hippocampus, Cb = cerebellum and Re = remainder of brain including thalamic and hypothalamus 
regions) in TetO-2CR mice, backcrossed to C57BL/6 for 5 generations, 12 months of age. Data are 
expressed as mean±SEM and analysed by 2-way ANOVA with Bonferroni posttests; n=5 per group. 
* p<0.05. 




5.3 The Dopaminergic System:  
It has been suggested that the 5-HT2C receptor plays a role in regulating dopamine 
(DA) release (De Deurwaerdere et al., 2004) and so aspects of the DA system were 
examined to determine if they were affected by altered 5-HT2C receptor levels. 
 
5.3.1 Tyrosine Hydroxylase mRNA levels 
 
Tyrosine hydroxylase (TH) is a rate-limiting enzyme in the production of dopamine 
and is present in the ventral tegmental area (VTA), the retrorubral fields and the 
substantia nigra (SN). The substantia nigra (SN) receives dense serotonergic input 
and 5-HT2C receptors are expressed in the cell bodies of GABA-containing neurones 
in both the SN pars reticulate and the VTA (Moga & Moore., 1997; Moyer & 
Kennaway., 1999; Di Matteo et al., 2001).  
 
TH mRNA levels were significantly reduced in C2CR.10 mice compared to WT 
mice (Figure 5.6a; p=0.0109), however no difference was found in C2CR.33 mice 
(Figure 5.6b; p=0.9426) compared to WT mice. Levels of TH mRNA were similar in 
the SN and VTA of TetO-2CR mice compared to WT mice (Figure 5.6c; p=0.388) 
suggesting that the DA production pathway may be unaltered by 5-HT2C receptor 
deficiency, however, changes in enzyme activity or pathway flux may occur without 
changes in mRNA levels. 
 




























































































Figure 5.6: Tyrosine Hydroxylase (TH) mRNA levels in substantia nigra/ventral tegmental 
area               
TH mRNA expression is reduced in the SN/VTA in C2CR.10 mice compared to WT mice (a). All 
mice were males backcrossed to C57BL/6 for 2 generations.  Compared to WT mice, TH mRNA 
expression was unaltered in C2CR.33 mice (b) in the SN/VTA. All mice were males backcrossed to 
C57Bl6 for 7 generations.  TH mRNA expression was unaltered in the SN/VTA (c) of TetO-2CR 
mice compared to WT littermate control mice. All mice were males, backcrossed to C57BL/6 for 2 
generations. Expression levels were measured by optical densitometry of in situ hybridisation 
autoradiographs. Data are expressed as mean±SEM;  C2CR.10, C2CR.33 or TetO-2CR mice were 
compared to WT littermate control mice by unpaired Student‟s t test; n=5-6. * p<0.05. 




5.3.2 Dopamine 2 receptor (D2) mRNA levels 
 
The dopamine 2 receptor (D2) is expressed in the caudate putamen (CPu), which is 
the end point of the nigrostriatal DA pathway (Drago et al., 1994). D2 receptor 
mRNA was unaltered in C2CR.10 mice compared to WT mice (Figure 4.7a; 
p=0.9373). In C2CR.33 and WT mice, D2 receptor mRNA was increased in the 
caudate putamen (CPu) compared to other regions tested (Figure 5.7b; F2,24=10.00; 
p=0.0007). D2 receptor mRNA levels did not differ between genotypes (Figure 5.7b; 
effect of genotype F1,24=0.37; p=0.5504; interaction of genotype with region 
F2,24=0.74; p=0.4866  

























































Figure 5.7: Dopamine 2 receptor mRNA expression in male C2CR.10 or C2CR.33 mice 
Dopamine 2 receptor (D2) is unaltered in the CPu in C2CR.10 mice (a) compared to WT mice. 
All mice backcrossed to C57BL/6 for 2 generations. In C2CR.33 mice D2 receptor is unaltered 
(b) compared to WT mice. All mice backcrossed to C57BL/6 for 7 generations. Expression 
levels were measured by optical densitometry of in situ hybridisation autoradiographs. Data are 
expressed as mean±SEM; C2CR.33 compared to WT littermate control mice by 2-way ANOVA 
with Bonferroni posttests; n=6 per group. 
CPu = caudate putamen; AcbC= nucleus accumbens core; AcbSh=nucleus accumbens shell 




5.3.3 DA and its metabolites 
 
DA is catabolised into homovanillic acid (HVA) and noradrenaline (NA) through 
two independent pathways (see Chapter 1). Levels of DA, HVA and NA were 
measured in four brain regions (cortex, hippocampus, cerebellum and the 
„remainder‟ of the brain which includes thalamic regions and the basal ganglia) by 
high performance liquid chromatography (HPLC) with fluorescence detection. 
 
In 5-HT2C receptor over-expressing mice (C2CR.33 mice) DA levels were 
significantly increased in the cortex, but not other regions, compared to WT mice 
(Figure 5.8a; interaction of genotype and region F2,25=10.99; p=0.0004; effect of 
genotype F1,25=32.50; p<0.0001).  The results for HVA in the „remainder‟ section 
were excluded in this group of mice due to large variation. Accordingly for analysis 
of DA and HVA levels, DA was reanalysed without the „remainder‟ section to allow 
for statistical analysis. In the hippocampus levels of HVA were reduced in C2CR.33 
mice compared to WT mice, with a trend of a significant interaction between 
genotype and region (Figure 5.8b; F2,25=2.96; p=0.0701).  In both genotypes HVA 
levels were elevated in the hippocampus compared to other regions (effect of region 
F2,25=24.41; p=<0.0001).  The ratio of DA to HVA (indicating DA breakdown) was 
increased in the cortex of C2CR.33 mice, but did not differ from WT mice in other 
regions of brain (Figure 5.8c; interaction F2,25=10.23; p=0.0006; effect of genotype 
F1,25=11.05; p=0.0027). These results suggest slower breakdown of DA into HVA in 
the cortex in C2CR.33 mice compared to WT mice. 
 
 


















































































































Figure 5.8: High performance liquid chromatography (HPLC) of catecholamines in male 
C2CR.33 mice               
DA levels were increased in the cortex of C2CR.33 mice (a) compared to WT controls. HVA 
levels were reduced in the hippocampus of C2CR.33 (b) and an increased DA to HVA ratio 
was found in the cortex of C2CR.33 (c).  High performance liquid chromatography (HPLC) 
analysis was used to analyse brain regions (Cx = cortex, Hi = hippocampus, Cb = cerebellum 
and Re = remainder of brain including thalamic and hypothalamus regions). All mice were 
males backcrossed to C57BL/6 for 7 generations.  Data are expressed as mean±SEM; 
C2CR.33 mice compared to WT littermate control mice by 2-way ANOVA with Bonferroni 
posttests; n=5-6 per group.  * p<0.05, *** p<0.001. 
 





As previously mentioned DA levels were re analysed including the „remainder‟ 
section and DA was still significantly increased in the cortex in C2CR.33 mice 
compared to WT mice (Figure 5.9a; interaction of genotype with region; F3,32=10.09; 
p<0.0001).  There was no difference in NA levels between C2CR.33 and WT mice 
in any region examined (Figure 5.9b; interaction F3,32=1.31; p=0.289 effect of 
genotype F1,32=0.67; 0.42).  Levels of NA were higher in the hippocampus of both 
genotypes compared to the other regions tested (F3,32=30.80; p<0.0001).  The ratio of 
DA to NA (indicating production of NA from DA) was increased in the cortex of 
C2CR.33 mice compared to WT mice (Figure 5.9c; interaction F3,32=2.86; p=0.0524) 
suggesting slower conversion of DA to NA.  
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Figure 5.9: High performance liquid chromatography (HPLC) of noradrenaline in male 
C2CR.33 mice                         
DA levels were re analysed (a) to incorporate the „remainder‟ fraction and the increased DA level in 
the cortex remained. NA was unaltered between genotypes (b) and the DA to HVA ratio was 
increased in the cortex of C2CR.33 (c).  High performance liquid chromatography (HPLC) analysis 
was used to analyse brain regions (Cx = cortex, Hi = hippocampus, Cb = cerebellum and Re = 
remainder of brain including thalamic and hypothalamus regions). All mice were males backcrossed 
to C57BL/6 for 7 generations.  Data are expressed as mean±SEM; C2CR.33 mice compared to WT 
littermate control mice by 2-way ANOVA with Bonferroni posttests; n=5-6 per group.  * p<0.05, *** 
p<0.001. 
 





In 5-HT2C receptor under-expressing mice (TetO-2CR mice)  DA levels did not 
differ between genotype in any region examined (Figure 5.10a; F1,32=0.04; p=0.84), 
although they were higher in the “remainder” section, which includes the basal 
ganglia, than in other regions in both genotypes (F3,32=28.68; p<0.0001).  
Homovanillic acid (HVA), a metabolite of DA, was lower in the cortex and 
“remainder” of TetO-2CR mice than in WT mice (Figure 5.10b; effect of genotype 
F1,32=8.05; p=0.008) although there was no interaction of genotype and region 
(F3,32=1.03; p=0.394). The ratio of DA to HVA (indicating DA breakdown) was 
increased in the “remainder” fraction of brain from TetO-2CR mice, but did not 
differ from WT mice in other regions of brain (Figure 5.10c; effect of genotype 
F1,32=5.38; p=0.027) with a significant interaction of the genotype with the region 
(F3,32=2.90; p=0.05).  These results suggest slower breakdown of DA into HVA in 
the cortex and „remainder‟ of TetO-2CR mice compared to WT control mice. 
 
Levels of noradrenaline (NA) differed in a genotype and region specific manner with 
higher levels in the hippocampus and reduced levels in the cortex and “remainder" of 
TetO-2CR mice compared to WT mice (Figure 5.10d; interaction of genotype and 
region F3,32=3.01; p=0.045).  NA is produced from DA, and the ratio of DA to NA 
was increased in both genotypes in the cortex and remainder compared to other 
regions (F3,32=38.90; p<0.0001) but did not differ between TetO-2CR and WT mice 
(Figure 5.10e; effect of genotype F1,32=2.54; p=0.121; interaction of genotype and 
region F3,32=1.29; p=0.294).  
 
 






























































































































































(b) HVA (c) DA:HVA
(d) NA (e) DA:NA
 
Figure 5.10:  High performance liquid chromatography (HPLC) in male TetO-2CR mice for 
DA, HVA and NA                                                                                                                                 
DA levels were unaltered between genotypes, although levels were higher in both genotypes in 
the “remainder” (a). HVA was reduced in the cortex and “remainder” of TetO-2CR mice 
compared to WT mice but no interaction of genotype and region was found (b). The ratio of DA to 
HVA was increased in the “remainder” of TetO-2CR mice compared to WT mice but was 
unaltered in other regions (c).  NA is increased in the hippocampus and decreased in the cortex 
and “remainder” of TetO-2CR mice compared to WT mice (d).  The ratio of DA to NA was 
increased in both genotypes in the cortex and remainder compared to other regions but no 
alterations were found between gentoypes (e).  High process liquid chromatography (HPLC) was 
used to analyse brain regions (Cx = cortex, Hi = hippocampus, Cb = cerebellum and Re = 
“remainder” of brain including thalamic and hypothalamus regions).  All mice were males, 
backcrossed to C57BL/6 for 5 generations, 12 months of age. Data are expressed as 
mean±SEM, TetO-2CR mice compared to WT littermate control mice by 2-way ANOVA with 
Bonferroni posttests; n=5 per group. ** p<0.01. 
 






It was established in Chapter 3 (Section 3.2.2) that C2CR.10 mice over-express the 
5-HT2C receptor in a region-specific manner while C2CR.33 mice had widespread 
over-expression in the forebrain. While, TetO-2CR mice under-express the 5-HT2C 
receptor throughout the brain (see Chapter 4 section 4.2.2). Because the 5-HT2C 
receptor is either over-expressed or deficient throughout development, normal 
development may be perturbed or other receptors/ pathways may have been altered 
during development to compensate for the increased or lack of signalling through the 
5-HT2C receptor.  Alterations in aspects of the central 5-HT system functioning such 
as TPH2 activity, 5-HT levels, MAO-A activity and 5-HT1A receptor levels are 
associated with altered aggression levels (Brown et al., 1979; Gibbons et al., 1979; 
Popova et al., 1991; Cases et al., 1995; Kulikov et al., 2005; Popova., 2008; Vage et 
al., 2010).   
 
5.4.1 5-HT1A receptor mRNA expression 
Down-regulation of 5-HT1A receptors is associated with depression and anxiety 
(Gross et al., 2000) and disruption of the 5-HT1A receptor gene increases anxiety-like 
behaviours (Parks et al., 1998; Ramboz et al., 1998; Gingrich et al., 2000; Gingrich 
& Hen., 2001; Olivier et al., 2001) with transgenic re-expression of 5-HT1A receptor 
in the amygdala and hippocampus being sufficient to rescue this behavioural 
phenotype (Gross et al., 2002). Motor coordination is not altered in 5-HT1A receptor 
knock-out (KO) mice (Heisler et al., 1998).  In 5-HT2C receptor KO mice, no 
alterations were found in 5-HT receptor subtypes (5-HT 1A, 1B/1D, 1F, 2A, 2B, 4 
and 7; Lopez-Gimenez et al., 2002). 
 
However, compared to WT mice, C2CR.10 mice had reduced 5-HT1A receptor 
mRNA levels in the CA1 field of the dorsal hippocampus in response to increased 5-




HT2C receptors in all regions of the dorsal hippocampus. This is consistent with 
C2CR.33 mice which had reduced levels of 5-HT1A receptor in all regions of the 
dorsal hippocampus in response to a much greater increase in 5-HT2C receptor 
mRNA in these regions.  No differences in 5-HT2C receptor or 5-HT1A receptor 
mRNA levels were found in the amygdala in C2CR.10 mice however C2CR.33 mice 
had increased and decreased mRNA of these receptors respectively.   Both an 
elevation in 5-HT2C receptor and reduction in 5-HT1A receptor signalling increase 
anxiety-like behaviour, hence this compensatory decrease in 5-HT1A receptor mRNA 
levels was not the cause of the normalisation in anxiety levels in C2CR.33 mice. In 
the TetO-2CR mice, 5-HT1A receptor mRNA levels were elevated in the CA1 field 
of the dorsal hippocampus and in the amygdala. This elevation in 5-HT1A receptor 
levels would be predicted to have a similar effect on anxiety-like behaviour to that 
hypothesised to results from the reduction in the 5-HT2C receptor.  These results 
demonstrate cross talk between the 5-HT2C receptor and 5-HT1A receptor. 
 
In the raphe nucleus somatodendritic 5-HT1A receptors act as autoreceptors causing a 
reduction in 5-HT synthesis and release into post synaptic sites (Blier et al., 1998; 
Richardson-Jones et al., 2010). In the dorsal and median raphe nucleus 5-HT2C 
receptor mRNA levels were unaltered in C2CR.33 mice and levels of 5-HT1A 
receptors were also unaltered between genotypes in this region. This suggests that 
there was no alteration in regulation of 5-HT synthesis by 5-HT1A autoreceptors.    
 
5.4.2 5-HT2A receptor mRNA expression 
The structures where 5-HT2A receptors are expressed modulate behaviours 
associated with anxiety state (Millan 2003).  Global disruption of 5-HT2A receptor 
signalling in mice reduces anxiety-like behaviour but does not affect depressive-like 
or fear-conditioned behaviour (Weisstaub et al., 2006).  Selective restoration of 5-
HT2A receptors in the cortex of these KO mice normalises conflict anxiety 
behaviours, suggesting a specific role for cortical 5-HT2A receptor function.  




Compared to WT mice, 5-HT2A receptor mRNA was unaltered in the ventral 
hippocampus of C2CR10 mice, however no increase in 5-HT2C receptor mRNA was 
found in the CA1 or CA2 fields of the ventral hippocampus.  Similarly, 5-HT2C 
receptor deficient mice (TetO-2CR) had unaltered 5-HT2A receptor mRNA levels in 
the ventral hippocampus. In C2CR.33 mice, 5-HT2C receptor mRNA levels were 
high in the ventral hippocampus and 5-HT2A receptor mRNA was found to be 
decreased in the CA1 of the ventral hippocampus. Both an elevation in 5-HT2C 
receptor and reduction in 5-HT2A receptor signalling increase anxiety-like behaviour, 
hence this compensatory decrease in 5-HT2A receptor mRNA levels would not have 
normalised anxiety levels in C2CR.33 mice.  
 
5.4.3 Other aspects of the 5-HT system 
 
Importantly, perturbation of the 5-HT system by disruption of the gene encoding the 
5-HT transporter has region-specific compensatory alterations in 5-HT receptors.  5-
HT1A receptors were decreased in the dorsal raphe and increased in the hippocampus 
(Fabre et al., 2000; Li et al., 2000), 5-HT1B receptors were decreased in the 
substantia nigra (Fabre et al., 2000) and 5-HT2A receptors were decreased in the 
claustrum, cerebral cortex and lateral striatum (Rioux et al., 1999) of 5-HTT KO 
mice.   The density of 5-HT2A receptors (increased in hypothalamus and septum but 
reduced in striatum) and 5-HT2C receptors (increased in amygdala and choroid 
plexus) are changed in a region-specific manner in 5-HTT KO mice (Li et al., 2003). 
5-HTT mRNA levels did not differ between C2CR.33 and WT mice in the raphe 
nucleus and It would be interesting to examine levels of 5-HTT in TetO-2CR mice to 
determine if transportation of 5-HT may be altered.    
 
Tryptophan hydroxylase 2 (TPH2) is the rate-limiting enzyme in the brain in 5-HT 
production. A single nucleotide polymorphism at the mTPH2 locus (C1473G) 
reduced 5-HT synthesis by 55% when expressed in PC-12 cells (Zhang et al., 2004) 




and in mice this polymorphism determines differences in 5-HT synthesis rates but 
not tissue content in C57BL/6 mice (Siesser et al., 2010). Female Tph2 KO mice 
have increased aggressive behaviour (Alenina et al., 2009) and female aggression is 
directly linked to anxiety and depressive disorders (Bosch et al., 2005). In the raphe 
nucleus in C2CR.33 mice TPH2 mRNA levels were reduced indicating less 5-HT 
may be produced.   
 
Another area to consider is if 5-HT levels and its main metabolite, 5-HIAA, have 
been affected and could potentially be normalising any anxiety-like or depressive-
like behaviour. Alterations in 5-HT levels play a role in mood with selective 
serotonin reuptake inhibitors (SSRIs) used as a treatment for major depression 
(Deshauer et al., 2008). 
 
5-HT levels and 5-HIAA (the main metabolite of 5-HT) were decreased in the 
hippocampus, but no other brain region, in C2CR.33 mice compared to WT mice. 
Although no alterations in the levels of 5-HT or the conversion rate of 5-HT to 5-
HIAA were found, 5-HIAA was elevated in the hippocampus of TetO-2CR 
compared to WT mice. These results suggest that less 5-HT is being produced for 
release in the hippocampus in mice that over-express 5-HT2C receptors, while in 
mice that under-express 5-HT2C receptors more 5-HT must be released and broken 
down in the hippocampus.  
   
5.4.4 5-HT2C receptor expression levels influence the 
mesocorticolimbic DA pathway 
 
5-HT is believed to exert an inhibitory control over both the mesolimbic and 
nigrostriatal DA systems through the 5-HT2C receptor, with antagonists of this 
receptor increasing DA release in the NA and prefrontal cortex by increasing the 




firing rate and bursting activity of DA-containing neurons in the VTA (Di Matteo et 
al 2001; McMahon et al 2001; Di Matteo et al 2002; Higgins & Fletcher 2003; De 
Deurwaerdere et al 2004).  It was therefore hypothesised that altered 5-HT2C receptor 
expression levels may have caused alterations in the DA system.  Tyrosine 
hydroxylase (TH) is the rate-limiting enzyme in DA production in the VTA. In 
C2CR.10 mice, 5-HT2C receptor mRNA levels were increased in the SN/VTA brain 
region (Chapter 3 section 3.2.2) and interestingly TH mRNA levels were reduced in 
this region.  Therefore, it was hypothesised that DA production may be reduced in 
C2CR.10 mice. Unfortunately due restraints HPLC analysis of DA levels and its 
metabolites was not carried out in this mouse line.  In C2CR.33 mice, 5-HT2C 




There are two major DA pathways; the mesocortcolimbic pathway and the 
nigrostriatal pathway. The mesocorticolimbic pathway projects from the VTA to 
cortical and limbic structures, including the nucleus accumbens and is altered in 5-
HT2C receptor KO mice, with increased DA levels in the nucleus accumbens 
(Abdallah et al., 2009). Loss of DA signalling in the nucleus accumbens is proposed 
to cause decreased activity of dopaminergic reward mechanisms, which underlie 
feelings of anhedonia. DA levels did not differ in TetO-2CR mice compared to WT 
mice. In response to 5-HT2C receptor over-expression in C2CR.33 mice DA levels 
were increased and HVA levels were decreased in the cortex. To estimate DA 
release and breakdown the ratio of DA to HVA was used and it was concluded that 
DA release was inhibited by increased 5-HT2C receptors in the cortex, where 5-HT2C 
receptor is not usually present (Chapter 3 section 3.2.2).  This suggests that the 
mesocorticolimbic pathway is more sensitive to increased or decreased levels of 5-
HT2C receptor signalling.   D1 receptor is present in the hippocampus and prefrontal 
cortex but due to problems with the riboprobe these in situ hybridisation experiments 
failed.  





The nigrostriatal DA pathway is involved in locomotion. Due to the strong 
hypolocomotor phenotype and reduced TH mRNA levels in the SN/VTA in 
C2CR.10 mice (from generation 2 mice; Chapter 3 section 3.2.5 and Chapter 4 
section 4.3.5) it was decided to examine both D1 and D2 receptors in the dorsal 
caudate putamen (CPu), which is part of the nigrostriatal system.  D1 and D2 
receptors are present on different populations of spiny projection neurones in the 
dorsal CPu.  The direct pathway projects from the CPu to the substantia nigra and 
entopeduncular nucleus (the output nuclei of the basal ganglia) and the neurons that 
give rise to these projections have high levels of D1 receptor and the neuropeptides 
substance P and dynorphin.  The indirect pathway projects from the CPu to the 
globus pallidus and the basal ganglia output nuclei indirectly and the neurons that 
give rise to this projection express high levels of D2 receptor and enkephalin (Drago 
et al 1994).  It is unlikely that alterations are present in the indirect pathway 
projecting from the nigrostriatal system as D2 receptor mRNA levels were unaltered 
in the dorsal CPu of C2CR.10 mice.  This was also the case in C2CR.33 mice 
providing further evidence for the hypothesis that it is the mesocorticolimbic 
pathway that is altered in response to 5-HT2C receptor signalling.  
 
Alterations in the DA system could contribute to the hyperlocomotion found in 
TetO-2CR mice in the wheel running cages (see Chapter 4).  It has been reported that 
under basal conditions 5-HT2C receptor KO mice show no difference in DA levels in 
the nucleus accumbens or dorsal striatum (Rocha et al., 2002).  However, more 
recently, increased basal DA levels were shown in the nucleus accumbens of 5-HT2C 
receptor KO mice (Abdallah et al., 2009).  No alterations in DA levels or TH, the 
rate limiting enzyme in DA production, were found in TetO-2CR mice compared to 
WT under basal conditions indicating that hyperlocomotion is not due to reduced 
inhibition on DA release as a consequence of 5-HT2C receptor deficiency in TetO-
2CR mice.   
 




Other aspects of the DA system could also be altered to compensate for 5-HT2C 
receptor deficiency in TetO-2CR mice which could alter locomotion or depressive 
behaviours. Levels of HVA, a major DA metabolite, are altered in the plasma of 
schizophrenic patients (Arrúe et al., 2010).  HVA was lower in the brain of TetO-
2CR mice and the ratio of DA to HVA was found to be increased in the remainder 
brain section (which contains the substantia nigra) in TetO-2CR mice indicating that 
breakdown of DA to HVA may be slower.  Hence in future studies it would be 
important to measure monoamine oxidase and catechol-O-methyl transferase as they 
are involved in DA breakdown and may not be functioning optimally when there is a 
deficiency in the 5-HT2C receptor.                                                                                                                                    
 
DA is also the precursor to noradrenaline (NA) which is involved in depression, 
influences the reward system and is involved in attention deficit/ hyperactivity 
disorder (Perona et al., 2008; Dell‟Osso et al., 2010; Lim et al., 2010).  In addition to 
its role in regulation of DA release, the 5-HT2C receptor agonist, RO 60-0175, 
suppresses frontal cortex NA levels in rats while the 5-HT2C receptor antagonist, SB-
242084, increases NA levels. (Millan et al., 1998).  Serotonin and noradrenaline 
reuptake inhibitors (SNRIs) are used in the treatment of some anxiety disorders.  
Noradrenaline levels were unaltered in C2CR.33 mice and the ratio of DA to 
noradrenaline was increased in the cortex.  These results taken in combination with 
those from the HVA pathway suggest that 5-HT2C receptor over-expression has 
caused less DA to be released in the cortex and, in order to maintain normal 
noradrenaline levels, the balance of the two DA catabolic pathways is altered in 
favour of noradrenaline production therefore causing a decrease in HVA levels.    
 
The ratio of DA to NA, indicating possible conversion rate, was unaffected in TetO-
2CR mice but interestingly NA levels were increased in the hippocampus.  5-HT and 
noradrenaline reuptake inhibitors (SNRIs) are used in the treatment of some anxiety 
disorders and so increased concentration of NA at the synapse is predicted to have a 
beneficial effect on mood, including recovery of motivation (Dell‟Osso et al., 2010).  




It would therefore be interesting to examine NA concentrations in the synapse of 
TetO-2CR mice which due to time constraints was not undertaken. One method to 
measure NA levels would be to use dual-probe microdialysis.   
 
Dihydroxyphenylacetic acid (DOPAC) is produced from DA after reuptake by the 
nerve terminal and so quantitation of DOPAC concentration would have given a 
more accurate idea of DA neurotransmission.  Another limitation to these results is 
the exclusion of an analysis of dihydroxyphenylacetic acid (DOPAC) concentration 
which was unable to be carried out due to a shortage in machine availability. 
 
    
5.4.5 Concluding Remarks 
 
These results suggest that over-expression of the 5-HT2C receptor in the 
hippocampus in C2CR.33 mice caused compensatory alterations which reduced 5-
HT1A receptor (also reduced in amygdala) and 5-HT2A receptor signalling.  Region-
specific 5-HT2C receptor over-expression in C2CR.10 mice caused region-specific 5-
HT1A receptor reduction while TetO-2CR mice had increased 5-HT1A receptor 
expression. This suggests influential cross talk between 5-HT2C receptors and 5-
HT1A receptors. 5-HT production (indicated by reduced TPH2) and release in the 
hippocampus was reduced in C2CR.33 mice but increased in TetO-2CR mice. Over-
expression of 5-HT2C receptors influences the DA system with reduced TH levels in 
response to increased 5-HT2C receptor in the SN/VTA in C2CR.10 mice. DA release 
in the cortex was inhibited by increased 5-HT2C receptor levels in the cortex in 
C2CR.33 mice. The hyperactive phenotype in TetO-2CR mice does not appear to be 
due to decreased inhibition of the DA system. It is hypothesised that the 
mesocorticolimbic DA pathway is more sensitive to 5-HT2C receptor signalling 
alterations than the nigrostriatal DA pathway. 






























Behavioural phenotypes caused by alterations in the 5-HT2C receptor appear to be 
sensitive to either the genetic background of the mice, environmental changes and/or 
alterations in other receptors to compensate for differences in 5-HT2C receptor 
signalling. This is suggested due to several reasons, the first being that C2CR.10 and 
C2CR.33 mice, which over-express the 5-HT2C receptor, originally had an 
anxiogenic and hypolocomotor phenotype which was lost in later generations 
(Chapter 3). Secondly TetO-2CR mice, which under-express the 5-HT2C receptor, 
originally had a hyperlocomotor phenotype which was lost for several generations 
before returning (Chapter 4). In order to hypothesise a cause for the alterations in 
phenotype several areas had to be considered. Sensitivity to environment could 
account for the difference in results in these 5-HT2C over-expressing and under-
expressing models as a move in animal facilities was carried out, afterwhich the 
behavioural phenotype was no longer found.  Another possibility was the genetic 
background of the mouse lines.  All three lines originated on a mixed genetic 
background, which differed between the over-expressing and the under-expressing 5-
HT2C receptor mice, and following backcrossing towards a congenic C57BL/6 
genetic background phenotypes were lost in all lines.  Interestingly 5-HT2C receptor 
KO mice had an anxiolytic phenotype (Heisler et al., 2007b) which was not found 
more recently (Hill et al., 2010).   
 
Alterations in other aspects of the 5-HT system or should also be investigated more 
thoroughly to compensate for altered 5-HT2C receptor levels in C2CR.10, C2CR.33 
and TetO-2CR mice. An inverse relationship was found to exist between the 5-HT2C 
receptor and 5-HT1A receptor levels. 5-HT levels are also suggested to be increased 
in response to 5-HT2C receptor deficiency in TetO-2CR mice or decreased in 
response to 5-HT2C receptor over-expression in C2CR.33 mice. In 5-HT2C receptor 
KO mice BDNF levels were found to be elevated (Hill et al., 2010) and so BDNF 
levels should also be examined in C2CR.10, C2CR.33 and TetO-2CR mice.  
 




The extent of editing of the 5-HT2C receptor is another area to consider when 
examining the interaction of the 5-HT2C receptor with other systems and the resulting 
behavioural phenotype.  The 5-HT2C receptor undergoes A to I editing which alters 
the G-protein coupling of the receptor, with the fully unedited form reported to be 
constitutively active and edited forms requiring more ligand in order to be activated 
(Burns et al., 1997, Fitzgerald et al., 1999, Niswender et al., 1999; Berg et al., 2008). 
Editing levels of 5-HT2C receptor have been found to be increased in depression 
(Dunlop et al., 2006) with elevated editing levels being found in depressed suicide 
victims (Gurevich et al., 2002; Iwamoto et al., 2003). Stress increases editing to 
isoforms which have reduced ligand sensitivity (Englander et al., 2005) and early life 
stress may permanently set this shift in editing levels (Bhansali et al., 2007).  In a 
study on 5-HT2C receptor KO mice it was suggested that mis-timed and higher leptin 
levels during early life in 5-HT2C receptor KO mice (increased leptin levels found at 
16, 18 and 20 days old) could programme a change in both feeding and stress 
neurocircuits (Akana., 2008).  It would be interesting to carry out an examination of 
the extent of editing in TetO-2CR mice as 5-HT2C receptors may be fully unedited to 
compensate for the reduced numbers.  Editing could also be affected by the 
deficiency in 5-HT2C receptor if TetO-2CR mice had altered levels of leptin (as seen 
in the 5-HT2C receptor KO mice) which could change stress neurocircuits and 
therefore editing.  The over-expressed 5-HT2C receptors in C2CR.10 and C2CR.33 
mice are fully unedited which means that the ratio of unedited to edited 5-HT2C 
receptor isoforms may be altered.  The endogenous 5-HT2C receptors may be fully 
edited in order to compensate for constitutive activity from the increased unedited 
isoforms or the number of receptors available on the cell surface may be altered. 
This is a further area that requires investigation in these lines. 
  
The 5-HT2C receptor has previously been proposed to influence both the nigrostriatal 
and mesolimbic DA systems (Di Matteo et al 2002; Higgins & Fletcher 2003; De 
Deurwaerdere et al 2004). Recently, increased DA levels were found in the nucleus 
accumbens of 5-HT2C receptor KO mice (Abdallah et al., 2009) suggesting the 
mesocorticolimbic DA pathway was altered in these mice.  In both C2CR.33 and 




TetO-2CR mice aspects of the mesocorticolimbic DA system were altered. 
Therefore, it is hypothesised that the 5-HT2C receptor plays a more prominent role in 
regulating the mesocorticolimbic DA system opposed to the nigrostriatal DA system. 
 
Further studies are required to investigate the extent of editing as well as a more 
thorough investigation of the DA system in C2CR.10, C2CR.33 and TetO-2CR 
mice. However, these models have provided evidence of compensation in both the 5-
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